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A review of the existing clinical outcome measures used for assessing 
impairment, disability, and handicap in multiple sclerosis revealed that none is 
satisfactory. 
I conducted a prospective study to assess the psychometric properties of the 
five commonly used clinical rating scales for multiple sclerosis in a cohort of 64 
patients, and found that none satisfied all the requirements of an ideal outcome 
measure although all had some desirable properties. 
I have devised a new clinical disability scale, the Guy's Neurological 
Disability Scale, and found it to be reliable, valid, and responsive in a cohort of 50 
patients. I showed that the scale could be satisfactory administered over the 
telephone or via a postal questionnaire. 
I have assessed the correlation between pathology as measured by total 
lesion load on TI- and T2-weighted brain magnetic resonance images and 
impairment, disability, handicap, and health related quality of life outcome measures 
used in multiple sclerosis. This study involved the same cohort of 50 patients and 
used a novel semi-automated computer assisted quantitative method. There was a 
modest correlation between the extent of pathology and some measures of 
impairment, disability and health related quality of life, but not with any handicap 
measure. 
I concluded that clinical disability rating scales should remain the gold 
standard for assessing the outcome of clinical trials in multiple sclerosis, and that the 
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HUMAN DISABLEMENT AND QUALITY OF LIFE IN 
NEUROLOGICAL DISORDERS 
1.1 Introduction 
The greatest problem facing anyone devising health-related outcome 
measures is to decide upon a logical, coherent, and comprehensive framework of 
classification which can be used in assessing the relation between disease and its 
consequences. The lack of such an adequate classification has hindered the 
development of health science research and complicated the interpretation of clinical 
trials. 
Over the last century, clinical and public health practices have transformed in 
response to the reduction in mortality from infectious diseases and the increase in 
chronic non-fatal degenerative diseases. This transformation has led to changes in 
the challenges posed by disease, and the measures needed to assess its consequences. 
Before these changes, the International Classification of Diseases (ICD) (World 
Health Organisation, 1993), which had existed since 1893, provided a valuable and 
relevant model for studying the disease process (Thuriaux, 1995). This model 
represented a concept of disease which has been depicted as a sequence: 
cure 
aetiology -7* pathology 9 manifestation 9 
death 
This concept provided an efficient model for disorders that could be 
prevented or cured, but did not encompass the non-fatal consequences of chronic 
disorders which have been collectively described as `disablement' (Granger and 
18 
Gresham, 1990b; Badley, 1993; Thuriaux, 1995). The conceptual model of disease- 
related phenomena thus needed further expansion. 
1.2 The International Classification of Impairments, Disabilities and 
Handicaps 
In the 1970's, the World Health Organisation (WHO) tried to develop a 
comprehensive scheme for measuring `disablement' which would be compatible 
with the principles underlying the structure of the ICD. However detailed 
deliberations between numerous individuals and various organisations led to the 
realisation that a single classification scheme conforming to the taxonomic 
principles of the ICD would not be satisfactory. Instead, a novel model of 
classification was structured along three levels, the body level (impairment - 1009 
items), the person level (disability - 338 items), and the society level (handicap - 72 
items). This model has been depicted as a sequence: 
disease (pathology) 9 impairment 9 disability 9 handicap 
This classification, which was published by the WHO in 1980 as the 
International Classification of Impairments, Disabilities and Handicaps (ICIDH) 
(World Health Organisation, 1980), provided a common language for research, and a 
comprehensive framework for discussing and understanding the consequences of 
diseases. 
The original model had a basic three-level hierarchical structure (Figure 1.1). 
Wade (1995a) argued that diseases need to be considered at four levels: pathology, 
impairment, disability, and handicap. These four levels form a continuum with 
many grey areas in between and share a diverse chain of inter-relations (Figure 1.2). 
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Figure 1.1 The essential components of the ICIDH model as adapted from Granger 
(1990b) 
Affected level of functioning 
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Figure 1.2 The WHO model of disease, illustrating the relationship between the 
patient and the environment in the four dimensions of the ICIDH as adapted from 
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1.2.1 Pathology 
The ICIDH defines the first principal event in the development of an illness 
as: 
"A chain of causal circumstances, the `etiology', gives rise to changes in the 
structural or functioning of the body, the pathology" (World Health Organisation, 
1980). 
Pathology is any abnormality of microscopic, macroscopic, or biochemical 
structure or function affecting a tissue, an organ, or an organ system. An example is 
areas of peri-ventricular demyelination in the brain such as occur in multiple 
sclerosis. Pathology forms the basis of the ICD, and is the traditional focus of 
clinical medicine which concentrates on diagnosing the disease and curing it or 
reducing its progress. The theme of pathology can be further sub-divided at the 
level of organs, tissues, cells, and molecular structures. Measurements at the level 
of pathology usually involve laboratory testing (blood analysis, imaging, electro- 
diagnostic procedures, biopsies, etc. ), which are undertaken primarily for diagnostic 
reasons. 
1.2.2 Impairment 
The ICIDH defines impairment as: 
"any loss or abnormality of psychological, physiological or anatomical structure or 
function" (World Health Organisation, 1980). 
Impairment is the immediate consequence of the underlying pathology which 
relates to body structures or functions. It is the constellation of symptoms and signs 
that are used by clinicians to deduce the likely underlying pathology. Impairments 
can therefore be divided into two types: 
A). Subjective: the conscious manifestations of the disease as perceived by the 
patient (e. g. blurred vision, numbness, weakness, etc. ). 
B). Objective: the external manifestations of the disease as detected by the health 
care professional, which often have no personal meaning to the patient (e. g. afferent 
pupillary defect, impaired vibration sense, brisk tendon reflexes). 
Impairment describes the situation at a particular point of time, and can be 
temporary or permanent, intermittent or continuous, and progressive, regressive, or 
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static. It is often specific to a disease or a group of diseases. Consequently, many 
specific scales of disease severity measure impairment. Examples of impairment 
measures include visual acuity measures (Acheson and Sanders, 1995), the Scripps 
Neurological Rating Scale (Sipe et al., 1984), and thermal and vibration perception 
thresholds (Hughes et al., 1995). 
The ICIDH model predicts a close relation between pathology and impairment. 
However pathology may occur without impairment and impairment may 
occasionally occur without pathology (Figure 1.2). Some post mortem studies, for 
example, have shown widespread areas of demyelination typical of multiple 
sclerosis in people with no recorded appropriate symptoms or appropriate clinical 
findings during life (Gilbert and Sadler, 1983). Conversely, impairments related to 
tension headache are not usually associated with any demonstrable pathology 
(Wade, 1996). The nature, size, and the location of the pathological process is not 
always directly related to the degree of impairment. Non-fluent Broca's aphasia, for 
example, can be a manifestation of an infarct, a tumour, or an abscess affecting the 
posterior part of the inferior frontal gyrus of the dominant hemisphere. Similarly, 
patients with a large cerebral lesion load in multiple sclerosis may remain 
asymptomatic, whereas others with small plaques in the brain stem or the spinal cord 
may have devastating symptoms and signs (Thompson et al., 1990). Finally, spastic 
paraparesis may result from lesions affecting the forebrain, brain stem, or cervical / 
dorsal spinal cord. As techniques for detecting pathology become more sensitive, 
the weakness in the links between pathological processes and impairment is 
becoming more apparent. For instance, magnetic resonance imaging in patients with 
clinically isolated optic neuritis often demonstrates widespread asymptomatic 
abnormalities in other parts of the central nervous system (Morrisey et al., 1993). 
1.2.3 Disability 
The ICIDH defines disability as: 
"any restriction or lack (resulting from impairment) of ability to perform an activity 
in the manner or within the range considered normal for a human being" (World 
Health Organisation, 1980). 
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Disability is the functional loss which arises either as a direct consequence of 
the physical impairment or as a psychological response to its presence. It is 
characterised by functional limitation in performing customary activities or 
behaviours which arise at the level of the person's interaction with the immediate 
environment. Disabilities can be temporary or permanent, reversible or irreversible, 
and progressive, regressive or static. Examples include difficulties in reading, 
grooming, or stair climbing, or needing a stick or crutches to ambulate. Impairment 
is not always readily separated from disability. However as one moves from 
impairment to disability, the functional loss develops an increasingly more personal 
meaning to the patient. For example, when testing strength to determine the 
presence or absence of weakness, an impairment, the action of flexing the hip or the 
knee has no intrinsic purpose to the patient other than following the instructions 
given. However the same action becomes more meaningful at the level of disability 
when the patient experiences difficulties with walking or climbing stair. Disability 
is usually measured using clinical rating scales such as the Ambulation Index 
(Hauser et al., 1983), the Functional Independence Measure (Keith et al., 1987b), 
and the Barthel Index (Mahoney and Barthel, 1965). 
The ICIDH model predicts that the links between pathology and the nature 
and extent of disability are relatively weak (Figure 1.2). Many magnetic resonance 
imaging studies in multiple sclerosis have shown no (Thompson et al., 1990) or only 
a weak relationship (The IFNB Multiple Sclerosis Study Group and The University 
of British Columbia MS/MRI Analysis Group, 1995) between total lesion load, as a 
measure of pathology, and clinical disability. The ICIDH model, on the other hand, 
predicts a relatively close relation between impairment and disability (Figure 1.2). 
However this relation is complicated by many intervening variables, the most 
important of which are the situational factors and the psychological well being of the 
patient. Aids, equipment, environmental adaptations and environmental changes 
allow patients to function more independently despite unchanging impairments. For 
instance, independence in some activity such as walking or stair climbing may be 
achieved by the provision of a foot-drop splint or moving to single storey 
accommodation. Patients may also learn to fulfil their behavioural goals in other 
ways in the presence of static impairments. For instance, patients may learn to walk 
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despite the presence of weak or spastic lower limbs. The relation between specific 
impairments and specific disabilities is therefore not static and may vary over time, 
as adaptation occurs, and between patients depending on their motivation, 
adaptability, and opportunities. 
1.2.4 Handicap 
The ICIDH defines handicap as: 
"a disadvantage for a given individual, resulting from an impairment or a disability, 
that limits or prevents the fulfilment of a role that is normal (depending on age, sex, 
and social and cultural factors) for that individual" (World Health Organisation, 
1980). 
Handicap refers to the social consequences of impairment and disability, 
which arise at the level of the patient's own social roles and activities. It is reflected 
in the discordance between the patient's performance or status and the expectations 
of their social group. The distinction between disability and handicap therefore rests 
on the difference between performing tasks and performing roles (Bury, 1987). The 
most important distinguishing characteristic of handicap is that normality is judged 
with reference to the patient's own immediate social context (family, friends, 
neighbourhood, etc. ), whereas normality for pathology, impairment and disability is 
generally judged with reference to the population at large. The evaluation of 
handicap is dependent on the cultural norms, so that a person may be handicapped in 
one group but not in another. Examples of handicap include the loss of a job or 
earning as a consequence of the inability to walk. Handicap is usually measured 
with clinical rating scales such as the Environmental Status Scale (International 
Federation of Multiple Sclerosis Societies, 1985), or the London Handicap Scale 
(Harwood et al., 1994). 
The ICIDH model predicts that the relation between pathology, impairment, 
and handicap is weak in either direction (Figure 1.2). In practice, handicap can arise 
directly from impairment, or even from pathology without impairment or disability. 
For example, a hemianopia, an impairment, may be asymptomatic causing no 
disability to the patient, but once detected it might lead to disqualification from 
driving and thus enormous handicap. Another example is the presence of HIV 
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infection. Once this pathological finding has been detected, even in the absence of 
any impairment or disability, it can severely affect the person's life style leading to 
loss of job, inability to obtain life insurance, and social isolation. The link between 
disability and handicap is also weak compared with the strong links between 
handicap and various environmental factors such as social expectations and 
prejudices, legal framework, family support, physical environment and financial 
support, which have a major effect upon the final level of handicap (Figure 1.2). For 
instance, the legal environment determines the degree of handicap arising from the 
impairment of epilepsy which may be mild and cause little or no impairment or 
disability and yet prevent driving. Conversely some patients with severe disabilities 
are able to lead successful lives with minimal handicap. 
Within the handicap domain, and indeed within the impairment and the 
disability domains, abnormality is considered to be a reduction of some pre-existing 
state that has occurred as a result of the underlying pathology. Unemployment and 
poor housing are therefore not handicaps by themselves. It is the loss of a job or the 
deterioration in housing as a result of a disease, which constitutes the handicap. 
1.3 Difficulties with the ICIDH model 
The ICIDH model which intended to offer a comprehensive framework for 
the classification of human `disablement' has succeeded to a great extent in making 
a very complex problem easily understandable. However practical experience as 
well as theoretical considerations have shown that the application of the ICIDH in 
certain situations may be difficult (Bury, 1987; Thuriaux, 1995). Some of these 
difficulties are semantic. The terms used in this classification were not new and had 
already been used to describe the consequences of disease in slightly different 
contexts. The term `handicapped', for example, is used in the United States to 
describe people with disability in a pejorative way (Badley, 1993). The three basic 
constructs of `disablement' describe closely related theoretical entities and 
consequently they overlap. The distinction between impairment and disability can 
be particularly difficult, as in the case of aural, visual, and language impairments and 
communication disabilities. The distinction between disability and handicap can 
also be difficult because the description of what constitutes handicap, particularly in 
26 
relation to mobility, physical dependence, and orientation, is equally explained in 
terms of disability. A further source of ambiguity relates to the concept of social 
role and to the distinction between disability in various activities of daily living, 
such as housework, laundry, and shopping and the social roles which these activities 
form. The self-reporting required to assess some of the ICIDH measures creates a 
potential source of subjectivity. Finally it is always necessary to add the dimension 
of time to the description of `disablement' since the ICIDH is a record of a static 
position. 
It is therefore important for this model to be used flexibly, and for its users 
not to be bound rigidly by it. It should also be remembered that the ICIDH does not 
classify diseases but attempts to classify situations which are themselves fluid and 
changing, and excessive concerns with terminology and the problem of overlap 
should not interfere with the final goal of this model. 
In the light of these shortcomings, the WHO has started a global initiative 
aimed to revise the ICIDH with the help of multiple partners using a consensus- 
building exercise guided by the present scientific thinking and the practical needs of 
health science research. These efforts have produced the ICIDH-2, which is 
currently in a draft format awaiting finalisation in the year 2000 following the end of 
the ongoing field trials (World Health Organisation, 1997). The revised version has 
kept the same three-tier structure but employed a slightly modified terminology to 
avoid some of the problems outlined above. The new terms include impairment, 
activities limitation (to replace disabilities), and participation restriction (to replace 
handicap) (Figure 1.3). The ICIDH-2 has also acknowledged the complex 
interactions between these three basic constructs, and the various environmental and 
personal contextual factors. 
Despite its difficulties, the ICIDH remains the best framework available for 
health science research. It provides a comprehensive view of long term disease 
consequences and emphasises the importance of the multidisciplinary approach to 
patients' care. 
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Figure 1.3 The ICIDH-2 model illustrating the current understanding of the relation 
between its three dimensions (World Health Organisation, 1997) 
Health Condition 
(disorder / disease) 





1.4 Quality of life 
Participation 
restriction 
Quality of life is a universally recognised term whose origin is unknown and 
whose meaning remains difficult to define 
definition of health as: 
In 1947, the WHO adopted a broad 
it a state of complete physical, mental, and social well-being, and not merely the 
absence of disease and infirmity " (World Health Organisation, 1947). 
Two years later, Karnofsky and Burchenal (1949) expanded the criteria for 
evaluating success in cancer trials to include functional status, mood and general 
well being. The term `quality of life' appeared in Index Medicus 
in 1975, and a 
specific section was dedicated to it in 1977 (Smith, 1993). Since then, quality of 
life 
issues have become steadily more important in health care research and practice. 
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1.4.1 Definition 
Researchers from different disciplines have approached quality of life 
assessment from different perspectives, and have consequently used different 
definitions as appropriate for their own work. This is partly due to the fact that the 
construct of quality of life encompasses not only health-related factors but also many 
other non-medical aspects of life including standard of living, quality of housing and 
neighbourhood, job satisfaction, etc. The specific term `health-related quality of 
life' has therefore been advocated for use in the context of health science research 
(Gill, 1995; Testa and Simonson, 1996). An acceptable definition of health-related 
quality of life is: 
"The functional impact of an illness, and its consequent therapy, upon the patient, as 
perceived by the patient" (Schipper et al., 1990). 
Health-related quality of life has traditionally been assessed in three principal 
domains: physical, psychological and social (Smith, 1993). The physical domain is 
concerned with the effect of disease on patients' abilities to carry out their normal 
activities of daily living (e. g. daily functioning, pain, vitality and energy). The 
psychological domain deals with the emotional aspects of disease (e. g. perception of 
well being, self-esteem, anxiety, and depression). The social domain considers the 
impact of disease on patients' social activities (e. g. social interactions with family, 
friends, work colleagues, and within the community) (Devinsky, 1995). 
Health-related quality of life measures have an important role in controlled 
clinical trials in determining the positive impact of treatments, and perhaps more 
importantly, in assessing the potential negative effect of these treatments on patients' 
quality of life which other traditional outcome measures fail to capture. They also 
allow direct comparison between the social and economic burden of different 
diseases on society and the effect of their treatment. They can inform policy 
decisions concerning the allocation of health care funds by quantifying what they 
can buy in terms of quality of life, and thus providing some basis for cost benefit and 
cost utility comparisons. These measures are also important in obtaining qualitative 
information on patients' preferences and subjective perceptions, which may have a 




Health-related quality of life measures can be divided into two types: generic 
and disease-specific. 
A). Generic Instruments 
These measures are designed to be broadly applicable across different types 
and severity of diseases, medical interventions, and demographic and cultural 
groups, so as to permit comparisons across studies. These measures can be further 
divided into health profiles and utility measures. 
1). Health profiles 
These multi-dimensional measures combine several discrete scales, which 
quantify the major dimensions of health-related quality of life by means of patients' 
self-reports. They are particularly helpful in providing an assessment of the various 
areas, which may be adversely influenced by ill health in the form of a composite 
score. Examples of these measures include the Sickness Impact Profile (Bergner et 
al., 1981) and its British version the Functional Limitation Profile (Patrick et al., 
1985), the Nottingham Health Profile (Hunt et al., 1981), and the Short Form 36 
Health Survey Questionnaire (Garratt et al., 1993). 
2). Utility measures 
These measures are based on the idea that quality of life may be viewed as a 
uni-dimensional phenomenon. They attempt to gain a single index value of health 
status by eliciting patients' preferences for their health status. Typically, these 
measures are presented as a single number, or `utility', ranging from 0 (death) to 1 
(full health), which can be combined with the estimated life duration to derive 
`quality-adjusted life years' (QALY's = number of years lived X the quality of life 
experienced per year). Such measures are potentially useful in understanding 
relative treatment benefits in both the quantity and quality of life, and in comparing 
different health care programs by combining the two main effects of therapy, 
survival and quality of life. Examples of these measures include the Quality of Well 
Being Scale (QWBS) (Kaplan and Anderson, 1988), the Quality-Adjusted Time 
without Symptom and Toxicity Scale (Q-TWIST) (Gelber et al., 1992), and the 
EuroQol visual analogue scale (EuroQol Group, 1990). 
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B). Disease specific instruments 
These instruments concentrate on quality of life issues particular to a specific 
disease, and are therefore most appropriate for clinical trials in which specific 
therapeutic interventions are being evaluated. The list of disease specific health- 
related quality of life instruments is nearly endless (Patrick and Deyo, 1989), but 
they all share the disadvantage of not allowing for direct comparisons between 
different diseases. A desirable approach is to supplement a short generic instrument, 
such as the SF-36, by additional disease specific items to create a comprehensive 
measure, such as the Multiple Sclerosis Quality of Life - 54 Instrument (Vickrey et 
al., 1995b), and the Epilepsy Surgery Inventory - 55 (Vickrey et al., 1995a). 
1.5 Health-related quality of life and medical ethics 
The interpretation of health-related quality of life varies between doctors on 
one hand, and health economists and administrators on the other. Clinical medicine 
is concerned with disease sufferers and its ethical perspective is therefore 
deontological: to do the best for the patient regardless of cost. Public heath concern 
is to reduce the burden of disease suffered by the population and its ethical 
standpoint is therefore utilitarian: to do the greatest good for the greatest number 
(Ebrahim, 1995). Health-related quality of life measures may therefore be used by 
doctors to decide which of a range of possible treatments will bring about the most 
favourable `quality of life'. Ironically the same measures, particularly QALYs, may 
be used by health care administrators to discriminate between patients in 
competition for limited resources. The elderly and very sick are the most obvious 
losers. 
Advocators of the utilitarian approach commit a logical error by failing to 
notice the important distinction between the `quality' of life and the `value' of life. 
They assume that the `value' of human life is not fixed but varies according to age, 
ability, and social status. The idea that human beings are unique and have qualities 
that cannot be measured is not considered. A person may be twenty or ninety, but 
their existence as a human being is equally important. The assumption that `if a 
person's quality of life decreases then the value of this person's life must 
proportionally decrease' is therefore fundamentally wrong (Seedhouse, 1994). The 
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uncertainty about the validity and the precision of these measures should also be 
considered. It is difficult, if not impossible, to be certain about how long people will 
live, or to judge whether one patient's suffering and pain is the same as another. 
Health-related quality of life calculation depends on difficult concepts and 
considerable assumptions, and their interpretation therefore requires cautious 
consideration. 
1.6 Health-related quality of life and the ICIDH 
One of the main justifications of using health-related quality of life measures 
is their intrinsic value in giving a patient-centred, rather than a physician-centred, 
view of disease consequences. Clinician-oriented outcome measures fail to address 
the subjectively assessed aspects of health status such as pain, vitality, and general 
well being, and may therefore provide an incomplete picture of the impact of illness 
on patients. Theoretically, health-related quality of life measures provide a more 
uniform method of administration (self-administration) and may therefore reduce 
observer bias and variability. In reality, health-related quality of life assessment is 
difficult to standardise because of the multiplicity of ways in which different 
individuals perceive, respond, and adapt to their illness. These measures are 
inherently subjective and may therefore be more difficult to be used in patients with 
psychological or cognitive impairment. This is particularly important since many 
patients with disabling neurological diseases have considerable deficits in both 
cognitive skills and emotional control (Wade, 1996). The ICIDH model, on the 
other hand, has the virtues of simplicity, comprehensiveness and international 
recognition. It provides an objective assessment of the health status, which is based 
on directly observable or easily ascertainable dimensions. Its self-reporting 
elements are not based on value judgements and can therefore be verified against a 
detailed history obtained from the patients, their families, close friends or carers. 
Where does health-related quality of life fit into the ICIDH model? There is 
no consensus in the literature on how to incorporate these two concepts (Gill, 1995; 
Wade, 1996; Hobart et al., 1996a). It has been suggested that health-related quality 
of life might be viewed as the final common pathway of impairment, disability and 
handicap, or as an `umbrella' which embodies these three measures (Ebrahim, 
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1995). In practice, health-related quality of life measures comprise a collection of 
items which reflect the impairment (pain, anxiety, etc. ), disability (inability to walk 
or climb stairs, etc. ), and handicap (inability to keep a paid job, etc. ) elements of 
health as perceived by the patient. In multiple sclerosis, objective impairment and 
disability assessments by clinicians using the Expanded Disability Status Scale 
(Kurtzke, 1983) correlate closely with patients' self-assessment of their own 
physical disablement using the physical functional domain of the Short Form 36 
Health Survey Questionnaire (r = 0.87) and the Functional Limitation Profile (r = 
0.77), but not with the overall health-related quality of life as measured with 
EuroQol (Hutchinson and Hutchinson, 1995; Rothwell et al., 1997). 
Health-related quality of life and the ICIDH are therefore better viewed as 
representing the subjective and objective sides of the health status (Hughes and 
Sharrack, 1998). They offer different but complementary and equally important 
accounts of health status. By augmenting rather than replacing one another, they 
could contribute to a more comprehensive outcome assessment (Figure 1.4). 
Figure 1.4 Conceptual scheme representing the relation between the three domains 
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1.7 Conclusion 
The comprehensive approach of the ICIDH has provided a successful model 
for understanding the differences between patients who have the same pathology but 
different impairments, disabilities, and handicaps. Health-related quality of life 
measures have incorporated the patients' distinctive values into the assessment 
process. The ICIDH and health-related quality of life measures represent the 
objective and the subjective sides of the health status. Together they provide a 




PATHOLOGY AND DISABLEMENT IN MULTIPLE SCLEROSIS 
2.1 Introduction 
Multiple sclerosis is a chronic disabling disease which affects approximately 
0.1 % of Caucasians of north and central European ancestry (Sadovnick et al., 1996). 
It is the most common cause of chronic neurological disability in young adults 
(Freeman et al., 1996; Thompson, 1996a). Diagnostic criteria define the age of 
onset as 10 to 59 years (Poser et al., 1983), but in the majority of cases the onset is 
between the age of 20 and 40. Females are affected 2 times more often than males 
(Compston, 1998). Most patients become disabled as the disease progresses, with 
approximately 50% requiring walking aids or the use of wheelchairs within 15 years 
of onset (Weinshenker, 1994). Despite this, life expectancy is not substantially 
altered by this disease. The mean survival is reported to ranges between 25 and 35 
years in various series (Poser et al., 1989) 
There is presently no cure for multiple sclerosis. Treatment of affected 
individuals has relied for a long time on supportive care, management of 
complications such as limb spasticity, bladder instability and infections, together 
with occasional courses of oral or intravenous corticosteroids during periods of acute 
deterioration (Ebers, 1994). More recently, a steady flow of new potentially 
effective agents have emerged with data resulting from phase II and III studies 
claiming effectiveness in reducing the number of relapses, or modifying the natural 
history of disease progression (Thompson and Noseworthy, 1996). 
2.2 Pathology 
The pathological hallmark of multiple sclerosis is the presence of multiple 
foci of demyelination, or plaques, in the central nervous system. Such plaques have 
a predilection for certain regions especially the periventricular areas, corpus 
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callosum, optic nerves, and the spinal cord (Moor, 1998; Lassmann, 1998). Acute 
plaques are characterised by focal areas of myelin loss with extensive infiltrates of 
lipid laden macrophages, lymphocytes, monocytes and reactive astrocytes, and 
intense perivascular cuffs of lymphocytes and monocytes (Raine, 1991). Significant 
degrees of axonal damage and oligodendroglial proliferation and remyelination are 
also frequently seen (Trapp et al., 1996; Lassmann, 1998). Chronic active plaques 
show a gradient of pathological changes. The central regions reflect older events 
whereas the borders show evidence of ongoing active demyelination and attempts at 
remyelination (Moor, 1998). Chronic silent plaques are relatively acellular, with 
complete demyelination, gliosis, and axonal loss (Moor, 1998). 
2.3 Pathophysiology 
The presence of demyelination, and to some extent inflammation, can cause 
conduction slowing or block in the affected axons which account for the acute 
deficits that characterise the early years of the disease (Ffrench-Constant, 1994). 
Recovery from these acute relapses has several mechanisms including the resolution 
of oedema and inflammation, remyelination, restoration of conduction in persistently 
demyelinated fibres by the insertion of new sodium channels into the internodal 
membrane, and cortical readaptation (Moll et al., 1991; McDonald, 1998). 
Irreversible deficits may be due to failure of the demyelinated fibres to restore 
conduction, or axonal loss which accounts for the progressive increase in disability 
that characterise the later stages of the disease. 
2.4 Aetiology 
The cause (s) of multiple sclerosis remains unknown. The evidence suggests 
that environmental, genetic, as well as immunological factors play part in the 
aetiology. Multiple sclerosis has a non-random geographical distribution with high 
prevalence rates in temperate latitudes of both northern and southern hemispheres. 
This gradient distribution often represent genetic variation within the population 
(Ebers and Sadovnick, 1993), but the seven fold difference between southern New 
Zealand and Tasmania (high prevalence) and northern Queensland (Low prevalence) 
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in ethnically similar populations points strongly to environmental factors (Hammond 
et al., 1988). The nature of these factors remains uncertain. 
Evidence for genetic susceptibility comes from three observations. Firstly 
the prevalence of multiple sclerosis varies between various ethnic groups, being high 
in Northern European Caucasians and low in Native and Black Americans and 
Asians even when they live in high prevalence areas (Kurtzke et al., 1979). 
Secondly the presence of specific Major Histocompatibility Complex class II 
associations especially with DRw15 and DQw6 in North Europeans (Olerup and 
Hillert, 1991). Thirdly the high concordance rate in monozygotic twins (25-31%) 
(Sadovnick et al., 1993; Mumford et al., 1994). The observation that an increased 
concordance rate is not seen in adoptive siblings also suggests that familial cases are 
due to shared genetic susceptibility rather than shared environment (Ebers et al., 
1995). Several susceptibility genes have been found to play a part, but their nature 
is not fully elucidated (Compston, 1998). 
The evidence that multiple sclerosis is an autoimmune disease is strong but 
circumstantial. A widely held view is that the immediate cause of the pathological 
process is an aberrant T-cell mediated immune response to a variety of myelin 
antigens which circulate in the blood of multiple sclerosis patients (Utz and 
McFarland, 1994). When activated, helper T-cells cross the blood-brain barrier to 
the central nervous system, under the influence of adhesion molecules, where they 
interact with specific antigens presented by the Major Histocompatibility Complex 
class II molecules on macrophages and astrocytes. This interaction results in 
cytokine secretion (tumour necrosis factor-a and interferon-y), T-cell proliferation, 
B-cell and macrophage / macroglia activation and synthesis of inflammatory 
mediators causing breakdown of the blood brain barrier (Hartung et al., 1995). 
Autoantibodies directed to myelin antigens cross the damaged blood brain barrier, or 
are locally produced by B-cells which have been stimulated by the T-cells, 
activating the complement system and leading to wide spread oligodendrocyte death 
and subsequent demyelination (Ffrench-Constant, 1994). Results from therapeutic 
trials with immunomodulatory agents support this concept since treatments that 
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augment immune function have exacerbated disease activity whereas 
immunosupressive drugs have produced modest clinical benefits (Goodkin, 1994). 
2.5 Clinical Course 
The clinical course of multiple sclerosis is highly variable. It ranges from a 
fulminating disorder which can be fatal within months, Marburg's disease 
(Weinshenker, 1994), to an asymptomatic condition which is only recognised 
incidentally at autopsy (Gilbert and Sadler, 1983) or by magnetic resonance imaging 
in the asymptomatic monozygotic co-twins of multiple sclerosis patients (Sadovnick 
et al., 1993). The most commonly observed clinical course is characterised by 
episodes of acute periods of worsening (relapses, exacerbations, bouts, attacks), 
gradual progressive deterioration of neurological function, or combinations of both. 
A recent international survey of 215 leading clinicians involved with multiple 
sclerosis revealed general consensus about four different clinical courses (Lublin and 
Reingold, 1996): 
A). Relapsing remitting multiple sclerosis 
The disease course is characterised by clearly defined relapses with full 
recovery or with residual deficit upon recovery. Periods between relapses are 
characterised by the lack of disease progression. 
B). Primary progressive multiple sclerosis 
The disease course is characterised by a progressive phase from onset with or 
without occasional plateaus and temporary minor improvements. 
Q. Secondary progressive multiple sclerosis 
The disease course is characterised by initial relapsing remitting phase which 
is followed by progression with or without occasional relapses, minor remissions or 
plateaus. 
D). Progressive relapsing multiple sclerosis 
The disease course is characterised by a progressive phase from onset with 
clear acute relapses which may be followed by partial or full recovery. Periods 
between relapses are characterised by continuing progression. 
In the majority of cases (60%), multiple sclerosis runs a relapsing and 
remitting course which culminates ultimately in a secondary progressive phase 
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(Weinshenker, 1994). In 15-20% of cases, the illness runs a `benign' course with 
relatively few attacks early on but without developing any, or with very little, 
permanent disability. Primary progressive multiple sclerosis accounts for 15% of all 
cases (Weinshenker, 1994). This variability presents researchers with major 
problems when assessing whether an apparent improvement in an affected individual 
represents a true response to a therapeutic intervention, or simply a natural remission 
which would be experience with the passage of time. 
2.6 Diagnostic criteria 
A diagnosis of multiple sclerosis is based on evidence of two or more lesions 
in the central nervous system, dissociated in both space and time. To ensure 
diagnostic uniformity for clinical research studies, several diagnostic criteria have 
been suggested. The Poser criteria are currently the most widly used (Poser et al., 
1983). According to these criteria, the diagnosis of multiple sclerosis is classified as 
clinically definite, laboratory supported definite, clinically probable, or laboratory 
supported probable based on the number of relapses experienced by the patient (one 
or more), the evidence on clinical examination of abnormal signs suggestive of the 
presence of one or more anatomically unrelated lesions in the central nervous 
system, the presence of paraclinical evidence (evoked potentials or magnetic 
resonance imaging) of central nervous system abnormalities suggestive of 
demyelination, and the presence of oligoclonal gammaglobulin banding in the 
cerebrospinal fluid. 
2.7 Symptoms and signs 
Plaques of demyelination can occur virtually anywhere in the central nervous 
system and in those cranial nerves (olfactory, optic, and auditory) in which the axons 
are supported by oligodendrocytes. The spectrum of the clinical features can 
therefore be extremely diverse although there are some reasonably predictable 
clinical presentations with variable combinations of visual, motor, sensory, and 
autonomic abnormalities. The severity of the symptoms and clinical signs is often 
related to the location rather than to the extent of the pathological process. 
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2.7.1 Initial symptoms 
The onset of multiple sclerosis is mono-symptomatic with symptoms 
referable to a single anatomical site or system in approximately 50% of patients 
(Matthews, 1991). Weakness of one or more limbs is present at onset in 20-40% of 
patients, and this is often accompanied by dysaesthesiae or sensory loss (McAlpine 
D, 1972; Weinshenker et al., 1989b; Matthews, 1998). The initial symptoms are 
mainly sensory in about 20-45% of the cases (Weinshenker et al., 1989b; Matthews, 
1991). Optic neuritis is present at onset in 17-25% of patients (Shibasaki et al., 
1981; Weinshenker et al., 1989b). Limb ataxia and impaired balance occur in about 
13% (Weinshenker et al., 1989b), diplopia in about 12% (McAlpine D, 1972; 
Weinshenker et al., 1989b), and vertigo in about 5% of cases (McAlpine D, 1972). 
More unusual presenting features e. g. epilepsy, facial palsy, retention of urine, or 
paroxysmal symptoms are present at the onset is about 5% of the patients and, if in 
isolation, their significance is often unrecognised (Matthews, 1991). 
2.7.2 Symptoms and signs during the course of the illness 
The mass of the published material on the clinical features during the course 
of multiple sclerosis consists largely of lists of the symptoms and signs encountered 
by patients in different series during the course of the disease. In two of such series, 
the results were similar. 
A). Poser's series 
Poser and co-workers reported large series of 1271 hospital patients with a 
mean age of 31.1 years and a mean disease duration of 11 years (Poser et al., 1979). 
Signs of upper motor involvement were present in 80% of the patients, weakness in 
78%, sensory change in 73%, optic nerve signs in 48%, ocular signs in 14%, 
brainstem and cerebellar involvement in 77%, cerebral (mainly mental) 
abnormalities in 36%, and autonomic disturbance, mainly sphincter disturbance, in 
56%. 
B). Shibaski 's series 
Shibaski and co-workers published the clinical features of a series of 204 
British and 60 Japanese hospital patients, with a mean age of 42 and 39 years and a 
mean disease duration of 11 and 8 years respectively (Shibasaki et al., 1981). Both 
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population groups showed the same preponderance of weakness (80% and 80% 
respectively), paraesthesiae (84% and 77%), sphincter disturbance (74% and 58%), 
ataxia (48% and 58%), optic atrophy (71% and 70%) and diplopia (39% and 35%). 
Notable differences were seen in dysphagia (3% and 23%), tonic seizures (4% and 
28%) and Lhermitte's sign (15% and 42%). 
These and other similar studies (Kurtzke, 1970; Shepherd, 1979) have 
provided important information on the clinical features of multiple sclerosis, but the 
great majority were related to hospital-based patients and none has included all 
potential patients in a defined population. These studies are likely therefore to have 
missed many patients with mild or severe diseases. An entirely accurate account of 
the symptoms and signs could only be compiled from series of a large 
geographically defined population studies of clinically or laboratory definite cases 
minutely observed over the whole course of the disease. Such studies are not 
available, and in default of such unattainable data the best alternative is cross 
sectional surveys of population-based cohorts. Swingler and Compston conducted 
such a study. 
Q. Swingler and Compston 's series 
Swingler and Compston described the frequency and spectrum of morbidity 
of multiple sclerosis in Southern Glamorgan County in South Wales (population of 
376,718) (Swingler and Compston, 1992). A total of 441 patients were identified 
through thorough case ascertainment, of whom 301 (68%) were seen and assessed. 
Three hundred and eighteen patients (71%) of the original cohort had clinically or 
laboratory supported definite multiple sclerosis and 42 patients (9%) had clinically 
or laboratory supported probable multiple sclerosis. The patients were interviewed 
and examined using a standard performa which was designed to collect information 
concerning demographic characteristics, symptoms, signs, the Expanded Disability 
Status Scale (EDSS) and its Functional Systems (Kurtzke, 1983) and the Ambulation 
Index (Hauser et al., 1983). The patients had a mean age of 48.7 years (range 10- 
85), a mean disease duration of 16.5 years, and a mean EDSS score of 5.0. 
1). Symptoms 
During the month before assessment, weakness was the most common 
complain having been reported by 80% of the patients, followed by sensory 
41 
disturbance, ataxia, bladder symptoms, fatigue, cramps, altered bowel functions, 
dysarthria, blurred vision, poor memory, diplopia, dysarthria, and vertigo (Table 
2.1). 
Table 2.1 Frequency (%) of symptoms in the MS population of South Glamorgan 
(n=301) 
Symptom At any time At onset At prevalence Persistent 
Weakness 89 22 80 62 
Sensory 87 34 73 52 
Ataxia 82 11 72 58 
Bladder 71 1 62 45 
Fatigue 57 2 48 31 
Cramps 52 0.6 44 26 
Diplopia 51 8 26 18 
Visual 49 13 33 23 
Bowel 42 0 37 19 
Dysarthria 37 0.6 25 16 
Vertigo 36 4.3 19 13 
Facial pain 35 2 14 9 
Poor memory 32 0.3 27 0 
Headaches 30 2 17 7 
Neuropsyciatric 23 0.3 16 7 
Deafness 17 0.6 13 8 
Facial weakness 16 1 5 3 
Dysphagia 13 0.3 10 5 
Skin sores 12 0 7 4 
Blackouts 11 0.6 4 2 
Agonise 6 0.3 2 0.3 
Others 10 1 8 5 
The tendency for impairments to accumulate with time was illustrated by the 
increasing frequency of complaints between onset and assessment day. Most 
symptoms had become two and six times more common 
by prevalence day, but 
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fatigue, cramp, sphincter disturbance, dysarthria, cognitive, and emotional problems 
showed disproportionate increases in frequency during the course of the illness. 
Symptoms of longer duration were recorded most commonly at onset. These 
symptoms included weakness (14.4 years), diplopia (14 years), sensory disturbance 
(13.1 years), ataxia (12.5 years), and blurred vision (12 years). Symptoms of shorter 
duration were commonly associated with the later stages of the disease. These 
symptoms included memory impairment (6.2 years) dysphagia (6.4 years), pressure 
sores (6.4 years), bowel dysfunction (6.0 years), bladder disturbance (8.1 years), and 
spasticity (8.3 years). 
2). Signs 
The most common finding in this survey was a defect of visual function 
(92%). Seventy-two percent of the patients had corrected visual acuity in one or 
both eyes of 6/9 or less, 26% had field defects, and 48% had nystagmus. Twenty- 
one percent of the patients had dysarthria, 6% had facial weakness and 6% had 
bulbar weakness and dysphagia. Limb weakness was seen in 74% of the patients 
ranging from monoparesis (7%) to quadriparesis (26%). Seventy-eight percent of 
the patients had evidence of sensory abnormality of the limbs. 
3). Mobility 
Sixty-nine percent of the patients in this survey were able to stand, 48% were 
able to walk unaided, 30% required a stick, crutches or a walker, 22% were 
wheelchair bound and only 25% walked with a normal gait. More detailed 
assessment was obtained by using the Ambulation Index which showed that only 
21% were asymptomatic and fully active. A further 28% reported symptoms but 
were able to walk 25 feet in<_ 20 second, 27% required unilateral or bilateral support 
and 23% were wheelchair bound half of whom were unable to transfer. 
As judged by the EDSS, a total of 22.6% of the patients were either free from 
the manifestations of the disease or had a minimal deficit, 25% had moderate 
dysfunction but were able to walk independently, 23% suffered a mixture of 
moderate and severe impairments and required regular assistance for walking, 16% 
were essentially wheelchair bound and 13% were severely impaired or restricted to 
bed. 
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2.8 Impairment, disability, and handicap 
To plan and evaluate the required services for the affected individuals with 
multiple sclerosis, it is important to characterise carefully the needs of these patients 
in a population-based cohorts. Few studies have assessed the degree of impairment 
in such cohorts as detected by the EDSS but without utilising other measures of 
disability and handicap (Weinshenker et al., 1989a; Weinshenker et al., 1989b; 
Runmarker and Andersen, 1993). Only two studies have assessed the degree of 
impairment, disability, and handicap in a comprehensive manner (Rodriguez et al., 
1994; Midgard et al., 1996). The results of these two studies were similar, and I will 
therefore only review the results of Mayo Clinic study (Rodriguez et al., 1994). 
In this study, all known cases of multiple sclerosis in Olmsted Country, 
Minnesota, USA (population of approximately 100,000) were identified via the 
computerised centralised index at the Mayo Clinic (Rodriguez et al., 1994). A total 
of 162 patients with a median age of 47.5 (range 17-87), median disease duration of 
15.4 years and a median EDSS of 3.5 (range 1-9.5) were identified and assessed. 
Ninety-four percent of the patients had clinically definite multiple sclerosis. Patients 
were assessed using the Minimal Record of Disability (International Federation of 
Multiple Sclerosis Societies, 1985) which included the EDSS as a measure of 
impairment, the Incapacity Status Scale as a measure of disability, and the 
Environmental Status Scale as a measure of handicap. The study therefore provided 
a cross sectional analysis of the level of impairment, disability and handicap in this 
cohort. 
A). Impairment 
The results of the neurological assessment using the EDSS Functional 
Systems are shown in Table 2.2. Thirty-three percent of the patients had marked 
paraparesis, paraplegia, hemiplegia or quadriparesis (pyramidal scores 3 to 6), 
13.0% showed moderate or severe truncal or limb ataxia or severe ataxia of all limbs 
(cerebellar scores 3 to 5), 12.9% showed severe extra-ocular muscle weakness, 
dysarthria or dysphagia (brain stem scores 3 to 5), 22.2% showed loss of vibration, 
proprioception or pain sensation (sensory scores 3 to 6), 24.7% had frequent urinary 
incontinence, a need for almost constant catheterisation, or needed constant 
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measures to evacuate stools (bowel and bladder scores 3 to 6), 9.3% had corrected 
visual acuity worse than 6/36 in either eye (visual scores 4 to 6), 3.7% had severe 
decrease in mentation or dementia (mental scores 4 and 5) and 27.2% had severe 
spasticity that resulted in major interference with function (spasticity score 3). 
Table 2.2 Neurological impairment (%) in the Mayo Clinic study as assessed by the 
Kurtzke's Functional Systems (n = 162) 
Grade 
Functional Systems 0123456 NA 
Pyramidal 15.4 17.9 15.4 17.9 13 16.7 3.7 0 
Cerebellar 38.9 16.0 25.9 9.3 3.7 0 - 6.2 
Brain stem 45.7 22.8 17.3 8 4.3 0.6 - 1.2 
Sensory 30.2 22.8 18.5 15.4 4.9 1.9 0 6.2 
Bowel & bladder 27.2 25.9 21.6 8 13.6 0.6 2.5 0.6 
Visual 16.7 37 27.2 6.2 3.1 3.1 3.1 3.7 
Mental 49.4 29 13 4.3 2.5 1.2 - 0.6 
Others (spasticity) 45.7 14.2 13 27.2 - - - - 
B). Disability 
The results of the constructed interview using the Incapacity Status Scale are 
shown in Table 2.3. The study showed that 58% of the patients needed assistance 
with stair climbing or were unable to perform this task (scores 2 to 4). Walking aids, 
orthoses or wheelchairs were required for locomotion in 41.4 % of the cases (scores 
2 to 4). Most patients reported normal or minimal problems with bowel (71%) or 
bladder function (51.9%) (scores 0 and 1). Human assistance (scores 3 and 4) was 
reported as necessary for various activities of daily living including bathing (22.8%), 
dressing (20.3%), grooming (13.6%), and feeding (8.7%). A minority of patients 
(11.7%) reported being able to read only very large print (score 3) or were legally 
blind (score 4). Dysarthria interfering with communication (score 2 to 4) was 
reported by 13.5% of patients. A minority of patients (4.3%) had mood or thought 
disturbance that required psychotherapy or hospitalisation (score 3 or 4). 
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Disturbance in mentation enough to interfere with everyday activities (score 2 to 4) 
were reported by 18.6% of patients. Many patients (43.3%) complained of fatigue 
troublesome enough to cause impairment of functioning (score 2 to 4). Most patients 
(62.3%) reported no difficulties with their sexual function. 
Table 2.3 Neurological disability (%) in the Mayo Clinic study as assessed by the 
Incapacity Status Scale (n = 162) 
Categories 0 1 
Grades 
2 3 4 
Stair climbing 28.4 13.6 31.5 3.7 22.8 
Ambulation 51.9 6.8 13 9.3 19.1 
Transfer 50.6 17.9 13.6 6.2 11.7 
Bowel function 49.4 22.2 11.1 15.4 1.9 
Bladder function 27.2 24.7 21 20.4 6.8 
Bathing 43.2 15.4 18.5 11.7 11.1 
Dressing 47.5 21.6 10.5 8.6 11.7 
Grooming 62.3 19.1 4.9 7.4 6.2 
Feeding 56.6 20.4 12.3 5.6 3.1 
Vision 45.1 37 6.2 8 3.7 
Speech and hearing 55.6 30.9 12.3 0 1.2 
Medical problem 54.3 28.4 14.2 1.9 1.2 
Mood and thought 39.5 43.8 12.3 4.3 0 
Mentation 57.4 24.1 9.9 5.6 3.1 
Fatigability 23.5 33.3 27.2 10.5 5.6 
Sexual function 62.3 9.3 8.3 8.6 11.1 
Q. Handicap 
Most patients (53.1%) were working full time. Sixty percent of men and 
45% of women were employed (97.5% of the patients were employed before disease 
onset). A minority of the patients (15.4%) identified themselves as unemployed, not 
having any housework, or not attending school. Most patients (77.1 %) were able to 
maintain their usual financial standard without external support. No or only minor 
personal assistance was required in 62.4% of the patients. Community services 
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(including seeing a doctor, nurse, physiotherapist, social worker, and home help) for 
more than one hour per week were needed by a very small number of patients 
(19.8%). Most patients reported normal or minimal difficulties with social activities. 
This study demonstrated that the functional status of patients with multiple 
sclerosis was more favourable than previously recognised. Approximately one-third 
of the patients had marked paraparesis, paraplegia, or quadriplegia, less than one- 
fourth needed intermittent or almost constant catheterisation for bladder dysfunction, 
and only few patients had severe cognitive impairment requiring supervision. 
2.9 The economic implications of multiple sclerosis 
Multiple sclerosis is very costly to the individual, health care system, and 
society. Studies attempting to calculate the true cost of this disease have considered 
the direct healthcare costs in terms of hospital care, drugs, and long-term care, and 
indirect costs in terms of loss of production due to morbidity and premature 
mortality (Jonsson and Henriksson, 1998). Based on the 1994 data, the annual cost 
of multiple sclerosis in the United States was estimated at over $34,000 per person, 
translating into a conservative estimate of national annual cost of $6.8 billion, and a 
total lifetime cost per case of $2.2 million (Whetten-Goldstein et al., 1998). Much 
of the cost (57%) was in the form of burdens other than direct personal health care, 
including loss of earning, the cost of formal and informal care. At least three studies 
addressing the cost of multiple sclerosis in the UK have been published (O'Brien, 
1987; Holmes et al., 1995; Blumhardt and Wood, 1996). Hospital costs were found 
to dominate the direct cost and in all studies, with the indirect costs far outweighing 
direct costs (Table 2.6). 
The cost of multiple sclerosis, both direct and indirect, increases with the 
severity of the disease as measured by the EDSS (The Canadian Burden of 
Illness 
Study Group, 1998). The burden of this disease in terms of long-term care is also 
considerable. In a recent study of community care for severely 
disabled people in 
the UK, patients with multiple sclerosis were found to receive the highest number of 
weekly hours of care at home from formal sources such as 
district nurses, local 
authority home help, private agencies and voluntary organisations 
(Phillips, 1995). 
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Table 2.4 Cost (£ million) of multiple sclerosis in the UK 
Cost 1986/19871 1993 / 1994 2 1994 3 
Direct costs 18.2 23.2 73.9 
Hospital 14.2 19.0 67.3 
GP 1.7 2.1 4.6 
Drugs * 2.4 2.1 2.0 
Indirect costs 100.0 250.1 395.0 
Total (f million) 118.2 273.2 468.9 
Study 1 (O'Brien, 1987) and study 2 (Blumhardt and Wood, 1996) included England and 
Wales only; study 3 (Holmes et al., 1995) included the entire UK; * Values were taken 
before the introduction of interferon beta 
2.10 Conclusion 
Multiple sclerosis is the most common cause of chronic neurological 
disability in young adults. The disease course is variable and unpredictable although 
progressive in nature. Classically, it begins with a relapsing and remitting course 
which progresses subsequently into a progressive phase with a gradual accumulation 
of wide ranging and often complex disabilities. This results in a major burden of 
suffering for patients and their families and makes substantial demands on health, 
social, and voluntary services. 
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Chapter 3 
THE EVALUATION OF NEUROLOGICAL OUTCOME MEASURES 
USED IN MULTIPLE SCLEROSIS 
3.1 Introduction 
Outcome measures allow the classification of patients according to the 
presence and severity of the disease process (pathology), the resulting disablement in 
terms of the clinical condition of the affected individuals (impairment), their 
functional capacity (disability / activities limitation), and their social disadvantages 
(handicap / participation restriction), or according to their subjectively perceived 
health related quality of life (Hughes and Sharrack, 1998). The choice of specific 
outcome measures in clinical trials depends on the nature of the study and the 
research hypothesis being tested, and on the psychometric properties of these 
measures. In phase II studies, which are designed to assess the biological effects of 
therapeutic interventions on patients, a measure of pathology or impairment would 
be appropriate. In phase III studies, which are designed to assess the clinical effect 
of therapeutic interventions on the functional capacity of patients, a disability, 
handicap, or health related quality of life measure would be more desirable. 
Regardless of their conceptual nature, the practical value of any outcome 
measure depends on its clinical usefulness and on its scientific integrity (Table 3.1). 
A clinically useful instrument must be appropriate for the research hypothesis being 
tested, acceptable to patients and clinicians, practical to administer, and cost 
effective (Whitaker et al., 1995). As clinical usefulness does not guarantee scientific 






Table 3.1 Desirable attributes of clinical outcome measures 
Desirable attributes Explanation 
Practical attributes 




The instrument should be easy and quick to administer by any health 
care personnel 
The instrument should be user friendly and should achieve high levels 
of clinician and patient compliance 
The instrument should be economical of time and resources 
Reliability The instrument should be internally consistent and able to generate 
reproducible scores when applied by the same (intra-) or different 
(inter-rater) observers or by the same patient (test-retest 
reliability) in the case of self-administered instruments 
Validity The instrument should be able to measure what is intended to be 
measured 
Responsiveness The instrument should be able to detect clinically significant change 
over an appropriate period of time 
Appropriateness The instrument should be able to discriminate between patients with 
differing degrees of disease severity, and should have no `ceiling' or 
`floor' effects 
3.2 Reliability 
Reliability considers whether an instrument is capable of producing 
measurements which are consistent, accurate, and reproducible. There are two 
forms of reliability: internal consistency and score reproducibility. 
3.2.1 Internal consistency 
Internal consistency assesses the homogeneity of multidimensional scales by 
measuring the extent to which their items measure the same concept. If items were 
chosen without regard for homogeneity the resulting scale could end up tapping 
different traits. However if the correlation between these items is too high, some of 
them may be redundant. One of the oldest methods of assessing homogeneity is 
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item-total correlation which assesses the correlation between an individual item and 
the rest of the scale after omitting this particular item. The usual `rule of thumb' is 
that each item should have a correlation coefficient with the total score of > 0.2 
(Streiner and Norman, 1995c). Items which do not achieve this target should be 
discarded. Another approach is the `split-half reliability' in which the scale is 
randomly divided into two sub-scales which are then correlated with each other. As 
there are many ways to divide the items of a scale, Cronbach devised a method, 
called Cronbach's alpha, which gives an average of all the possible split-half 
reliabilities of a scale (Cronbach, 1951). The value of Cronbach's alpha should be 
above 0.70 but not higher than 0.90. 
3.2.2 Reproducibility 
Reproducibility addresses the stability of the scores when the scale is 
administered on different occasions by the same (intra-rater reliability) or by two 
different observers (inter-rater reliability), or by the same patient (test-retest 
reliability) in the case of self-report instruments. Reproducibility assesses the degree 
of random error which could be attributed to the measure itself, the person doing the 
measurement, or to the person being measured. It is necessary therefore to examine 
each type of these random errors separately for a comprehensive evaluation. 
Reproducibility is assessed by examining the correlation between the scores 
of two independent observations provided that the patient's clinical status has 
remained stable in between. There has been considerable debate in the literature 
about the most appropriate statistical method for assessing reproducibility. 
A). Pearson correlation coefficient 
This coefficient is based on regression analysis (Norman and Streiner, 
1993e). It measures the extent to which the relationship between two variables can 
be described as a straight line, the regression line, regardless of the intercept value. 
This coefficient does not differentiate between random and bias errors and tends to 
give high correlation values as long as there is a constant relation between the two 
variables. It is also affected by the range of the variables so that the wider the range 
the higher the correlation even if agreement remains the same (Streiner and Norman, 
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1995b). The Pearson correlation coefficient is therefore inappropriate as a measure 
of reproducibility. 
B). Percentage of agreement 
The simplest way to assess agreement is to calculate the proportion of paired 
responses in which the two observations are identical. Although simple, this method 
is strongly influenced by the distributions of the observations so that a 
preponderance of particular values may achieve high agreement by chance alone 
(Streiner and Norman, 1995b). The method is only appropriate for dichotomous and 
categorical scales. 
Q. Bland and Altman method 
This method was initially designed to assess the agreement between two 
outcome measures and is capable of separating rater bias from random error (Bland 
and Altman, 1986). It illustrates rater bias graphically by plotting the difference 
between each pair of observations against their mean. It also allows the calculation 
of the `limits of agreement' (equal to the mean score difference +/- twice the 
standard error of measurement, i. e. the 95% confidence intervals of the mean score 
difference), and the `repeatability coefficient' (1.96 times the standard deviation of 
the mean score difference). The latter coefficient, which has been used by the 
British Standard Institute as a measure of the reliability of scientific measurements, 
is an indication of the maximum score difference required to achieve 95% rater 
agreement (British Standards Institution, 1979). 
D). Kappa coefficient 
This coefficient was suggested by Cohen to correct for the effect of chance 
agreement on rater reliability by examining the proportion of total agreement 
responses in relation to those agreement responses which will 
be expected by chance 
only (Cohen, 1960). This coefficient is only appropriate 
for dichotomous and 
categorical scales, or ordinal scales which have a small number of possible scores. 
E). Weighted kappa / interclass correlation coefficient 
Kappa coefficient only considers total agreement and does not give any 
credit to observations which differ by only one or two points and 
is therefore 
inappropriate for continuous scales which have a large number of possible scores. 
Cohen suggested a statistical method which focuses on partial agreement by using a 
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weighting system which accounts for the amount of discrepancy between each pair 
of observations (quadratic weights) giving a partial agreement corrected reliability 
(Cohen, 1968). This coefficient is practically equal to intraclass correlation 
coefficient which is calculated from the analysis of variance (Shrout and Fleiss, 
1979). 
Kappa, weighted kappa and intraclass correlation coefficients scores are 
interpreted conventionally as: <0 poor agreement, 0-0.2 slight agreement, 0.21-0.4 
fair agreement, 0.41-0.6 moderate agreement, 0.61-0.8 substantial agreement, 0.81-1 
almost perfect agreement (Landis and Koch, 1977). As reliability estimates are 
population dependent, 95% confidence intervals can be constructed for both kappa 
(1.96 times the standard error of kappa) (Norman and Streiner, 1993b), and 
intraclass correlation coefficients (Fleiss and Schrout, 1978). 
3.3 Validity 
To determine that an instrument is measuring what is intended to be 
measured, some evidence of validity is required. Validity therefore considers the 
relation between the concept being measured and the instrument used to assess this 
concept. There are three main approaches to assessing validity. 
3.3.1 Face and content validity 
This form of validity addresses the extent to which an instrument is 
representative of the conceptual domain it is intended to cover. Evidence for this 
type of validity is commonly obtained by comprehensive review of the literature, 
consensus expert opinion, quantitative patient interviews, and by examining existing 
measures of the same or different concepts. The evidence for face and content 
validity is mainly logical, but statistical analysis can also be undertaken to assess the 
extent to which groups of experts or patients agree with or disapprove of a particular 
instrument. 
3.3.2 Criterion related validity 
Evidence for this type of validity is provided by examining the correlation 
between the instrument and a gold standard. The difficulty with this approach is 
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usually related to the lack of gold standards which is what justifies the development 
of the new scale in the first instance. There are two approaches for assessing 
criterion related validity which refer to whether the instrument is being compared 
with a gold standard at the same time (concurrent criterion validity) or in the future 
(predictive criterion validity). 
3.3.3 Construct validity 
In the absence of a gold standard, validity is established through a series of 
strategies to examine the relation between the instrument and other measures or 
behaviours. In practice, evidence for construct validity is gathered by undertaking a 
series of studies to determine: 
A). Convergent validity 
The extent to which the measure correlates with measures of related entities. 
B). Discriminant validity 
The extent to which the measure does not correlate with measures of 
different entities. 
C). Group difference and Hypothesis testing 
The extent to which the measure is able to detect differences in groups of 
patients known to differ in the concept being measured, or to support various 
hypotheses generated from theoretically based conceptions. 
The process of determining construct validity therefore depends of the 
accumulation of all three types of evidence. 
Validity is assessed using Pearson's and Spearman rank correlation 
coefficients for interval and ordinal scales respectively. Correlation coefficients of 
0.35-0.49 have traditionally been interpreted as weak, those of 0.50-0.79 as 
moderate, and those of 0.80 or greater as strong (Sharrack et al., 1999c). 
3.4 Responsiveness 
Responsiveness addresses the ability of an instrument to detect clinically 
significant change over a relatively short period of time. As the ultimate goal of 
most therapeutic interventions is to induce change in patients' health status, 
responsiveness is an essential requirement of all outcome measures. Responsiveness 
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can be determined in several ways including serial administration of the instrument 
at different times when clinical change is expected to occur such as before and after 
treatment of known efficacy or through comparison with other criteria of change 
such as staff and patient perceptions of change. Responsiveness is assessed using 
Student-t test (Norman and Streiner, 1993a) or Wilcoxon Signed Rank test (Norman 
and Streiner, 1993f) for continuous and ordinal data respectively. It is also assessed 
using effect size calculated by dividing the difference between the scores of the first 
and the second assessments by the standard deviation of the first assessment scores 
(Kazis et al., 1989). Effect size values have traditionally been interpreted as: <0.19 
unresponsive, 0.2-0.49 small, 0.5-0.79 moderate, and 0.8-1 large (Cohen, 1977). 
3.5 Appropriateness 
Appropriateness refers to the ability of an instrument to discriminate between 
patients with differing degrees of disease severity (Streiner and Norman, 1995a; van 
der Putten et al., 1999). It is assessed by examining the instrument's mean / median, 
score range / standard deviation, and its `floor' and `ceiling' effects. The mean / 
median indicates the central tendency of the scores and should ideally lie near the 
midpoint of score range. Score range / standard deviation indicates the extent to 
which the instrument is able to demonstrate variability between subjects. When 
applied to large populations, the scores of a desirable scale should have a near 
normal distribution with no `floor' or `ceiling' effects. `Floor' and `ceiling' effects 
are calculated as the percentage of the patients scoring the minimum and the 
maximum possible scores respectively. Values exceeding 20% are considered to be 
significant (Holmes and Shea, 1997). 
3.6 Clinical disablement scales used for multiple sclerosis 
The need for a scoring system to assess the effect of experimental interventions 
in multiple sclerosis has prompted many researchers to develop different clinical rating 
scales. Many of these scales were developed well before the WHO published the 
ICIDH (World Health Organisation, 1980), although some of the more recent scales 
have incorporated this terminology in their framework. None of these scales has been 
universally accepted, and only a few have been widely adopted for clinical trials. 
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3.6.1 The Expanded Disability Status Scale (EDSS) 
The EDSS has become the best known and the most widely used scoring 
method in multiple sclerosis (Kurtzke, 1983). It combines impairment and disability in 
a 20-step ordinal scale which ranges between 0 (normal status) and 10 (death due to 
MS). In this scale, patients are graded according to the history and the findings of a 
standard neurological examination in the appropriate grades of a complementary set of 
eight Functional System scales which include: pyramidal, cerebellar, brain stem, 
sensory, bowel and bladder, visual, cerebral and `others'. An overall EDSS score is 
obtained by combining the different Functional System scores with the patient's ability 
to ambulate, use their upper limbs, communicate, and swallow. The lower EDSS 
grades (0 to 3.5) depend largely on the Functional Systems, but the higher grades are 
determined by the degree of ambulation (4.0 to 7.5), upper limb dysfunction (8.0 to 
8.5), or bulbar dysfunction (9.0 to 9.5). The EDSS can only be administered by 
trained staff, usually neurologists. 
A). Face / content validity and appropriateness 
Despite its popularity in clinical trials, the EDSS has many problems. The 
term EDSS itself is a misnomer since the scale rates a mixture of impairment (in the 
lower grades) and disability (in the higher grades). Subjective variables, particularly 
in relation to ambulation, play a major role in allocating the final scores. The 
differences between grades 5.5,5.0,4.5 and 4.0 depend on the ability to walk 100, 
200,300 or 500 metres respectively without aid or rest, which are often estimated 
and not measured objectively. It is often difficult for most patients and many 
neurologists to estimate these distances accurately and for both parties to reach a 
mutual agreement on them (Sharrack and Hughes, 1997). The scale lacks precision 
in defining some of its Functional System grades due to the use of vague terms such 
as `mild', `moderate', or `severe' which are open to 
different interpretations. 
Combining the results of the Functional Systems to allocate patients to the 
appropriate EDSS grades can also be difficult 
for patients with high scores on the 
Functional Systems but relatively normal ambulation. Significant relapses do not 
necessarily affect grading as ambulation-dependent 
EDSS scores are not affected by 
relapses which do not alter the ambulation status of patients. 
The scale is rather 
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insensitive to cognitive and upper limb dysfunction, or to the severity of items 
incorporated in the two-grade Functional System for `others' such as fatigability. 
vertigo, pain, or oscillopsia. Cross sectional studies have shown the EDSS to have a 
bimodal distribution with paucity of patients in the middle value grades (Willoughby 
and Paty, 1988; Goodkin et al., 1989; Rodriguez et al., 1994). Goodkin and co- 
workers (1989) studied 425 patients with multiple sclerosis and found that 45.9% 
scored between 1.0 and 3.5,21.2% scored between 6.0 and 6.5, and only 4.7% 
scored between 4.0 and 5.5. Progression in the EDSS is non-linear as patients 
progress faster between steps 1 to 5 than between steps 5 to 7 (Myers et al., 1992). 
Ellison and co-workers (1994) have proposed a strategy to cope with this non- 
linearity in clinical trials by defining worsening as a change of 1.0 EDSS units (i. e. 
two 0.5 steps) maintained for 90 days for patients with an entry score of 1.0 to 5.0, 
but 0.5 EDSS units (i. e. one 0.5 step) if the entry score is 5.5 to 7.0 units. 
B). Reliability 
At least eight reliability studies of the EDSS have been conducted 
(Noseworthy, 1994). These studies reported high inter- and intra-rater reliability of 
the Functional Systems scores with 97-100% rater agreement when allowing a 
difference of 2 points (Amato et al., 1988; Noseworthy et al., 1990; Goodkin et al., 
1992), fair to substantial inter-rater reliability of the EDSS (kappa coefficient 0.32- 
0.76) (Amato et al., 1988; Noteworthy et al., 1990; Francis et al., 1991), and 
moderate to almost perfect intra-rater reliability of its lower (1.0 to 3.5) grades 
(frequency of perfect agreement 50-60%, intraclass correlation coefficient 0.88- 
0.96) (Goodkin et al., 1992). 
Q. Responsiveness 
Ellison and co-workers (1993) found the Disability Status Scale (the previous 
version of the EDSS) to be insensitive to worsening of patient's clinical status as 
judged by the assessing neurologist. Hobart and co-workers (1996d) have also 
found the EDSS to be unresponsive in a group of 64 patients with moderate to 
severe disability (EDSS 5.0-9.0). 
D). Construct validity 
The face validity of the EDSS as a measure of combined impairment and 
disability is confirmed by its high correlation with the Scripps Neurological Rating 
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Scale (r = -0.84 to -0.89) (The IFNB Multiple Sclerosis Study Group and The 
University of British Columbia MS/MRI Analysis Group, 1995), and patients' self- 
assessment of disability using the physical functioning domain of the SF-36 (r =- 
0.87) (Rothwell et al., 1997), and the Barthel Index (r = 0.89) (Hobart et al., 1996c). 
The EDSS has also been found to strongly correlate with physical disability as 
measured by non-medically qualified assistants using the disability questionnaire of 
the Office of Population Censuses and Surveys (OPCS) (r = 0.84) (Martin et al., 
1988; Rothwell et al., 1997). The OPCS disability instrument was developed as 
generic measure of disability which can be administered by non-medically qualified 
personnel for the use the 1985 survey of disability among adults. 
Despite its shortcomings, the EDSS has been used as an outcome measure in 
almost all published clinical trials of multiple sclerosis. It has also been used 
extensively in studying the natural history of multiple sclerosis (Weinshenker, 1994). 
The use of this scale in future clinical trials is therefore mandatory until such a time that 
a suitable alternative is devised and universally accepted. 
3.6.2 The Scripps Neurological Rating Scale (SNRS) 
The SNRS is a 22-item ordinal impairment scale which converts the standard 
neurological examination into a numerical score using a 3-level scoring system (Sipe 
et al., 1984). A normal individual receives the full score of 100 points with 
progressive loss of points for mild, moderate or severe impairment until the worst 
possible score of 0 point. The SNRS can only be administered by trained staff, 
usually neurologists. 
A). Face / content validity and appropriateness 
The SNRS does not adequately reflect cognitive dysfunction. The total points 
allocated for each neurological system are weighted arbitrarily with high scores for the 
visual, sensory, motor and cerebellar systems, and low scores for mentation and mood, 
tendon reflexes and plantar responses. The scale lacks precision as guidelines for 
defining the degree of impairment (mild, moderate, or severe) of its various items are 
not provided. This stricture applies particularly to items such as visual fields, optic 
discs, pupils, and eye movements in which impairment has not traditionally been 
graded. The SNRS has been reported by Koziol and co-workers (1996) from the 
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Scripps clinic to have a near normal frequency distribution. This observation has 
never been re-evaluated by other independent groups. 
B). Reliability 
Koziol and co-workers (1996) reported high inter-rater agreement with a 
weighted kappa coefficient of 0.83 and 0.85% score agreement when allowing a 
difference of 10 points, and high intra-rater reliability with weighted kappa 
coefficients for the two examiners of 0.98 and 0.99. No other reliability studies by 
independent groups have been published. 
Q. Responsiveness 
Koziol and co-workers (1996) reported that score changes of the SNRS are 
`more gradual' in comparison with those on the EDSS, suggesting that the SNRS is 
not sensitive to clinical change. There are no other published reports in the literature 
addressing the responsiveness of the SNRS. 
D). Construct validity 
The face validity of the SNRS as an impairment measure is supported by its 
high correlation with the EDSS (r = -0.84 to -0.89) (The IFNB Multiple Sclerosis 
Study Group and The University of British Columbia MS/MRI Analysis Group, 
1995). 
3.6.3 The Ambulation Index (AI) 
The Al is a semi-quantitative scale which converts ambulation-related 
disability into an ordinal scale based on the speed and assistance needed for walking 
25 feet by specifying 10 grades between 0 (normal status) and 9 (wheelchair-bound 
and unable to transfer independently) (Hauser et al., 1983). The scale is simple and 
can be administered by any health care personnel. 
A). Face / content validity and appropriateness 
Compared with the EDSS, the Al provides a more precise measure of 
ambulation. However it usefulness as an outcome measure in clinical trials 
is 
limited by its mono-dimensional nature and its inability to take into account the wide 
range of disabilities experienced by patients with multiple sclerosis. The Al 
has a 
bimodal distribution with a paucity of scores 7 and 8 (Goodkin et al., 1989; Swingler 
and Compston, 1992) 
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B). Reliability 
The Al has moderate to substantial inter-rater reliability (kappa coefficient 
0.5-0.72) with 95% score agreement when allowing for a difference of 1 point 
(Francis et al., 1991). No intra-rater reliability studies have been reported in the 
literature. 
Q. Responsiveness 
Although the Al detected more clinical change than the EDSS in at least one 
clinical trial (British and Dutch Multiple Sclerosis Azathioprine Trial Group, 1988), 
there are no published reports in the literature addressing its responsiveness. 
D). Construct validity 
The face validity of the Al as a disability scale is supported by its high 
correlation with the EDSS (Herndon and Goodkin, 1997). 
3.6.4 The Functional Independence Measure (FIM) 
The FIM is an 18-item ordinal disability scale which rates the level of 
assistance required to perform various activities of daily living using a7 level 
scoring system with sum scores ranging between 124 (normal status) and 18 (totally 
dependent) (Hamilton et al., 1987; Keith et al., 1987a). The FIM can be 
administered by any health care personnel. However it is a somewhat cumbersome 
scale which requires reference to a 48-page instruction book and training for its 
administration. 
A). Face / content validity and appropriateness 
The FIM does not account for the whole range of disabilities experienced by 
patients with multiple sclerosis by failing to cover visual, speech, swallowing, 
affective, or sexual disabilities. The scale's 7 point scoring system lacks precision in 
some of its items. The ambulation item gives a score of 6 for `modified mechanically 
assisted independence', which means that the same score will be given to patients who 
need unilateral or bilateral support. The same score will also be given to someone who 
walks slowly but independently, whether or not gait is abnormal. In a study of 201 
patients with moderate to severe disability (EDSS 5.0 to 9.0), van der Putten and co- 
workers (1999) found the FIM sum score to have small `ceiling' and `floor' effects. 
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B). Reliability 
Given the multidimensional nature of this scale, the internal consistency of 
its items is surprisingly very high (Cronbach's alpha 0.94-0.95) suggesting that some 
items may be redundant (Brosseau and Wolfson, 1994; Streiner and Norman, 
1995c). Previous reliability studies showed high inter-rater reliability of the FIM 
sum scores with intraclass correlation coefficients of 0.83-0.96; high inter-rater 
reliability of the motor (intraclass correlation coefficients of 0.95-0.97) and the 
cognitive domains sum scores (intraclass correlation coefficients 0.84-0.88); and 
variable item score inter-rater reliability (intraclass correlation coefficients 0.14- 
0.98) (Brosseau and Wolfson, 1994; Hobart et al., 1996b). There are no published 
reports addressing the intra-rater reliability of this scale. 
Q. Responsiveness 
The FIM sum score is responsive to clinical change thereby enhancing the 
usefulness of this scale in clinical trials of MS (Hobart et al., 1996d). 
D). Construct validity 
The face validity of the FIM as a disability measure is supported by the high 
correlation between this scale and the EDSS and the burden of care (Granger et al., 
1990a; Hobart et al., 1996c). 
3.6.5 Other scales 
A). The Minimal Record of Disability 
In 1985, The International Federation of Multiple Sclerosis Societies committee 
on rating systems suggested a Minimal Record of Disability for multiple sclerosis 
which was based on the ICIDH and comprised of three scales: the EDSS as an 
impairment scale, the Incapacity Status Scale as a disability scale and the 
Environmental Status Scale as a handicap scale (International Federation of Multiple 
Sclerosis Societies, 1985). 
The Incapacity Status Scale is a 16-item ordinal scale with a 5-point scoring 
system from 0 (normal function) to 4 (loss of function). 
The scale is administered by 
patient interview and describes patients' performance 
in stair climbing, ambulation, 
toilet/chair/bed transfer, bowel function, bladder function, bathing/dressing, grooming, 
feeding, vision, speech and hearing, medical problems, mood and thought disturbances, 
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mentation, fatigability and sexual function. Like other activity of daily living scales, 
this scale is biased towards upper and lower limb dysfunction which are reflected in 
more than one of its items. 
The Environmental Status Scale is a 7-items ordinal scale with a 6-point 
scoring system from 0 (normal) to 5 (worst dysfunction). The scale rates the social 
and environmental impact of multiple sclerosis on patients in terms of actual work 
status, financial/economic status, personal residence/home, personal assistance 
required, transportation, community services and social activity. 
Both the Incapacity Status Scale and Environmental Status Scale can be 
administered by allied health professionals or trained volunteers. To date only the 
EDSS has been adopted and widely used in clinical trials. 
B). The Cambridge Multiple Sclerosis Basic Score (CAMBS) 
The CAMBS is an ordinal scale which rates the individual contributions of 
disability, relapse, disease progression, and handicap by using four separate sub- 
scales and a 5-level scoring system giving a four component score for each 
assessment (Mumford and Compston, 1993). The CAMBS has been found to be 
reproducible, with high correlation between its disability component and the EDSS and 
between its handicap component and both the Barthel Index and the Nottingham 
Health Profile (Mumford and Compston, 1993). This scale was not designed as an 
outcome measure for clinical trials or as a substitute for existing scales, but as a useful 
shorthand record for clinical neurological practice and retrospective case note analysis. 
Q. Composite scores 
In response to the need to develop a new scoring system for multiple 
sclerosis, the U. S. National Multiple Sclerosis Society convened a task force to 
develop recommendations for optimal assessment measures for use in future 
multiple sclerosis clinical trials (Rudick et al., 1996a). The task force proposed a 
new measurement approach based on the use of quantitative functional composites 
which consist of simple quantitative functional measures combined into a single 
score. In the absence of such an ideal composite, the task force recommended the 
use of a three-tier composite (timed 25-foot walk, the nine-hole peg test, and paced 
auditory serial addition test) as a secondary outcome measure in future clinical trials 
whilst awaiting the development of more refined composites (Rudick et al., 1996b). 
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Unfortunately the proposed multidimensional composite consists primarily of 
impairment measures which cover only one aspect of the disablement process and 
are therefore incapable of providing a comprehensive appraisal of patients' health 
status. These measures also have clear `ceiling' effects and are not applicable to 
patients with advanced multiple sclerosis who are unable to walk, manipulate fine 
objects with their hands or process mental arithmetic (Sharrack and Hughes, 1999b). 
3.7 Conclusion 
Many neurological rating scales have been proposed to assess the impact of 
multiple sclerosis on patients, but none has been universally accepted. The EDSS 
has been the most widely used despite its problems. It combines impairment and 
disability and is heavily weighted toward ambulation. The SNRS attempts to 
quantify impairment as measured by the traditional neurological examination. 
However this and other impairment scales lack direct relevance to patients' 
functional health status. The Al is a simple and reproducible scale, but it only 
measures limited aspects of the wide range of disabilities encountered in multiple 
sclerosis. Current scales of disability and activities of daily living, such as the FIM 
are not comprehensive to the type of dysfunction which occurs in multiple sclerosis. 
The recently suggested composite outcome measures comprise mainly impairment 




THE RELIABILITY OF DISTANCE ESTIMATION 
4.1 Introduction 
The assessment of patients' walking ability is a simple and practical method 
of evaluating the functional health status in neurological, respiratory, cardiovascular 
and peripheral vascular diseases. Such assessments correlate well with more 
sophisticated measurements of cardiorespiratory function or muscle strength 
(Sinclair and Ingram, 1980; Bernstein et al., 1994), and are important in assigning 
scores in many clinical rating scales including the EDSS and the FIM. 
The two most commonly used methods are the assessment of the maximum 
distance that a patient can walk, or the distance that they can walk till the onset of 
symptoms. These distances are hardly ever measured in everyday clinical practice. 
Doctors have traditionally relied on their own or their patients' estimates of the 
distances walked around familiar places. A previous study assessing the accuracy of 
trained and untrained observers in estimating target distances ranging between 600 
to 1550 metres showed wide variability (Fine and Kobrick, 1983). There were no 
published studies assessing the accuracy of distance estimates made by doctors and 
patients (Sharrack and Hughes, 1997). 
4.2 Subjects and methods 
I sent a standard questionnaire to all the consultants at Guy's Hospital 
explaining the aim of the study and asking them to estimate (in yards or metres) the 
dimensions of a hospital ward, and the distances between 5 familiar sites in and 
around the hospital. A category for `don't know' was provided to prevent guessing. 
One hundred and five questionnaires were returned (return rate of 53%), of which 
100 were completed. The same questionnaire was given to 100 consecutive adult 
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patients from a general medical / neurology hospital ward and a neurology outpatient 
clinic in the same hospital. No help or clarification was provided to any of the 
patients, and none of them had any overt psychiatric disorder or cognitive 
dysfunction. All study sites were later measured with an architect's tape measure. 
Data were tabulated and analysed using SPSS 7.5 for windows. 
4.3 Results 
The consultants were more familiar with the hospital sites than the patients. 
The number of consultants giving estimates for the six distances varied between 45 
and 97 and the number of patients between 10 and 62 (Table 4.1 and 4.2). Both 
consultants and patients were inaccurate at estimating distances. Their mean 
estimates correlated moderately with the measured distances (r = 0.73 and 0.56 
respectively), and the range of their estimates was very wide and generally greater 
for consultants. The estimates for the whole group differed by up to 14.6 fold from 
the measured distances, and the difference between the minimum and the maximum 
estimates was up to 62.5 fold. This wide variability was partly due to the presence 
of a few outliers (Figure 4.1) since the differences between the measured distances 
and the median estimates of both groups were relatively small. 
When estimates were expressed as percentages of the measured distances, 
the estimates of the shorter distances were more inaccurate than those of the longer 
distances. The patients' mean estimate of a ward 7.2 yards wide was 19 yards, an 
error of 163.9 %, while the consultants' mean estimate of the same ward was 11 
yards, an error of 52.8%. On the other hand, the patients mean estimates of a 349 
yard walk to the local station was 495 yards, an error of 41%, while the consultants' 
mean estimate of the same distance was 371 yards, an error of only 6.3%. However 
the differences between the mean estimates of both groups were not statistically 
significant, with the exception of the 349 yard distance (p = 0.023). 
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Table 4.1 Estimates of distances (in yards) by consultants (n = 100) 
Measured Number of Median (range) of Mean (SD) of the 
distance estimates estimates differences * 
7.2 45 9 (4 to 75) 4.3 (11.1) 
20.6 46 30 (15 to 300) 24.6 (46.2) 
45.6 95 40 (8 to 500) 7.3 (55.6) 
126.9 94 100 (11 to 450) - 14.7 (67.2) 
140 97 120 (24 to 547) - 1.4 (90.5) 
349 94 300 (100 to 3282) 21.8 (375.1) 
* Between estimated and measured distances. 
Table 4.2 Estimates of distances (in yards) by patients (n = 100) 
Measured Number of Median (range) of Mean (SD) of the 
distance estimates estimates differences * 
7.2 31 10 (4 to 100) 13.5 (26.5) 
20.6 30 33 (8 to 200) 25.5 (39.7) 
45.6 15 27 (10 to 500) 24.9 (121.6) 
126.9 10 70 (18 to 247) - 33.7 (83.2) 
140 62 164 (21 to 500) 26.6 (109.6) 
349 58 440 (88 to 1200) 146.3 (287.8) 
* Between estimated and measured distances. 
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Figure 4.1 Differences between estimated and measured distances (in yards) for 





























This study suggests that people are inaccurate at estimating distances and 
that medical education is no safeguard. The range of estimates was very wide 
suggesting that decisions about health status based on individual distance estimates 
are unreliable. Although the estimates were proportional to the measured distances, 
indicating that consultants and patients were capable of comparing distances and 
therefore possibly able to estimate changes, the potential value of this observation 
needs to be evaluated against the intra-rater variability of these estimates which was 
not addressed in this study. The comparable inaccuracy of both groups suggests that 
selecting of patients with mainly neurological disorders (90%) did not bias the 
results or limit their generalisability to other patient groups. Participants are also 
unlikely to have deliberately provided spurious estimates since the outlier values 
were from participants who had given more reasonable estimates for other distances. 
The implications of these results are unmistakable. Clinical assessments and 
therapeutic decisions are often based on such estimates. For example the severity of 
angina, claudication, and chronic respiratory failure, and the effect of treatment on 
these conditions is usually assessed by the distance a patient can walk before the 
onset of symptoms. The results of some of the most hailed clinical trials in multiple 
sclerosis have been based on ambulation biased clinical rating scales including the 
EDSS (The IFNB Multiple Sclerosis Study Group and The University of British 
Columbia MS/MRI Analysis Group, 1995; Jacobs et al., 1996). A 1.0 step change 
on this 20 grade scale is regarded as a significant change, however the difference 
between grades 5.5,5.0,4.5,4.0 is the ability to walk 100,200,300, or 500 metres 
respectively. Such distances are usually estimated and are rarely measured 
objectively in hospital wards or outpatient clinics. 
The economic implication of distance estimation is considerable. There are 
over 1.2 million claimants in the UK in receipt of the higher rate mobility 
component of the Disability Living Allowance currently £33.9 per week 
(Department of Social Security, personal communication). This allowance is paid to 
five categories of patients including `people who have difficulty with walking' 
(Steadman, 1993). The eligibility of a person to this allowance is based solely on a 
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self-assessment questionnaire without the need for any objective examination 
(Steadman, 1992). 
4.5 Conclusion 
Assessing the maximum distance that a patient can walk is a simple way of 
evaluating their functional health status. These distances are usually estimated and 
rarely measured. I conducted a study to assess the accuracy of distance estimation 
by asking 100 patients and 100 doctors to estimate 6 distances around Guy's 
Hospital. Both doctors and patients were inaccurate at estimating distances. The 
ranges of their estimates were wide suggesting that health related decisions based on 
individual distance estimates are unreliable. 
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Chapter 5 
THE PSYCHOMETRIC PROPERTIES OF CLINICAL RATING 
SCALES USED FOR MULTIPLE SCLEROSIS 
5.1 Introduction 
Clinical rating scales allow the physician to classify patients according to 
their degree of impairment, disability / activities limitation, handicap / participation 
restriction, or quality of life, assist in predicting the course of the illness, and provide 
tools to monitor the response to experimental treatments. Over the last forty years, 
more than 15 different clinical rating scales have been devised and used in MS 
research (Sharrack and Hughes, 1996). The scales most commonly used are 
Kurtzke's EDSS and its related Functional Systems (FS) (Kurtzke, 1983), the 
Scripps Neurological Rating Scale (SNRS) (Sipe et al., 1984), and the Ambulation 
Index (Al) (Hauser et al., 1983). The generic Functional Independence Measure 
(FIM) (Hamilton et al., 1987; Keith et al., 1987a) and the Cambridge Multiple 
Sclerosis Basic Score (CAMBS) (Mumford and Compston, 1993) have also been 
proposed as potentially useful clinical scales (Noseworthy, 1994). It is surprising 
that despite the wide use of these scales in clinical research, data related to their 
psychometric properties in terms of reliability, responsiveness, validity, and 
appropriateness remain incomplete. Such data are of paramount importance for 
assessing the results of previous clinical trials and for designing future trials. This 
study was designed to assess the reliability, responsiveness, construct validity and 
appropriateness of these five commonly used scales in MS research. Face and 
content validity of these scales have already been reviewed in chapter 
3. 
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5.2 Patients and Methods 
This study was performed in the MS research clinic at Guy's Hospital, 
London, and was approved by the ethics committee of the local health authority. All 
subjects consented to take part in the study, and were only recruited if they had 
clinically or laboratory supported definite relapsing remitting or secondary 
progressive MS. Sixty-four adult patients were recruited. These patients consisted 
of 25 patients taking part in a multi-centre randomised double-blind placebo- 
controlled study of interferon beta la in relapsing remitting multiple sclerosis 
(PRISMS Study Group, 1998), 25 patients taking part in a multi-centre randomised 
double-blind placebo-controlled study of interferon beta 1a in secondary progressive 
multiple sclerosis (Paty, 1999), and 14 patients in long-term residential care. 
The 50 trial patients were recruited from the general neurology outpatient 
clinics at Guy's Hospital and other teaching and general district hospitals in and 
around London. Patients with relapsing remitting multiple sclerosis were eligible if 
they were aged 18-55 years, had a baseline EDSS score of 0-5.0 and a recorded 
history of a least two relapses in the preceding two years. Patients with secondary 
progressive multiple sclerosis were eligible if they were aged 18-55 years, had a 
baseline EDSS score of 3.0-6.5 and a recorded history of a least two relapses or 1.0 
point (or more) increase in EDSS in the preceding two years. The exclusion criteria 
included the use of immunosuppressive or immunomodulatory treatment during the 
three months before entry into the study, pregnancy or breast feeding in female 
patients, and the presence of serious intercurrent illnesses such as cancer, 
uncontrolled epilepsy, or decompensated liver disease. The 14 patients with more 
advanced disabilities (EDSS 7.0-9.5) represented all the patients with multiple 
sclerosis in a local nursing home and at the time of recruitment. 
This study overlapped with the two ongoing interferon beta la studies (in 
which patients were assessed every three months) and with the Guy's Neurological 
Disability Scale study which will be discussed in chapter 6 (Figure 5.1). 
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Figure 5.1 Overall study design in relation to the ongoing interferon beta la trials 
and the GNDS / GNDS-R studies 
Assessment n* 
1st 






(9 months) 3rd 
4th 
Study Outcome measures assessed 
64 Reliability EDSS, SNRS, Al, FIM, CAMBS, GNDS 
50 Reliability GNDS 







*n= number of patients in the study 
5.2.1 Inter-rater reliability study 
EDSS, SNRS, Al, FIM, CAMBS, GNDS-R 
EDSS, SNRS, AI, FIM, CAMBS, GNDS-R 
Sixty-four adult patients were recruited for this study. These patients 
consisted of a cohort of 50 patients attending a multiple sclerosis research clinic and 
14 patients in long-term residential care. Patients were assessed by three raters, two 
neurologists (including myself) and a neurology research nurse, who were familiar 
with the clinical scoring scales used in multiple sclerosis from experience in 
previous clinical trials and teaching workshops. To standardise the methods of 
applying the various scales by the three raters, training sessions were conducted 
prior to the beginning of this study, during which 10 subjects were examined and 
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scored jointly. Each patient in this study was assessed in the same session 
independently by the three raters (Figure 5.1). All patients were allocated scores on 
the EDSS, FS, SNRS, and the Al by the two assessing neurologists, and scores on 
the FIM and the CAMBS (50 patients only) by one neurologist (myself) and the 
neurology research nurse. 
5.2.2 Intra-rater reliability and responsiveness study 
The three raters followed a cohort of 50 MS patients attending the Guy's 
Hospital MS research clinic for nine months with assessments every three months. 
During each visit, patients were asked to compare their clinical condition with how 
they felt on the previous occasion, and indicate whether their condition had since 
worsened, remained stable, or improved. At the same time, one of the neurologists 
(myself), who had assessed the patients on the previous occasions, subjectively 
designated their clinical status as worse, stable, or better. Patients' overall status 
were later classified as stable, improved, or worsened, if both the patients' and the 
neurologist's assessments were identical indicating no change, improvement, or 
worsening respectively. Patients' overall status were otherwise designated as 
`uncertain', and all related data were excluded from the final analysis. Patients were 
also asked to complete the EuroQol health related quality of life questionnaire 
(EuroQol Group, 1990), and were assigned scores on the EDSS, SNRS, and Al by 
one neurologist and scores on the FIM, CAMBS, and the Barthel Index (Mahoney 
and Barthel, 1965) by the other neurologist (myself). In the absence of a gold 
standard for assessing clinical `stability' and `change', and in accord with the 
methodology of previous studies, intra-rater reliability was tested on the pairs of 
assessments between which patient's overall status were judged to have remained 
stable, whereas responsiveness was tested on the pairs of assessment between which 
they had changed (improved or worsened) (Deyo et al., 1991; Ellison et al., 1993). 
5.2.3 Validity study 
The validity of the five scales was assessed in the same cohort of 50 patients 
who took part in the intra-rater and responsiveness study described above. During 
their third visit, all patients were asked to complete the London Handicap Scale 
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(Harwood et al., 1994) and the Short Form 36 health survey questionnaire (SF-36) 
(Garratt et al., 1993), and were ranked by myself according to their ability to work, 
do their housework, and look after themselves. They were also ranked 
independently by two raters (myself and the research nurse) according to their 
subjectively perceived degree of disability. Convergent and discriminant construct 
validity were tested by assessing the degree to which each scale in this study 
correlated with the other four scales, and with other measures of disability (Barthel 
Index), handicap (London Handicap Scale), and health related quality of life (SF- 
36). Group differences construct validity was assessed by testing the extent to which 
the scores of these scales correlated with the severity of disability as judged by the 
two raters. Hypothesis testing construct validity was assessed by testing the 
hypothesis that scores on any impairment, disability, or handicap scale should be 
more abnormal in patients who were unable to work or do their housework because 
of multiple sclerosis, and in patients who were dependent on others for some or all 
of their activities of daily living. 
5.2.4 Blinding 
The majority (78%) of the patients in the inter-rater reliability study and all 
the patients in the intra-rater reliability, responsiveness, and validity studies were 
taking part in a double-blind therapeutic trial in which the two neurologists were the 
`examining' and the `treating' physicians, and the research nurse was the `trial co- 
ordinator'. In this trial, the `examining' neurologist was responsible for assessing 
the patients relapse status and assigning scores on the various clinical scales, the 
`treating' neurologist was responsible for the overall medical management of the 
patients, and the research nurse was responsible for the administrative aspects of the 
study. To comply with the required blinding for both the ongoing therapeutic trial 
and the current study, the raters refrained from discussing the patients' clinical 
conditions amongst themselves, and none of them had access to their own or the 
other raters' previous scores which were kept separate from the patients' clinical 
records. To reduce the effect of patients' bias on the 
inter-rater reliability which 
may result from practice effect or fatigue, no fixed order for the examination of the 
patients by each rater was observed. Data for the intra-rater reliability study were 
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collected at three monthly intervals to reduce raters' and patients' bias, which may 
result from recall of previous assessments. 
5.2.5 Statistical analysis 
Data were tabulated and analysed using SPSS 7.5 for Windows. Two tailed 
tests were used for all statistical analyses. The EDSS, SNRS, FIM, Al, CAMBS, 
Barthel Index, and the disability ranks were treated as ordinal scales, whereas the 
London Handicap Scale and the SF-36 were treated as interval scales. Reciprocal, 
logarithmic and square root transformations of the ordinal and skewed data were 
performed and found to be unhelpful. Descriptive statistics were used to describe 
the study population in terms of demographic, disease characteristics and score 
distributions. Inter- and intra-rater reliabilities were assessed with kappa (Cohen, 
1960) and intraclass correlation coefficients (Shrout and Fleiss, 1979). Ninety-five 
percent confidence intervals were constructed for both kappa and intraclass 
correlation coefficients. The reliability was also expressed as the mean and 95% 
confidence intervals of inter- and intra-rater score differences to estimate rater bias 
and the repeatability coefficient as discussed in chapter 3 (Bland and Altman, 1986). 
Internal consistency of the two multidimensional scales (SNRS and FIM) was 
assessed using Cronbach's alpha (Cronbach, 1951). The individual contribution of 
the various scale items to the sum score of the two multidimensional scales was 
assessed using factor analysis (Norman and Streiner, 1993d). Responsiveness was 
assessed using Wilcoxon Signed Ranks test and effect size (Kazis et al., 1989). 
Construct validity was assessed using Pearson's and Spearman rank correlation 
coefficients for interval and ordinal scales respectively. 
5.3 Results 
5.3.1 Inter-rater reliability and appropriateness 
Sixty-four patients with a wide spectrum of disabilities, ranging from being 
asymptomatic to being bedridden and completely dependent, were recruited for this 
study. The group consisted of 42 women and 22 men with a median age 40 years 
(range 22-74), and median disease duration of 13 years (range 2-35). Inter-rater 
reliability of the CAMBS was assessed on a subgroup of 50 patients (31 women and 
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19 men) with a median age of 36 years (range 24-51), median EDSS score of 4.5 
(range 0-7.5), and a median disease duration of 12 years (range 2-17). 
A). EDSS 
The median (range) scores of the two raters were identical at 5.5 (0-9.5). 
The frequency distribution of the two score sets was bimodal with fewer patients 
scoring at EDSS 4.0 and 7.0 (Figure 5.2a). Inter-rater agreement on the different 
Functional System scores was variable with kappa coefficients ranging between 0.41 
and 0.67 (moderate to substantial), intraclass correlation coefficients ranging 
between 0.81 and 0.95 (almost perfect), and repeatability coefficients ranging 
between 1.2 and 1.6 points (Table 5.1). The largest score differences between the 
two raters were 2 points for the pyramidal, cerebellar, bladder and bowel, and mental 
Functional Systems, and 3 points for the brain stem, sensory, and visual Functional 
Systems. Inter-rater agreement on the EDSS scores was 69%, 89%, 96%, and 100% 
when agreement was defined as no difference, a difference 5 0.5 point (one 0.5 
EDSS step), S 1.0 point (two 0.5 EDSS steps), and < 1.5 points (three 0.5 EDSS 
steps) respectively (Figure 5.3a), with a repeatability coefficient of 0.9 points, a 
kappa coefficient of 0.65 (substantial) and an intraclass correlation coefficient of 
0.99 (almost perfect) (Table 5.1). 
B). SNRS 
The median (range) scores of the two raters were similar at 69.5 (0-100) and 
67 (0-100). The frequency distribution of the two score sets was positively skewed 
to the `normal' end of the scale with a smaller cluster at the `severely impaired' end 
of the scale (Figure 5.2b). Inter-rater agreement on the different scale items was 
variable with kappa coefficients ranging between 0.30 and 0.72 (fair to substantial), 
intraclass correlation coefficients ranging between 0.54 and 0.93 (moderate to 
almost perfect), and repeatability coefficients ranging between 1.1 and 4.6 points 
(Table 5.2). Inter-rater agreement on the sum scores was 14%, 59%, 85%, 97%, and 
100% when agreement was defined as no difference, a difference <_ 5 points, <_ 10 
points, <_ 15 points, and < 19 points respectively (Figure 5.2b), with a repeatability 
coefficient of 12.1 points, and an intraclass correlation coefficient of 0.97 (almost 
perfect) (Table 5.3b). 
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C). FIM 
The median (range) scores of the two raters were almost identical at 119 (18- 
126) and 119 (27-126). The frequency distribution of the two score sets was 
positively skewed to the `less disabled' end of the scale with a smaller cluster at the 
`severely disabled' end of the scale (Figure 5.2c). Inter-rater agreement on the 
different scale items was variable with kappa coefficients ranging between 0.26 and 
0.88 (fair to almost perfect), intraclass correlation coefficients ranging between 0.56 
and 0.99 (substantial to almost perfect), and repeatability coefficients ranging 
between 0.5 and 2.7 points (Table 5.3). Inter-rater agreement on the sum scores was 
25%, 86%, 95.2%, and 100% when agreement was defined as no difference, a 
difference <_ 5 points, <_ 9 points, and <_ 13 points respectively (Figure 5.3c), with a 
repeatability coefficient of 8.1 points, and an intraclass correlation coefficient of 
0.99 (almost perfect) (Table 5.3). 
D). Al 
The median (range) scores of the two raters were similar at 2 (0-9) and 3 (0- 
9). The frequency distribution of the two score sets was bimodal with more patients 
scoring at the `normal' end of the scale and fewer patients scoring between 7 and 8 
(Figure 5.2d). Inter-rater agreement was 77%, and 100% when agreement was 
defined as no difference, or a difference <_ 1 point (Figure 5.3d), with a repeatability 
coefficient of 1 point, a kappa coefficient of 0.73 (substantial), and an intraclass 
correlation coefficient was 0.96 (almost perfect) (Table 5.4). 
E). CAMBS 
The median (range) scores of the two assessments for the scale's four 
domains were similar: disability 2 (1-4) and 3 (1-4); relapse 1 (1-3) and 1 (1-4); 
progression 1 (1-3); and handicap 2 (1-4). The frequency distribution of the two 
relapse and progression domain score sets was skewed to the `normal' end of the 
scales (Figure 5.2f and 5.2g). In comparison, the frequency distribution of the 
disability domain score sets was skewed to the `severely disabled' end of the scale, 
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Figure 5.2 Score frequency distributions of the EDSS, SNRS, FIM, 
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Figure 5.3 Inter-rater reliability: score differences between the two raters for the EDSS, SNRS, FIM, 
Ambulation Index (n = 64), and CAMBS (n = 50) 
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Inter-rater reliability agreement on the different domains was variable with 
kappa coefficients ranging between 0.45 and 0.69 (moderate to substantial), 
intraclass correlation coefficients ranging between 0.61 and 0.88 (substantial to 
almost perfect), and repeatability coefficients ranging between 0.9 and 1 points 
(Table 5.4). The largest score differences between the two raters were 1 point for 
the disability domain, 2 points for the relapse domain, 2 points for the progression 
domain, and 2 points for the handicap domain (Figure 5.3e - 5.3h). 
F). Raters' bias 
With the exception of the cranial nerves item, bladder, bowel and sexual 
item, and some of the motor and the cerebellar items of the SNRS, the mean score 
differences between the two raters were generally small with narrow 95% 
confidence intervals which included the "0" value indicating the absence of raters' 
bias. 
5.3.2 Intra-rater reliability 
Thirty-five patients had remained stable between two visits on at least one 
occasion during the 9 months follow up period. To avoid introducing any statistical 
bias, only one pair of assessments (the first) per patient was included in the final 
analysis. This cohort consisted of 20 women and 15 men with a median age of 38 
years (range 24-51 years), and median disease duration of 11 years (2-17 years). To 
compensate for the design of the relapse and the progression domains of the 
CAMBS (which have been devised to assess disease stability over a time longer than 
three months), intra-rater reliability of these two domains was assessed in a sub- 
group of 23 patients after excluding all patients who had any relapses during the 9 
months before the first assessment (9 patients) or between the first and the second 
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The median (range) scores of the two assessments were identical at 4.5 (0- 
7.5). Intra-rater agreement on the different Functional System scores was variable, 
with kappa coefficients ranging between 0.42 and 0.66 (fair to substantial), intraclass 
correlation coefficients ranging between 0.67 and 0.92 (substantial to almost 
perfect), and repeatability coefficients ranging between 1.3 and 1.8 points (Table 
5.1). The largest score differences between the two assessments were 2 points for 
the pyramidal, sensory, bladder and bowel, and mental Functional Systems, and 3 
points for the cerebellar, brain stem, and visual Functional Systems. Intra-rater 
agreement on the EDSS scores was 63%, 89%, and 100% when agreement was 
defined as no difference, a difference of <_ 0.5 point (one EDSS step), and <_ 1.0 point 
(two 0.5 EDSS steps) respectively (Figure 5.4a), with a repeatability coefficient of 
0.8 point, a kappa coefficient of 0.7 (substantial), and an intraclass correlation 
coefficient of 0.99 (almost perfect) (Table 5.1). 
B). SNRS 
The median (range) scores for the two assessments were very similar at 73 
(33-98) and 71 (34-98). Intra-rater agreement on the different scale items was 
variable with kappa coefficients ranging between 0.33 and 0.75 (fair to substantial), 
intraclass correlation coefficients ranging between 0.52 and 0.92 (moderate to 
almost perfect), and repeatability coefficients ranging between 0.8 and 4.7 points 
(Table 5.2). Intra-rater agreement on the sum scores was 6%, 67%, 76%, and 100% 
when agreement was defined as no difference, a difference of <_ 5 points, <_ 10 
points, and <_ 14 points respectively (Figure 5.4b), with a repeatability coefficient of 




The median (range) scores of the two assessments were identical at 123 (90- 
126). Intra-rater agreement on the different scale items was variable with kappa 
coefficients ranging between 0.55 and 1 (moderate to perfect), 
intraclass correlation 
coefficients ranging between 0.60 and 1 (substantial to perfect), and repeatability 
coefficients ranging between 0 and 2.2 points 
(Table 5.3). Intra-rater agreement on 
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the sum scores was 37%, 92%, and 100% when agreement was defined as no 
difference, a difference of <_ 5 points, and <_ 9 points respectively (Figure 5.4c), with 
a repeatability coefficients of 6.1 points, and an intraclass correlation coefficient of 
0.94 (almost perfect) (Table 5.3). 
D). AI 
The median (range) scores of the two assessments were identical at 2 (0-8). 
Intra-rater agreement was 66%, 94%, 97%, and 100% when agreement was defined 
as no difference, a difference <_ 1 points, <_ 2 points, and <_ 3 points respectively 
(Figure 5.4d), with a repeatability coefficient of 1.5 points, a kappa coefficient of 
0.59 (moderate), and an intraclass correlation coefficient of 0.93 (almost perfect) 
(Table 5.4). 
E). CAMBS 
The median (range) scores of the two assessments for the scale's four 
domains were identical: disability 2 (1-4), relapse 1 (1-3), progression 1 (1-3), and 
handicap 2 (1-4). Intra-rater agreement on the different domains was very high with 
kappa coefficients ranging between 0.58 and 0.80 (moderate to substantial), 
intraclass correlation coefficients ranging between 0.71 and 0.85 (substantial to 
almost perfect), and repeatability coefficients ranging between 0.8 and 1.4 points 
(Table 5.4). The largest score differences between the two assessments were 1 point 
for the disability domain, 2 points for the relapse domain, 1 point for the progression 
domain, and 2 points for the handicap domain (Figure 5.4e-5.4h). 
F). Raters' bias 
With the exception of the lower cranial nerves item of the SNRS, the mean 
score differences between the two raters were generally small with narrow 95% 
confidence intervals which included the "0" value indicating the absence of raters' 
bias. 
5.3.3 Internal consistency and factor analysis 
Internal consistency and factor analysis of the two multidimensional scales 
assessed in this study (SNRS and FIM) were evaluated using the inter-rater 
reliability data set. Internal consistency was very high with Cronbach's alpha of 0.92 
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for the SNRS and 0.98 for the FIM. Factor analysis of SNRS suggested a five factor 
solution which accounted for 79.3% of the total variance (cumulative percentage of 
52.8%, 63.0%, 69.7%, 74.8%, and 79.3%; eigenvalues of 11.6,2.2,1.5,1.1,1 
respectively). The first factor of the rotated matrix (cerebellar factor) correlated 
with the "upper and lower limb cerebellar" (the latter also correlated with the fourth 
factor), "eye movements", "lower cranial nerves", and "nystagmus" items. The 
second factor (cerebral / visual / upper limb motor factor) correlated with the 
"mentation and mood", "visual acuity", "fields/discs/pupils", "upper limb motor", 
and "reflexes" items. The third factor (sensory factor) correlated with the "upper 
and lower limb sensory" (the latter also correlated with the fourth factor) items. The 
fourth factor (lower limb / spinal factor) correlated with the "lower limb motor", 
"lower limb cerebellar", "gait", and "bladder & bowel & sexual function" items. 
The fifth factor (Babinski factor) correlated with the "Babinski reflex" item only. 
Factor analysis of the FIM suggested a two factor solution which accounted for 
89.4% of the total variance (cumulative percentage of 83% and 89.4%; eigenvalues 
of 14.9 and 1.2 respectively). The first factor of the rotated matrix (motor factor) 
correlated with the "motor" items of the scale (items A to M), and the second factor 
(cognitive factor) correlated with the "communication" and "social cognition" items 
(items N to R). 
5.3.4 Responsiveness 
Of the 50 patients assessed, 25 were found to have changed on at least one 
occasion during the 9 months follow up period. This group consisted of 20 women 
and 5 men with a median age of 36 years (range 24-51), median EDSS of 5.5 (range 
0-7.5), and a median disease duration of 10 years (range 2-22). To avoid 
introducing any statistical bias, only one pair of assessments (the first) per patient 
was included in the final analysis. The order of assessment in each pair (15 patients 
worsened, and 10 improved) was latter re-arranged so as to make all the changes of 
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Figure 5.4 Intra-rater reliability: score differences between the two assessments for the EDSS, 
SNRS, FIM, Ambulation Index, and CAMBS (n = 35) 
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Patients' subjective assessments of their own health status using the EuroQol 
visual analogue scale was moderately sensitive to clinical change (effect size 0.55, p 
_ <0.001). Similar subjective assessment by myself using the EuroQol visual 
analogue scale was weakly sensitive to clinical change (effect size 0.36, p= <0.001). 
A). EDSS 
The EDSS was not sensitive to clinical change (effect size 0.11, p=0.051). 
Most of the Functional Systems were also unresponsive except for the mental 
Functional System which was weakly responsive (effect size 0.38, p=0.0 12) mainly 
on account of mood changes (Table 5.5). 
B). SNRS 
The SNRS sum score was unresponsive (effect size 0.17, p=0.253). The 
individual scale items were also unresponsive except for the mentation and mood 
item which was weakly sensitive to clinical change (effect size 0.36, p=0.043) 
(Table 5.6). 
Q. FIM 
The FIM sum score was weakly sensitive to clinical change (effect size 0.46, 
p= <0.001). Many `motor' items (eating, grooming, sphincter control, bed and 
toilet transfer, and locomotion) were also weakly to moderately responsive (effect 
size 0.25 to 0.67, p=0.044 to 0.039), but none of the cognitive items were 
responsive (Table 5.7). 
D). AI 
This scale was weakly sensitive to clinical change (effect size 0.20, p= 
0.039) (Table 5.8). 
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Table 5.5 Responsiveness of the Functional Systems and the EDSS (n = 25) 
Scale Time 1 Time 2P* Effect size 
Median (range) Median (range) 
Functional Systems 
Pyramidal 2 [0 to 5] 3 [0 to 5] 0.160 0.13 
Cerebellar 1 [0 to 5] 2 [0 to 3] 0.766 - 0.06 
Brain stem 0 [0 to 4] 0 [0 to 3] 0.683 0.06 
Bladder & Bowel 2 [0 to 4] 2 [0 to 4] 0.470 0.13 
Sensory 0 [0 to 6] 1 [0 to 6] 0.210 0.14 
Mental 0 [O to 2] 1 [O to 3] 0.012 0.38 
Visual 0 [0 to 5] 1 [0 to 5] 0.386 0.09 
EDSS 5.5 [0 to 6.5] 6 [0 to 7.5] 0.051 0.11 
* Wilcoxon Signed Ranks test 
E). CAMBS 
The relapse and progression domains were moderately sensitive to clinical 
change (effect size 0.67, p=0.001 and 0.78, p= <0.001 respectively), whereas the 
disability domain was only weakly responsive (effect size 0.39, p=0.008), and the 
handicap domain was unresponsive (effect size 0.14, p=0.206) (Table 5.8). 
To assess the responsiveness of the five scales at different levels of disease 
severity, the patients were categorised into one of three levels of disease severity 
according to their baseline EDSS scores: mild (EDSS 0.0-4.5), moderate (EDSS 5.0- 
6.0), and severe (EDSS 6.5-7.5). Sub-group analysis showed the responsiveness of 
these scales within each band of disease severity to be similar to the results of the 
whole group. 
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Table 5.6 Responsiveness of the Scripps Neurological Rating Scale (n = 25) 
Time 1 Time 2p* Effect size 
Median (range) Median (range) 
Mentation and mood 
Cranial nerves 
Visual acuity 
Fields, discs, pupils 
Eye movements 
Nystagmus 
Lower cranial nerves 
10 [4 to 10] 7 [6 to 10] 0.043 0.36 
5[lto5] 5[lto5] 0.414 0.14 
4[2to4] 4[2to6] 1 0 
5 [O to 5] 5 [O to 5] 0.071 0.16 
5 [O to 51 5 [O to 51 0.461 0.17 
5[0to51 5[lto5] 0.396 0.1 
Motor 
Right upper limb 5 [0 to 5] 5[0 to 5] 0.317 0.15 
Left upper limb 5 [0 to 5] 5 [0 to 5] 1 0 
Right lower limb 3 [0 to 5] 1 [0 to 5] 0.368 0.12 
Left lower limb 3 [0 to 5] 3 [0 to 5] 0.831 0.04 
Deep tendon reflexes 
Upper limbs 4 [1 to 4] 4 [1 to 4] 0.792 0.06 
Lower limbs 1 [0 to 4] 3 [0 to 4] 0.455 0.12 
Babinski 
Right 0 [O to 2] 0 [O to 2] 0.317 0.09 
Left 0 [0 to 2] 0 [0 to 2] 0.157 0.17 
Sensory 
Right Upper limb 3 [0 to 3] 3 [0 to 3] 0.564 - 0.09 
Left Upper limb 3 [0 to 3] 3 [0 to 3] 0.414 - 0.05 
Right Lower limb 3 [0 to 3] 2 [0 to 3] 0.132 0.21 
Left Lower limb 3 [0 to 3] 3 [0 to 3] 0.317 0.09 
Cerebellar 
Upper limb 5 [O to 5] 5 [O to 5] 0.317 -0.13 
Lower limb 5 [0 to 5] 3 [0 to 5] 0.546 0.09 
Gait, trunk & balance 7 [0 to 10] 7 [0 to 10] 0.161 0.19 
Bladder, bowel & sexual -3 [-10 to 0] -3 [-10 to 0] 0.951 
0.06 
Total SNRS score 70 [34 to 98] 66 [29 to 98] 0.253 0.17 
* Wilcoxon Signed Ranks test 
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Table 5.7 Responsiveness of the Functional Independence Measure (n = 25) 
Time 1 Time 2p* Effect size 
Median (range) Median (range) 
Self-care 
A) Eating 7 [3 to 7] 7 [3 to 7] 0.059 0.28 
B) Grooming 7 [6 to 7] 7 [4 to 7] 0.015 0.39 
C) Bathing 7 [3 to 7] 7 [3 to 7] 0.393 0.07 
D) Dressing-upper body 7 [3 to 7] 7 [3 to 7] 0.593 0.07 
E) Dressing-lower body 7 [3 to 7] 7 [3 to 7] 0.739 0.09 
F) Toileting 7 [5 to -7] 7 [5 to 7] 0.655 0.07 
Sphincter control 
G) Bladder 6 [1 to 7] 6 [1 to 7] 0.008 0.54 
H) Bowel 7 [I to 7] 7 [l to 7] 0.48 -0.19 
Mobility - Transfer 
I) Transfer bed/chair 7 [4 to 7] 7 [2 to 7] 0.039 0.67 
J) Transfer toilet 7 [6 to 7] 7 [6 to 7] 0.048 0.25 
K) Transfer tub/shower 6 [3 to 7] 6 [3 to 7] 0.832 0.13 
Mobility - locomotion 
L) Walking 6 [2 to 7] 6 [2 to 7] 0.041 0.48 
M) Stairs 6 [2 to 7] 6 [1 to 7] 0.038 0.66 
Communication 
N) Comprehension 7 [4 to 7] 7 [4 to 7] 0.18 0 
0) Expression 7 [6 to 7] 7 [4 to 7] 0.317 0 
Social cognition 
P) Social interaction 7 [6 to 7] 7 [6 to 7] 1 0 
Q) Problem solving 7 [3 to 7] 7 [3 to 7] 0.414 
0.15 
R) Memory 7[3to7] 7[3to7] 0.034 0.19 
Total FIM score 123 [91 to 126] 120 [90 to 126] <0.001 
0.46 
* Wilcoxon Signed Ranks test 
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Table 5.8 Responsiveness of the CAMBS, the Ambulation index, and the Barthel 





P* Effect size 
Ambulation index 2 [0 to 6] 2 [0 to 9] 0.039 0.20 
CAMBS 
Disability 2 [1 to 4] 2 [1 to 5] 0.008 0.39 
Relapse 1 [I to 2] 2 [1 to 4] 0.001 0.67 
Progression 1 [I to 2] 2 [1 to 3] <0.001 0.78 
Handicap 2 [1 to 4] 2 [1 to 5] 0.206 0.14 
Barthel index 20 [10 to 20] 20 [10-20] 0.042 0.25 
* Wilcoxon Signed Ranks test 
5.3.5 Validity 
Convergent validity was assessed on the same cohort of 50 patients who took 
part in the intra-rater reliability and responsiveness study. The group consisted of 31 
women and 19 men, with a median age of 36 years (range 24-51), median EDSS 
score of 4.5 (range 0-7.5), and a median disease duration of 12 years (range 2-17). 
A). Convergent and discriminant validity 
The Barthel index correlated highly with the FIM (r = 0.88), and moderately 
with the EDSS (r = -0.74), SNRS (r = 0.69), Al (r = -0.72), and the disability and 
the handicap domains of the CAMBS (r =-0.69, and -0.61 respectively) (Table 5.9). 
In comparison, the London Handicap Scale correlated moderately with the EDSS (r 
= -0.69), SNRS (r = 0.71), Al (r = -0.72), and the 
disability and the handicap 
domains of the CAMBS (r = -0.59 and -0.65 respectively), and weakly with the FIM 
(r = 0.43) (Table 5.9). The physical functioning item of the SF-36 correlated 
highly 
with the EDSS (r = -0.82), SNRS (r = 0.82), FIM (r = 0.88), Al 
(r = -0.87), and 
moderately with the disability and the handicap domains of the CAMBS 
(r = -0.71 
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Slightly weaker but statistically significant correlations were also found 
between the SF-36 physical role limitation item and the EDSS (r = -0.50), SNRS 
(r = 0.46), FIM (r = 0.36), Al (r = -0.52), and the handicap domain of the 
CAMBS (r = -0.54); the SF-36 general health perception item and the EDSS (r =- 
0.47), SNRS (r = 0.44), the FIM (r = 0.41), Al (r = -0.38), and the handicap 
domain of the CAMBS (r = 0.39); the SF-36 social functioning item and the 
EDSS (r = -0.47), SNRS (r = 0.37), FIM (r = 0.43), Al (r = -0.42), and the 
disability and the handicap domains of the CAMBS (r = -0.33 and -0.53 
respectively); the SF-36 vitality item and the EDSS (r = -0.41), SNRS (r = 0.36), 
FIM (r = 0.38), Al (r = -0.39), and the disability and the handicap domains of the 
CAMBS (r = -0.45 and -0.48 respectively), and between SF-36 bodily pain item 
and the FIM (r = 0.34) (Table 5.9). The correlation between the five scales 
assessed in the study is reported in Table 5.10. 
B). Group differences and hypothesis testing 
The two disability rank lists, which were compiled by myself and the 
research nurse, were almost identical (r = 0.99). All five scales, particularly the 
SNRS, correlated highly with the mean ranks of disability (Table 5.11). Each of 
the scales also correlated moderately with the patients' ability to work and do their 
house work, and weakly with the degree of patient's independence. 
5.4 Discussion 
Multiple sclerosis is a multifaceted disease characterised by a wide 
variability of clinical manifestations and natural history. Clinical rating scales 
used in this illness require relevant scale items, need to be able to embrace the 
whole range of affected domains, and should have high levels of reliability, 
validity, and responsiveness. Face and content validity of the currently existing 
scales have already been addressed by many researchers (Sharrack and Hughes, 
1996) and reviewed by me in chapter 3. This study was designed to assess 
comprehensively the other psychometric properties of these scales. 
5.4.1 EDSS 
As reported by other researchers (Willoughby and Paty, 1988; Goodkin et 
al., 1989; Koziol et al., 1996), 1 found the frequency distribution of the EDSS 
scores to be bimodal with relative paucity of the middle scores. This bimodality 
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is unlikely to have been artefactual, despite the relatively small number of patients 
in this study, given the concordance between my findings and those obtained in 
cross-sectional studies of large population-based incident cohorts (Rodriguez et 
al., 1994; Midgard et al., 1996). Inter- and intra-rater reliabilities of the 
Functional System scores were comparably high. Similar to the previously 
reported studies, a difference of 2 points on the various Functional System scales 
achieved 97-100% rater agreement (Amato et al., 1988; Noseworthy et al., 1990; 
Goodkin et al., 1992) . Inter- and 
intra-rater reliabilities of the EDSS scores were 
equally high. Complete intra-rater and 96% inter-rater agreements were obtained 
by allowing a difference of 1.0 point (two 0.5 EDSS steps). These inter-rater 
reliability results are generally in accordance with the previously reported studies 
(Amato et al., 1988; Noseworthy et al., 1990; Goodkin et al., 1992), although 
Francis and co-workers reported the score difference between the two raters to 
vary between 2.0-4.0 points (four to eight 0.5 EDSS steps) in 10% of cases 
(Francis et al., 1991). Compared with my results, Goodkin and co-workers (1992) 
reported very high intra-rater reliability in a group of 10 patients with EDSS 
scores of 1-3.5, with complete intra-rater agreement obtained by allowing a 
difference of 0.5 points (one EDSS step). The discrepancy between these results 
and mine is likely to be due to the differences in the level of disease severity 
between the two cohorts, and to the time between the first and the second 
assessments. The assessments in my study were separated by three months 
whereas in the Goodkin study they were done on the same day and a practice 
effect cannot therefore be totally excluded. Although part of the difference 
between the first and the second assessments' scores in my study might have been 
due to a real but unreported change in the patients' clinical status, patients' 
variability between the two assessments was greatly minimised by including only 
those patients in whom clinical `stability' was reported by both the patient and the 
rater. 
The EDSS and its associated Functional Systems, with the exception of the 
mental Functional System, were insensitive to clinical change. 
The 
responsiveness of the EDSS has not been assessed previously in a manner exactly 
comparable to that used in my study. However, Ellison and co-workers 
(1993) 
found the Disability Status Scale (the previous version of the EDSS) to be 
insensitive to worsening of patient's clinical status as judged by the treating 
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neurologist, and Hobart and co-workers (1996d) found the EDSS to be 
unresponsive in a group of 64 patients with moderate to severe disability (EDSS 
5.0-9.0). The face validity of the EDSS as a measure of combined impairment 
and disability was confirmed by its high correlation with the SNRS (particularly at 
the lower EDSS grades), the FIM, patients' disability ranks, and patients' self- 
assessment of disability using the physical functioning domain of the SF-36, and 
its moderate correlation with the Barthel Index. Similar high correlation with the 
physical functioning domain of the SF-36 has recently been reported by Rothwell 
and co-workers (1997), but sub-group analysis of the patients with EDSS scores 
of 5.0-7.5 in my cohort failed to replicate the high correlation between the EDSS 
and the Barthel Index reported by Hobart and co-workers (1996c) in 66 patients 
with moderate to severe disability (EDSS 5.0-9.0). As expected for any 
impairment / disability scale, the EDSS correlated moderately with measures of 
handicap and quality of life, and with patients' ability to work and do their 
housework. 
5.4.2 SNRS 
Contrary to the report of Koziol and co-workers (1996) that the SNRS has 
a near normal frequency distribution, I found the SNRS scores to be skewed to the 
`normal' end of the scale with an additional cluster at the `severely impaired' end 
of the scale suggesting both `floor' and `ceiling' effects. This discrepancy might, 
at least partially, be due to the differences in the range of disease severity, as 
assessed by the EDSS, between the two studies (2.0-8.0 in the Koziol study and 
0-9.5 in my study). The internal consistency of the scale items was found to be 
surprisingly very high given the multidimensional nature of the scale suggesting a 
degree of item redundancy (Streiner and Norman, 1995c). Factor analysis showed 
the scale items, with the exception of the lower limb sensory and cerebellar items, 
to have segregated into five relatively `meaningful' factors which explained most 
of the variance. Inter- and intra-rater reliabilities of the different SNRS items 
were variable, ranging between poor to substantial, depending on the definition of 
agreement. Although complete inter- and intra-rater agreements were only 
obtained by allowing a difference of 19 and 14 points respectively, partial 
agreement corrected reliability of the sum scores was high. A difference of 10 
points only achieved 76% intra-rater and 85% inter-rater agreement, but a 
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difference of 13 points achieved more than 95% inter- and intra-rater agreement. 
These reliability results are similar to those published from the Scripps clinic 
(Koziol et al., 1996). 
Despite this high reliability, neither the SNRS sum score nor any of its 
items were sensitive to clinical change. The only exception was the mentation 
and mood item, which was responsive mainly on the account of mood changes. 
The responsiveness of the SNRS was assessed in one previous study (Koziol et 
al., 1996), in which score changes on this scale were found to be `more gradual' in 
comparison to those on the EDSS. Although direct comparison between this 
study and mine is not possible because of the methodological differences, I found 
both these scales to be unresponsive. The face validity of the SNRS as an 
impairment measure was supported by its high correlation with the EDSS. 
Surprisingly, the SNRS correlated highly with patients' disability ranks, the FIM, 
the disability domain of the CAMBS, and the physical functioning domain of the 
SF-36, but, as expected for an impairment scale, only moderately with the Barthel 
Index, patients' ability to work and do their house work, and other measures of 
handicap and quality of life. 
5.4.3 FIM 
The FIM sum scores were severely skewed to the `less disabled' end of the 
scale, with a smaller cluster at the `severely disabled' end of the scale suggesting 
both `ceiling' and `floor' effects. In a study of 201 patients with moderate to severe 
disability (EDSS 5.0 to 9.0), van der Putten and co-workers (1999) found the FIM 
sum scores to have span the entire scale range and to have a near Normal distribution 
with small `ceiling' and `floor' effects. The discrepancy between these results and 
mine is likely to be related to the differences in the level of disease severity between 
the two cohorts. As reported by Brosseau and Wolfson (1994), I found the internal 
consistency of the scale items to be surprisingly very high given the 
multidimensional nature of this scale suggesting a degree of item redundancy 
(Streiner and Norman, 1995c). Factor analysis suggested two factors which 
segregated the `mobility' and the `cognitive' items of the scale and accounted 
for 
most of the variance (although the latter accounted for only 6.4% of the total 
variance). Inter- and intra-rater reliabilities of the mobility items were generally 
comparably high. In comparison, the cognitive items were more reliable when 
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applied by the same rater reflecting their ambiguity and the lack of precision in 
differentiating between their different grades. Although complete inter- and intra- 
rater agreements were only obtained by allowing a difference of 13 and 9 points 
respectively, partial agreement corrected reliability of the FIM sum scores was 
high, and a difference of 9 points achieved more than 95% inter-rater agreement. 
These findings are consistent with other published reliability results in which the 
inter-rater reliability for the sum scores was found to be comparably high, and the 
inter-rater reliability of the mobility items to be higher than that of the cognitive 
items (Hall et al., 1993; Brosseau and Wolfson, 1994). There are no published 
data addressing the intra-rater reliability of this scale. As reported by others (Hall 
et al., 1993; van der Putten et al., 1999), 1 found the responsiveness of the FIM sum 
score and many of its mobility items to be high, thereby supporting the usefulness 
of this scale in clinical trials of MS. The face validity of the FIM as a disability 
scale was supported by the high correlation between this scale and other disability 
scales particularly the EDSS, the Barthel index (which is not surprising given the 
generic similarities between the two scales), the disability domain of the CAMBS, 
patients' self-assessment of disability using the physical functioning domain of the 
SF-36, and patients' disability ranks, and its moderate correlation with the Al. As 
expected for any disability scale, the FIM correlated moderately with other 
handicap and quality of life scales, but surprisingly highly with the SNRS. 
The usefulness of the FIM in clinical trials of MS should be considered in 
the light of its limited content validity (Sharrack and Hughes, 1996). This scale is 
not comprehensive to the potential disabilities which could occur in this illness as 
it does not rate visual, speech, swallowing, affective, or sexual disabilities. It is 
my impression that the cognitive items of the FIM are the least useful part of this 
scale in the context of multiple sclerosis as they have a poor inter-rater reliability, 
are unresponsive, and explain only 6.4% of the total variance (factor analysis: 
mental factor). The FIM is also a somewhat cumbersome scale which requires 
reference to a 48-page instruction book and training for its application. 
5.4.4 AI 
As reported by other workers (Goodkin et al., 1989; Swingler and 
Compston, 1992), the frequency distribution of the Al scores was found to be 
bimodal with relative paucity of scores 7 and 8. 
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Rater reliability of this scale was very high. Complete inter-rater and 
94.3% intra-rater agreement obtained by allowing a difference of a single point. 
These results are similar to the previously reported inter-rater reliability in a group 
of 20 patients which suggested that 95% of the raters would score within 1 point 
of the `correct' score (Francis et al., 1991). No other rater reliability studies on 
this scale have been reported in the literature. Despite its high reliability, the Al 
was found to be weakly sensitive to clinical change. This is not surprising since 
this scale addresses only one dimension of the potential disabilities which could 
occur in this illness. The face validity of the Al as a disability scale was 
supported by its high correlation with patients' disability ranks, and patients' self- 
assessment of disability using the physical functioning domain of the SF 36. The 
Al correlated moderately with the EDSS, the FIM, and the Barthel index, 
reflecting its mono-dimensional nature in relation to the other disability scales. 
As expected for a disability scale, the Al correlated moderately with impairment, 
handicap, and quality of life scales. 
5.4.5 CAMBS 
As reported in its original publication (Mumford and Compston, 1993), the 
frequency distribution of the relapse and progression domains of this scale was 
skewed to the `normal' end of the scales suggesting a `floor' effect, which 
reflected the natural history of the illness and the patient population used in the 
study. In comparison, the frequency distribution of the disability domain was 
skewed to the `severely disabled' end of the scale suggesting a `ceiling' effect, 
whereas the handicap domain was evenly distributed. Rater reliability of this 
scale's four domains was reasonably high. Complete inter- and intra-rater 
agreement was obtained by allowing a difference of 1-2 points on the various 
domains. With the exception of handicap domain, a difference of 1 point 
achieved more than 95% rater agreement. The only published reliability data on 
this scale are those of Mumford and Compston (1993) who suggested a moderate 
reliability of the combined scores (calculated as kappa coefficient < 0.66) which is 
somewhat higher than what I found (kappa coefficient of 0.41). Nevertheless, 
these figures are of doubtful significance since a sum score is not used in the 
scale. The scale's relapse and progression domains were moderately sensitive to 
clinical change, reflecting their simple definition and the design of my 
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responsiveness study. The disability domain was weakly sensitive to clinical 
change, whereas the handicap domain was unresponsive. 
The face validity of the disability domain of the CAMBS was supported 
by its high correlation with patients' disability ranks, the FIM, the EDSS, and the 
patients' self-assessment of disability using the physical functioning domain of 
the SF-36, and its moderate correlation with the Barthel index. This domain also 
correlated moderately with other impairment, handicap, and quality of life scales. 
Surprisingly, the correlation between the handicap domain of the CAMBS and the 
London Handicap Scale, patients' independence, and patients' ability to work and 
do their housework, was only moderate or weak, whereas its correlation with the 
EuroQol VAS was high thereby throwing doubt on the validity of this domain as a 
handicap scale. The previously reported high correlation between this domain and 
the Nottingham Health Profile was based on a study of only 10 patients (Mumford 
and Compston, 1993). 
5.4.6 Raters' and patients' bias 
This study was designed to minimise the effect of raters' and patients' bias 
on the assessment of reliability and responsiveness. All the raters were blinded to 
their own and other raters' previous scores, and open discussions about patients' 
clinical conditions were avoided amongst themselves. In the inter-rater reliability 
study, patients were assessed independently by the three raters and no fixed order 
for the examination was observed. The latter was designed to reduce the effect of 
patients' bias due to fatigue or recall of answers to specific questions required to 
obtaining some of the clinical scores. The effect of these potential sources of bias 
is unlikely to have been significant since the inter-rater reliability figures were not 
consistently higher than the intra-rater reliability figures which were based on 
assessments separated by three months periods. For the same reason, it is also 
unlikely that the familiarity of the patients with the assessors have increased the 
intra-rater reliability on the account of raters' recall of their previous scores, since 
such figures were often lower than the inter-rater reliability figures which were 
obtained in the same day by comparing the scores of two different raters. 
Although inter-rater reliability was assessed on scores obtained by either 
two neurologists (EDSS, SNRS and AI) or a neurologist and a research nurse 
(FIM and CAMBS), it is unlikely that this has affected the validity of cross-scale 
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reliability comparison since the application of the FIM and the CAMBS was 
based on patients interview rather than neurological examination, and since 
previous studies have found these two scales to be equally reliable when applied 
by a neurologist and a nurse (Mumford and Compston, 1993), two therapists 
(Brosseau and Wolfson, 1994), or a neurologist and a multidisciplinary team 
comprising a doctor, an occupational therapist, a physiotherapist, a speech 
therapist, and a nurse (Kidd et al., 1995). Furthermore, the reliability of these 
scales was comparable when they were applied by the same neurologist twice (in 
the intra-rater reliability study), or by a neurologist and a research nurse (in the 
inter-rater reliability study). 
A degree of rater bias was observed in the application of the SNRS 
reflecting the lack of clear guidelines for assessing the severity of impairment in 
this scale (Sharrack and Hughes, 1996). The reliability confidence intervals, 
particularly intra-rater, were relatively wide reflecting the small number of 
patients recruited for this study, as standard errors of measurements, used to 
construct the 95% confidence intervals, are inversely related to the sample size 
(Norman and Streiner, 1993b). 
5.5 Conclusions 
This study has comprehensively assessed the psychometric properties of 
five commonly used clinical scales in MS research. None of these scales 
completely satisfied the requirements of an ideal outcome measure, although 
many were found to have some desirable properties. The EDSS was reliable 
within 1.0 point (two 0.5 steps), valid as an impairment and disability scale, but 
not responsive. The SNRS was internally consistent, reliable within 13 point, 
valid as an impairment scale, but not responsive. The FIM was internally 
consistent, reliable within 9 point, valid as a disability scale, sensitive to clinical 
change, but had a limited content validity. The Al was reliable within 1 point, 
valid as an ambulation-related disability scale, but weakly sensitive to clinical 
change. The CAMBS was generally reliable within 1 point in each of its domains, 
and had valid disability and responsive relapse and progression domains. These 




THE GUY'S NEUROLOGICAL DISABILITY SCALE 
6.1 Introduction 
The recent therapeutic trials in multiple sclerosis have highlighted the 
importance of measuring clinical outcomes but at the same time illustrated the 
inadequacies of the measures currently available. The need for a new outcome 
measure has become even more imperative with the increasing number of partially 
effective therapeutic agents which need to be assessed at a very high cost 
(Thompson and Noseworthy, 1996). In 1994, the U. S. National Multiple 
Sclerosis Society sponsored an international workshop entitled: "Outcome 
measures in multiple sclerosis clinical trials: a critical analysis" (Whitaker et al., 
1995). This workshop was attended by over 100 investigators, statisticians, and 
other health care professionals who concluded that none of the current scales was 
adequate and that there was a need for the development of a new scoring system. 
Similar consensus was reached in other international workshops including the 
Second Algero Workshop on Multiple Sclerosis which was held in 1995 
(Sharrack and Hughes, 1999b). 
6.2 The need for a new outcome measure 
To affirm the need for a new clinical scale for multiple sclerosis and to 
investigate its desirable properties, I conducted a postal survey among 49 leading 
neurologists from Europe, North America, Australia and New Zealand. The names 
of these neurologists were retrieved from the referee database of the Journal of 
Neurology, Neurosurgery and Psychiatry according to their clinical or research 
interest in multiple sclerosis and health measurement scales. All the participants 
were sent a questionnaire designed to ascertain whether they thought that existing 
clinical outcome measures in multiple sclerosis were adequate and whether there 
was a need for a new scale. They were also asked to indicate whether such a scale 
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should be patient or doctor orientated, ordinal or quantitative, uni- or 
multidimensional, and whether it should be biased towards any particular disability. 
Thirty-five participants (71.4%) completed and returned their questionnaires. 
The majority of the respondents felt that currently existing outcome measures in 
multiple sclerosis were inadequate (85%) and that there was a need for a new scale 
(97%) which should be multidimensional (83.3%), ordinal (40%), patient orientated 
(46.6%), and not biased towards any particular disability (56.7%) (Table 6.1). 
Table 6.1 The need for a new outcome measure for multiple sclerosis: results of 
the postal survey (n = 35) 
Questions Results Missing data * 
1. Do you think that currently 
available clinical outcome measures 
for multiple sclerosis are adequate? 
2. Is there a need for a new 
outcome measure for multiple 
sclerosis? 
3. Should the new outcome 
measure be patient or 
doctor orientated? 
4. Should the new outcome 
measure be ordinal or 
quantitative? 
5. Should the new outcome 
measure be uni- or multi- 
dimensional? 
6. Should the new outcome measure 
be biased towards any particular 
disability? 
Yes No 
13.3% 83.4% 3.3% 
Yes No 
96.7% 0% 3.3% 
Patient Doctor Both 
orientated orientated 
46.6% 23.3% 20% 10% 
Ordinal Quantitative Both 
40% 30% 13.3% 16.7% 
Uni-dimensional Multi-dimensional 
0% 83.3% 16.7% 
Yes No 
20% ** 56.7% 23.3% 
* Some of the respondents left part of the questionnaire unanswered; ** Mainly towards 
lower limb disability 
In response to these needs and to the growing consensus that disability 
should be the main focus of such a measure (Thompson and 
Hobart, 1996b), I 
undertook to develop a novel clinical disability scale 
for multiple sclerosis, which 
I have called the Guy's Neurological Disability Scale (GNDS). 
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6.3 GNDS conceptual model and development 
Of the three dimensions of human disablement (impairment, disability, 
and handicap), disability is the main disease consequence that has a direct and 
practical relevance to patients as it determines their ability to perform their 
various daily activities. It is equally important to health services as it defines the 
level of care needed by the affected individuals and to society at large as it defines 
the social and economic impact of the illness on the affected individuals. 
Disability is therefore the common pathway by which the diverse consequences of 
complex diseases such as multiple sclerosis can be assessed. 
The GNDS is based on the concept that disability in multiple sclerosis is 
multidimensional, and can be considered in several separate categories (Sharrack 
and Hughes, 1999a). A list of the various disability domains relevant to patients 
with multiple sclerosis was compiled from a review of previously published 
morbidity literature (Swingler and Compston, 1992; Rodriguez et al., 1994; 
Midgard et al., 1996) and existing outcome measures (Sharrack and Hughes, 
1996), supplemented by open interviews with 5 patients with multiple sclerosis. 
Twelve separate categories of mutually exclusive human functions capable of 
capturing all the aspects of disability which could be encountered in multiple 
sclerosis were identified. These categories included cognition, mood, vision, 
speech, swallowing, upper limb function, lower limb function, bladder function, 
bowel function, fatigue, sexual function, and `others' to cover disabilities resulting 
from dysfunction of other less defined systems such as pain, spasms, vertigo, etc. 
These 12 dimensions were later confirmed independently by Thompson and 
Hobart (1996b) as being the most commonly affected aspects of human function 
in patients with multiple sclerosis. 
This model differed conceptually from the EDSS Functional Systems in 
that it divided some of these systems into their constituent parts (sphincters into 
bladder, bowel, and sexual function; cerebral into cognition and mood; and brain 
stem into speech and swallowing), incorporated others into regional 
functions 
(pyramidal, cerebellar and sensory are replaced by upper and lower limb 
function), kept others as separate categories (vision, others), and created a new 
category for fatigue which is often a troublesome and a disabling problem in 
multiple sclerosis (Table 6.2). 
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Table 6.2 Conceptual correlation between the GNDS categories and EDSS 
Functional Systems 









Speech and communication, Swallowing 
Upper limb, Lower limb 
Bladder, Bowel, Sexual 
Fatigue 
Other 
The new model also differed conceptually from other scales of activities of 
daily living, such as the Barthel Index and the FIM, in that such activities were 
considered at their basic anatomical levels to avoid any bias towards upper and 
lower functions (Table 6.3). It also had the advantage of being able to cover the 
whole range of activities of daily living without the need to name them 
individually or risk selection bias. 
The level of disability in each one of these 12 categories was graded 
according to its severity and its impact on patients as judged by the help required 
to perform these functions according to a 7-level scoring system which was 
adapted from the WHO ICIDH disability severity scale (World Health 
Organisation, 1980). This scoring system ranged from 0 (normal status) to 6 (total 
loss of function) (Table 6.4). 
The range of the possible disabilities which could be encountered in each 
one of the 12 dimensions and the stages at which they occur in relation to the 
disease severity and duration were based on detailed review of the literature 
supplemented by input from 10 experts in neurology, neuropsychology, 
neurourology, and health status measurements at the Guy's, 
King's and St. 
Thomas' School of Medicine (Professor RAC Hughes, Professor J Weinman), the 
National Hospital for Neurology and Neurosurgery (Professor A Thompson, 
Professor M Ron, Dr. G Plant, Dr. C Fowler), the Institute of Psychiatry 
(Professor G Dunn, Dr. S Wessely), the Rivermead Rehabilitation Centre (Dr. D 
Wade), and the University of Wales College of Medicine (Professor M Wiles). 
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Table 6.3 Conceptual correlation between the GNDS categories and other scales 
of activities of daily living 












Self-care: toileting, Mobility: 
transfer to toilet 
Eating 
Transfer: bed/chair, tub/shower 
Mobility: walking 






Social cognition: social 
interaction, problem solving, 
memory 
Bladder, Bowel 
Upper limb function 
Upper limb function, Lower limb 
function, 
Upper limb function, Swallowing 
Upper limb function, Lower limb 
function, 
Lower limb function 
Upper limb function 
Lower limb function 

















Level of disability 
Normal function 
Symptoms of no consequences 
Symptoms causing difficulties, but not disabilities 
Disability, but no help is required 
Disability requiring help 
Almost total loss of function 
Total loss of function 
X Unknown 
This information was utilised to create 12 separate disability sub-scales in 
which the range of individual disabilities was graded according to their severity. 
These grades were arranged so that each step represented as far as possible the 
same level of disability in each dimension according to the GNDS severity 
scoring system. To optimise the reproducibility of the GNDS, each sub-scale was 
further supplemented by an interview section which consisted of a set of questions 
designed to ascertain the presence and the severity of individual disabilities as 
outlined in the relevant disability sub-scale. Individual disability scores could 
thereafter be deduced from the patient's answers according to the relevant 
`scoring sections' and an overall score, describing the patient's total disability, 
could be reached by summing all the different sub-scores giving a sum score ranging 
between 0 (no disability) and 72 (maximum possible disability). This process 
generated a 12-item scale. 
The face and content validity of GNDS were assessed during the 
international postal survey described earlier by inviting the same cohort of 49 
neurologist to review the scale and indicate the degree of their approval or 
disapproval using a standard questionnaire. The referees were also invited to 
provide constructive criticisms and suggestions to improve the scale and its 
different items. The results of this study showed that the majority of the referees 
(73%) approved the scale therefore confirming its face validity. However many 
referees provided critical comments in relation to the scale contents which 
suggesting that the scale needed to be revised. 
The GNDS was piloted on the same cohort of 64 patients who took part in 
the inter-rater reliability study of the five commonly used multiple sclerosis scales 
(described in chapter 5) to assess its inter-rater reliability and construct validity, 
and on the sub-group of 50 patients who took part in the intra-rater reliability and 
responsiveness study (described in chapter 5) who were followed up for 6 months 
to assess its intra-rater reliability and responsiveness (Figure 6.1). The study 
design was identical to the one described in chapter 5. This pilot study showed 
the GNDS to be internally consistent (Cronbach's alpha of 0.79), have high inter- 
and intra-rater reliability (intraclass correlation coefficients 0.99 and 0.96 
receptively), and to be moderately responsive to clinical change (effect size 0.54, 
p= <0.001). However the frequency distribution of the GNDS scores was skewed 
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to the `less disabled' end of the scale suggesting a floor effect. The GNDS 
therefore needed to be revised. 
Figure 6.1 GNDS / GNDS-R study design 
Assessment n 
Ist 



















n= number of patients in the study 
Outcome measures assessed 
EDSS, SNRS, Al, FIM, CAMBS, GNDS 
GNDS 
GNDS 
EDSS, SNRS, AI, FIM, CAMBS, GNDS-R 
EDSS, SNRS, AI, FIM, CAMBS, GNDS-R 
6.4 The Revised GNDS 
The critical comments of the 35 referees who responded to the GNDS face 
and content validity questionnaire were categorised into general comments related 
to the conceptual model of the scale, its general structure, and its dimensions, and 
specific comments related to its 12 sub-scales. Taking into account the general 
comments, the GNDS severity scoring system was modified by reducing the 
disability steps from 7 to 6 (Table 6.5). 
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Table 6.5 GNDS-R severity grades 
Grade Level of disability 
0 Normal status 
1 Symptoms causing no disability 
2 Mild disability - not requiring help from others 
3 Moderate disability - requiring help from others 
4 Severe disability - almost total loss of function 
5 Total loss of function - maximum help required 
The specific comments were utilised to revise the GNDS creating the 
Revised Guy's Neurological Disability Scale (GNDS-R). These revisions resulted 
in a new scale which specified 60 points between 0 (no disability) and 60 
(maximum possible disability) (Appendix 1). 
6.5 The psychometric evaluation of the GNDS-R 
The changes suggested by the referees were of such a magnitude as to 
have resulted in a scale which is substantially different from the original version. 
The psychometric properties of the revised scale therefore needed to be re- 
assessed again, ideally on a naive cohort of patients to avoid any bias resulting 
from training effects (Peto et al. 1995). However due to administrative 
difficulties in recruiting and following a second cohort of patients, the evaluation 
was conducted on the same cohort of 50 patients who took part in the intra-rater 
and responsiveness assessment of the GNDS and the five commonly used 
multiple sclerosis scales (described in chapter 5) (Table 6.1). This strategy was 
felt to be appropriate since the revisions have effectively resulted in a new scale, 
and since the frequent administrations of the GNDS during the intra-rater and 
responsiveness study were separated by three monthly intervals which minimised 
any subject or rater bias resulting from the effect of training or recall of previous 
answers. 
6.5.1 Face validity 
Copies of the revised scale were posted to the same group of 49 
international referees who took part in the first face and content study. The 
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referees were invited to critically study the GNDS-R and indicate the degree of 
their approval or disapproval of the scale and its 12 categories using a 6-point 
scoring system (Table 6.6). 
Thirty-three referees (67.3%) responded to the questionnaire, 4 of whom 
left parts of the questionnaire unanswered. As compared with the first face 
validity study, more referees strongly approved / approved of the revised scale. 
Eighty two percent of the respondents expressed their approval of the scale in 
general. The majority of the responders also approved the cognitive (88%), mood 
(73%), vision (85%), speech (85%), swallowing (88%), upper limb (85%), lower 
limb (85%), bladder (91%), bowel (94%), fatigue (82%), sexual function (82%) 
and the `others' (79%) sub-scales (Table 6.6). These results support the validity 
of the GNDS-R as a disability scale for multiple sclerosis. 
6.5.2 Inter-rater reliability 
Inter-rater reliability was assessed on the same cohort of 50 patients with 
multiple sclerosis described in the in intra-rater reliability and responsiveness 
study in chapter 5. This cohort consisted of 31 women and 19 men with a median 
age of 36 years (range 24-51), median EDSS score of 4.5 (range 0-7.5), and a 
median disease duration of 12 years (range 2-17). All patients were assessed 
independently at the same session by myself and a second neurologist who was 
familiar with the GNDS-R. To prevent any systematic bias resulting from 
practice effect or fatigue, no fixed order for the examination of the patients by 
each rater was observed. The median (range) of the GNDS-R sum and sub-scores 
of the two assessments were almost identical (Table 6.7). 
The frequency distribution of the sum scores of both raters was slightly 
skewed to the normal end of the scale (Figure 6.2), which reflects the mild to 
moderate degree of disability in this cohort. 
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Table 6.6 Face validity of the GNDS-R 

























15.2 48.5 24.2 6.1 3 3 0 
9.1 54.5 9.1 21.1 0 6.1 0 
30.3 33.3 21.1 6.1 6.1 3 0 
24.2 42.4 18.2 9.1 6.1 0 0 
30.3 48.5 9.1 9.1 3 0 0 
21.1 39.4 24.2 12.1 3 0 0 
24.2 39.4 21.1 3 3 0 0 
24.2 48.5 21.1 3 0 6.1 0 
24.2 48.5 21.1 3 3 0 0 
24.2 48.5 9.1 15.2 3 0 0 
21.1 39.4 21.1 12.1 6.1 0 0 
12.1 45.5 21.2 3 3 3 12.1 
15.1 45.5 21.2 9.1 6.1 0 3 
* Some of the referees left part of the questionnaire unanswered. 
Table 6.7 Median (range) scores of the GNDS-R inter-rater reliability study 
(n = 50) 
Scale item Rater 1: Median (range) Rater 2: Median (range) 
Cognitive disability 0 [0 to 3] 0 [0 to 3] 
Mood disability 0 [0 to 4] 0 [0 to 4] 
Visual disability 0 [0 to 2] 0 [0 to 2] 
Speech disability 0 [0 to 3] 0 [0 to 3] 
Swallowing disability 0 [0 to 2] 0 [0 to 2] 
Upper limb disability 1 [0 to 4] 1 [0 to 4] 
Lower limb disability 2 [0 to 4] 2 [0 to 4] 
Bladder disability 2 [0 to 4] 2 [0 to 4] 
Bowel disability 0 [0 to 5] 0 [0 to 5] 
Fatigue 2 [0 to 4] 2 [0 to 4] 
Sexual disability 0 [0 to 5] 1 [0 to 5] 
Other disabilities 1 [0 to 4] 1 [0 to 4] 
GNDS-R sum score 12 [0 to 26] 12 [0 to 28] 
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Figure 6.2 The frequency distribution (with the superimposed normal curve) of 
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GNDS-R sum score 
The largest score difference between the two raters was 0 point for the 
swallowing disability sub-scale, 1 point for the speech, upper limb, and lower 
limb disability sub-scales, 2 points for the cognitive, mood, visual, bladder, 
bowel, fatigue, and other disabilities sub-scales, and 3 points for the sexual 
function disability sub-scale (Table 6.8). 
Inter-rater agreement on the different GNDS-R sub-scales was high with 
kappa coefficients ranging between 0.54 and 1 (moderate to perfect), intraclass 
correlation coefficients ranging between 0.82 and 1 (almost perfect to perfect), 
and repeatability coefficients ranging between 0 and 1.5 points. Inter-rater 
agreement on the GNDS-R sum scores was 35.4%, 70.8%, 93.8%, and 100% 
when agreement was defined as no difference, a difference <_ 1,2, and 3 points 
respectively (Table 6.8), with a repeatability coefficient of 2.6 points, a kappa 
coefficient was 0.31 (moderate), and an intraclass correlation coefficient was 0.98 
(almost perfect) (Table 6.9). The mean score differences between the two raters 
for all GNDS-R sub-scores and the sum score was very small with narrow 95% 
confidence intervals which included the `0' value suggesting the absence of any 
rater bias. 
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Table 6.8 GNDS-R inter-rater score agreement (%) (n = 50) 
Scale items 0 point 1 point 2 points 3 points 
Cognitive disability 89.6 95.8 100 NA 
Mood disability 89.6 97.9 100 NA 
Visual disability 89.6 97.9 100 NA 
Speech disability 89.6 100 NA NA 
Swallowing disability 100 NA NA NA 
Upper limb disability 89.6 100 NA NA 
Lower limb disability 91.7 100 NA NA 
Bladder disability 81.3 97.9 100 NA 
Bowel disability 89.6 95.8 100 NA 
Fatigue 81.3 97.9 100 NA 
Sexual disability 79.2 91.7 97.9 100 
Other disabilities 66.8 95.9 100 NA 
GNDS-R sum score 35.4 70.8 93.8 100 
Table 6.9 GNDS-R inter-rater reliability (n = 50) 
Scale item Kappa ICC Mean (95% CI) RC 
(95% CI) (95% CI) score difference 
Cognitive disability 0.79 0.90 0.15 0.9 
[0.63 to 0.95] [0.68 to 0.99] [0.01 to 0.28] 
Mood disability 0.82 0.93 0.13 0.8 
[0.68 to 0.96] [0.69 to 0.99] [0.01 to 0.24] 
Visual disability 0.82 0.85 0.04 0.8 
[0.67 to 0.97] [0.46 to 0.99] [-0.16 to 0.08] 
Speech disability 0.74 0.94 0.06 0.6 
[0.52 to 94] [0.79 to 0.99] [-0.03 to 0.16] 
Swallowing disability 1 1 0 0 
N/A N/A N/A 
Upper limb disability 0.86 0.96 -0.06 0.6 
[0.74 to 0.98] [0.86 to 0.99] [-0.16 to 0.03] 
Lower limb disability 0.89 0.98 0.04 0.6 
[0.79 to 0.99] [0.93 to 0.99] [-0.04 to 0.13] 
Bladder disability 0.74 0.92 -0.06 1.1 
[0.59 to 0.89] [0.73 to 0.99] [-0.24 to 0.11 ] 
Bowel disability 0.80 0.95 0.10 0.9 
[0.66 to 0.94] [0.80 to 0.99] [-0.03 to 0.24] 
Fatigue 0.74 0.94 0 1 
[0.59 to 0.99] [0.77 to 0.99] [-0.15 to 0.15] 
Sexual disability 0.70 0.89 0.06 1.5 
[0.54 to 0.86] [061 to 0.99] [-0.28 to 0.16] 
Other disabilities 0.54 0.82 0.10 1.3 
[0.36 to 0.72] [0.64 to 0.99] [-0.09 to 0.29] 
GNDS-R sum score 0.31 0.98 0.42 2.6 
[0.16 to 0.46] [0.95 to 0.99] [0.04 to 0.79] 
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ICC = intraclass correlation coefficient; RC = repeatability coefficient; Cl = confidence intervals. 
6.5.3 Internal consistency 
Internal consistency was assessed using the inter-rater reliability data set. 
Cronbach's alpha of the GNDS-R was 0.79 indication satisfactory internal 
consistency. The deletion of individual sub-scales did not lead to a significant 
increase in the Cronbach's alpha suggesting that the various scale items were 
homogeneous (Table 6.10). Item-total correlation showed that none of the scale 
items correlated with the total score below 0.32. Split-half reliability showed the 
two randomly created halves of the scale to be highly correlated with each other with 
a Spearman-Brown correlation coefficient of 0.79. 
Table 6.10 Internal consistency of GNDS-R 
Scale item Item-total correlation Cronbach's alpha if item deleted 
Cognitive disability 0.36 0.79 
Mood disability 0.33 0.80 
Visual disability 0.40 0.80 
Speech disability 0.33 0.77 
Swallowing disability 0.42 0.80 
Upper limb disability 0.67 0.76 
Lower limb disability 0.74 0.75 
Bladder disability 0.56 0.77 
Bowel disability 0.32 0.80 
Fatigue 0.45 0.78 
Sexual disability 0.38 0.80 
Other disabilities 0.39 0.80 
6.5.4 Intra-rater reliability and responsiveness 
Intra-rater reliability and responsiveness of the GNDS-R were as assessed 
on same cohort of 50 patients with multiple sclerosis at the time of the intra-rater 
reliability and responsiveness study of the five commonly used multiple sclerosis 
scales which was described in chapter 5. The patients were followed for nine 
months with three monthly assessments. During each visit, patients underwent a 
full neurological examination, and were assigned scores on the SNRS, EDSS, 
FIM, Al, CAMBS, 10 metre walk, and the Barthel Index, and they were asked to 
complete the EuroQol health related quality of life visual analogue scale 
(VAS) 
(EuroQol Group, 1990). 1 also completed a separate copy of the EuroQol VAS to 
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reflect my subjective perception of the patient's health status. As with the intra- 
rater reliability and responsiveness study described in chapter 5, patients' overall 
status were classified as stable, improved, or worsened, if both the patients' and 
my assessments were identical indicating no change, improvement, or worsening 
respectively. Intra-rater reliability was tested on the pairs of assessment between 
which patients' overall status were judged to have remained stable, whereas 
responsiveness was tested on the pairs of assessment between which they had 
changed (improved or worsened). 
A). Intra-rater reliability 
Thirty-five patients had remained stable between two visits on at least one 
occasion during the 9 months follow up period. To avoid introducing any 
statistical bias, only one pair of assessments (the first) per patient was included in 
the final analysis. This cohort consisted of 20 women and 15 men with a median 
age of 38 years (range 24-51 years), a median EDSS of 4.5 (0-7.5), and median 
disease duration of 11 years (2-17 years). The median (range) of the GNDS-R 
sum and the sub-scores of the two assessments were identical (Table 6.11) 
Table 6.11 Median (range) scores of the GNDS-R intra-rater reliability study 
(n=35) 






Upper limb disability 






0 [0 to 3] 
0 [0 to 2] 
0 [0 to 3] 
0 [0 to 2] 
1 [0 to 4] 
2 [0 to 4] 
2 [0 to 4] 
0 [0 to 4] 
2 [0 to 4] 
0 [0 to 4] 
0[0to3] 
0 [0 to 3] 
0 [0 to 2] 
0 [0 to 3] 
0 [0 to 2] 
1 [0 to 4] 
2 [0 to 4] 
2 [0 to 3] 
0 [0 to 4] 
1 [0 to 4] 
0 [0 to 4] 
Other disabilities 0 [0 to 3] 0 [0 to 3] 
GNDS-R sum score 9 [0 to 25] 9 [0 to 25] 
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The largest score differences between the two assessments were 1 point for 
the vision, lower limb, and sexual function sub-scales, 2 points for the cognition, 
speech, swallowing, and upper limb sub-scales, 3 points for the mood, bladder, 
fatigue, and the other disabilities sub-scales, and 4 points for the bowel sub-scale 
(Table 6.12). 
Table 6.12 GNDS-R intra-rater score agreement (%) (n = 35) 












Cognitive disability 77.1 88.6 100 NA NA NA 
Mood disability 57.1 85.7 94.3 100 NA NA 
Visual disability 74.3 100 NA NA NA NA 
Speech disability 91.4 97.2 100 NA NA NA 
Swallowing disability 97.1 97.1 100 NA NA NA 
Upper limb disability 74.3 97.2 100 NA NA NA 
Lower limb disability 85.7 100 NA NA NA NA 
Bladder disability 80 94.3 94.3 100 NA NA 
Bowel disability 85.7 97.2 97.2 97.2 100 NA 
Fatigue 68.6 85.8 97.3 100 NA NA 
Sexual disability 85.7 100 NA NA NA NA 
Other disabilities 71.4 85.7 97.2 100 NA NA 
GNDS-R sum score 22.9 60 85.7 91.5 91.5 100 
Intra-rater agreement on the different sub-scales was variable, with kappa 
coefficients ranging between 0.46 and 0.87 (moderate to almost perfect), 
intraclass correlation coefficients ranging between 0.77 and 0.96 (substantial to 
almost perfect), and repeatability coefficients ranging between 0.7 and 
1.8 points. 
Intra-rater agreement on the GNDS-R sum scores was 23%, 60%, 86%, 92%, 
92%, and 100% when agreement was defined as no difference, a 
difference of <_ 1, 
2,3,4, and 5 points respectively, with a repeatability coefficient of 4.1 points, a 
kappa coefficient of 0.18 (poor), and an intraclass correlation coefficient of 0.96 
(almost perfect) (Table 6.11 and 6.13). With exception of the bowel disability 
sub-scale, the mean score differences between the two assessments were small 
with relatively narrow 95% confidence intervals 
indicating the absence of any 
raters' bias. 
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Table 6.13 GNDS-R intra-rater reliability (n = 35) 
Scale item Kappa ICC Mean (95% CI) RC 
(95% Cl) (95% Cl) score difference 
Cognitive disability 0.64 0.80 0.06 1.5 
[0.40 0.88] [0.36 to 0.99] [-0.31 to 0.21 ] 
Mood disability 0.46 0.70 0.06 2.1 
[0.24 to 0.68] [0.31 to 0.99] [-0.43 to 0.31 ] 
Visual disability 0.61 0.91 -0.13 1 [0.32 to 0.90] [0.42 to 0.99] [0.21 to 0.15] 
Speech disability 0.84 0.92 -0.03 1 [0.56 to 0.99] [0.26 to 0.99] [-0.21 to 0.15] 
Swallowing disability 0.87 0.94 0.06 0.7 
[75 to 0.99] [0.59 to 0.99] [-0.06 to 0.17] 
Upper limb disability 0.61 0.87 -0.11 1.1 [0.51 to 0.71] [0.58 to 0.99] [-0.31 to 0.08] 
Lower limb disability 0.80 0.96 0.09 0.7 
[0.72 to 0.88] [0.87 to 0.99] [-0.04 to 0.21] 
Bladder disability 0.76 0.89 0.14 1.6 
[0.66 to 0.86] [0.45 to 0.99] [-0.13 to 0.42] 
Bowel disability 0.51 0.81 0.71 1.5 
[0.28 to 0.74] [0.37 to 0.99] [-0.09 to 0.43] 
Fatigue 0.56 0.74 0.03 1.9 
[0.36 to 0.76] [0.26 to 0.99] [-0.29 to 0.36] 
Sexual disability 0.80 0.96 -0.14 0.7 
[0.61 to 0.99] [0.91 to 0.99] [-0.28 to -0.02] 
Other disabilities 0.59 0.77 0 1.8 
[0.36 to 0.82] [0.49 to 0.99] [-0.33 to 0.33] 
GNDS-R sum score 0.18 0.96 0.06 4.1 
[0.01 to 0.35] [0.93 to 0.99] [-0.64 to 0.76] 
ICC = intraclass correlation coefficient; RC = repeatability coefficient; CI = confidence intervals. 
B). Responsiveness 
Of the 50 patients assessed, 25 were found to have changed on at least one 
occasion during the 9 months follow up period. This group consisted of 20 
women and 5 men with a median age of 36 years (range 24-51), median EDSS of 
5.5 (range 0-7.5), and a median disease duration of 10 years (range 2-22). To 
avoid introducing any statistical bias, only one pair of assessments (the first) per 
patient was included in the final analysis. The order of assessment in each pair 
(15 patients worsened, and 10 improved) was later re-arranged so as to make all 
the changes of one direction (stable or improved to worsened). Patients' 
subjective assessments of their own health status using the EuroQol VAS was 
moderately sensitive to clinical change with an effect size of 0.55, p <0.001. 
Similar subjective assessment by myself using the EuroQol VAS was weakly 
sensitive to clinical change with an effect size of 0.36, p <0.001. The GNDS-R 
sum score was sensitive to clinical change with an effect size of 0.58, p <0.001 
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(moderate). The mood, vision, upper limb, lower limb, bladder, fatigue, and other 
disabilities sub-scales were also sensitive to clinical change with effect size values 
ranging between 0.23, p=0.021 (small) to 0.92, p=0.00 1 (large). The other sub- 
scales (cognition, speech, swallowing, bowel, and sexual) were unresponsive in 
this cohort (Table 6.14). 
Table 6.14 GNDS-R responsiveness (n = 25) 
Scale item Time 1 
Median (range) score 
Time 1 
Median (range) score 
p* Effect size 
Cognitive disability 0 [0 to 3] 0 [0 to 3] 0.185 0.19 
Mood disability 0 [0 to 3] 1 [0 to 4] 0.023 0.55 
Visual disability 0 [0 to 2] 1 [0 to 2] 0.011 0.49 
Speech disability 0 [0 to 3] 0 [0 to 3] 0.863 0.04 
Swallowing disability 0 [0 to 2] 0 [0 to 2] 1 0 
Upper limb disability 1 [0 to 3] 1 [0 to 3] 0.014 0.30 
Lower limb disability 1 [0 to 4] 2 [0 to 4] 0.021 0.23 
Bladder disability 2 [0 to 4] 3 [0 to 5] 0.035 0.37 
Bowel disability 0 [0 to 4] 0 [0 to 5] 0.035 0.15 
Fatigue 0 [0 to 3] 2 [0 to 3] 0.002 0.92 
Sexual disability 0 [0 to 4] 0 [0 to 5] 0.096 0.17 
Other disabilities 0 [0 to 5] 1 [o to 4] 0.005 0.58 
GNDS-R sum score 9 [0 to 23] 15 [1 to 30] <0.001 0.58 
* Wilcoxon Signed Ranks test 
6.5.5 The reliability of the GNDS-R when applied by other health care 
personnels and by patients' close relatives or carers 
To simplify and reduce the cost of clinical trials, the GNDS-R was 
designed as a simple scale which could be applied by any health care personnel. 
Inter-rater reliability of the scale when applied by a neurologist and a research 
nurse, or by a neurologist and a patient's relative or carer was therefore tested on 
the same cohort of 50 patients during the intra-rater reliability and responsiveness 
study. During the first of the three monthly visits, the GNDS-R was administered 
independently by myself and a research nurse in the same session. A patient's 
relative or close friend, unfamiliar with the scale, was also provided with a copy 
of the scale during the second of the three monthly visits, and was asked to 
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administer it at home within 72 hours and post it back to me. Records of the time 
needed to apply the scale by all the raters were kept to assess the burden of the 
scale application both on patients and raters. 
A). Doctor-nurse administration 
All 50 patients took part in this study. The median (range) of the GNDS-R 
sum and sub-scores of the neurologist's (mine) and the nurse's assessments were 
almost identical (Table 6.15). 
Table 6.15 Median (range) scores of the GNDS-R doctor-nurse reliability study 
(n = 50) 
Scale item Doctor: median (range) Nurse: median (range) 
Cognitive disability 0 [0 to 4] 0 [0 to 4] 
Mood disability 0 [0 to 3] 0 [0 to 3] 
Visual disability 0 [0 to 2] 0 [0 to 2] 
Speech disability 0 [0 to 3] 0 [0 to 3] 
Swallowing disability 0 [0 to 2] 0 [0 to 2] 
Upper limb disability 1 [0 to 4] 1 [0 to 4] 
Lower limb disability 3 [0 to 5] 2 [0 to 5] 
Bladder disability 0 [0 to 4] 0 [0 to 4] 
Bowel disability 0 [0 to 5] 0 [0 to 5] 
Fatigue disability 2 [0 to 5] 2 [0 to 5] 
Sexual disability 0 [0 to 5] 0 [0 to 5] 
Other disabilities 1 [0 to 3] 1 [0 to 3] 
GNDS sum score 13 [0 to 28] 13 [0 to 28] 
Inter-rater agreement on the different sub-scales was high, with kappa 
coefficients ranging between 0.58 and 0.95 (moderate to almost perfect), 
intraclass correlation coefficients ranging between 0.87 and 0.96 (almost perfect), 
and repeatability coefficients ranging between 0.2 and 1.7 point. Inter-rater 
agreement on the GNDS-R sum score was equally high with kappa coefficient of 
0.25 (fair), an intraclass correlation coefficient of 0.96 (almost perfect), and a 
repeatability coefficient of 4.3 point (Table 6.16). The mean score differences 
between the two raters were small with relatively narrow 95% confidence 
intervals which included the `0' value indicating the absence of any raters' bias. 
The mean (SD) of the time required for scale administration and scoring was 4 
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minutes and 30 seconds (2 minutes) for the neurologist (myself) and 6 minutes 
and 23 seconds (4 minutes and 22 seconds) for the nurse. 
Table 6.16 GNDS-R doctor-nurse inter-rater reliability (n = 50) 




Mean (95% CO RC 
score difference 
Cognitive disability 0.69 0.78 -0.20 1.7 [0.49 to 0.89] [0.34 to 0.99] [-0.46 to 0.05] 
Mood disability 0.81 0.82 0.12 1.1 
[0.66 to 0.96] [0.45 to 0.99] [0.04 to 0.28] 
Visual disability 0.74 0.87 0.06 0.7 
0.58 to 0.90] [0.52 to 0.99] [-0.05 to 0.17] 
Speech disability 0.79 0.93 0 0.6 
[0.62 to 0.96] [0.76 to 0.99] [-0.08 to 0.08] 
Swallowing disability 0.93 0.97 -0.02 0.3 
[0.87 to 0.99] [0.85 to 0.99] [-0.06 to 0.02] 
Upper limb disability 0.95 0.98 -0.04 0.4 
[0.91 to 0.99] [0.95 to 0.99] [-0.09 to 0.02] 
Lower limb disability 0.89 0.98 -0.04 0.6 
[0.79 to 0.99] [0.94 to 0.99] [-0.12 to 0.04] 
Bladder disability 0.87 0.98 0 0.2 
[0.76 to 0.98] [0.95 to 0.99] [-0.08 to 0.08] 
Bowel disability 0.82 0.87 0.06 1.3 
[0.67 to 0.96] [0.57 to 0.99] [0.11 to 0.26] 
Fatigue 0.58 0.90 0.12 1.5 
[0.42 to 0.74] [0.67 to 0.99] [-0.34 to 0.10] 
Sexual disability 0.76 0.89 0.04 1.7 
[0.58 to 0.94] [0.62 to 0.99] [-0.21 to 0.29] 
Other disabilities 0.73 0.87 0 1.2 
[0.58 to 0.88] [0.60 to 0.99] [-0.18 to 0.18] 
GNDS sum score 0.25 0.96 0.16 4.3 
[0.05 to 0.45] [0.85 to 0.99] [-0.79 to 0.47] 
ICC = intraclass correlation coefficient; RC = repeatability coefficient; CI = confidence intervals. 
B). Doctor - relative / carer administration 
Thirty-nine patients took part in this study. The other 11 patients did not 
have a close relative or a carer available to administer the scale in the specified 
time frame. The median (range) of the GNDS-R sum and sub-scores of the 
neurologist's (mine) and the patient relatives' assessments were very close (Table 
6.17). 
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Table 6.17 Median (range) scores of the GNDS-R doctor-relative reliability 
study (n = 39) 
Scale item Doctor: median (range) Relative: median (range) 
Cognitive disability 0 [0 to 4] 0 [0 to 4] 
Mood disability 0 [0 to 3] 0 [0 to 3] 
Visual disability 0 [0 to 3] 0 [0 to 3] 
Speech disability 0 [0 to 3] 0 [0 to 3] 
Swallowing disability 0 [0 to 2] 0 [0 to 2] 
Upper limb disability 1 [0 to 4] 1 [0 to 4] 
Lower limb disability 3 [0 to 5] 3 [0 to 5] 
Bladder disability 0 [0 to 5] 2 [0 to 5] 
Bowel disability 0 [0 to 4] 0 [0 to 4] 
Fatigue 3 [0 to 4] 2 [0 to 4] 
Sexual disability 0 [0 to 5] 0 [0 to 5] 
Other disabilities 1 [0 to 4] 1 [0 to 4] 
GNDS sum score 12 [0 to 28] 13 [0 to 33] 
Inter-rater agreement on the different sub-scales was variable, with kappa 
coefficients ranging between 0.24 and 0.72 (fair to substantial), intraclass 
correlation coefficients ranging between 0.46 and 0.91 (moderate to almost 
perfect), and repeatability coefficients ranging between 0.4 and 2.9 point. Inter- 
rater agreement on the GNDS-R sum score was relatively high with kappa 
coefficient of 0.12 (fair), an intraclass correlation coefficient of 0.91 (almost 
perfect), and a repeatability coefficient of 11.1 point (Table 6.18). The mean 
score differences between the two raters for many GNDS-R sub-scales, but not the 
GNDS-R sum score, were slightly biased towards the patient's relatives 
suggesting that they tended to over estimate patient's disabilities. 
The mean (SD) of the time needed for scale administration and scoring 
was 4 minutes and 37 seconds (2 minutes and 36 seconds) for the neurologist 
(myself), and 7 minutes and 37 seconds (6 minutes and 25 seconds) for the 
patients' relatives. 
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Table 6.18 GNDS-R doctor-relative inter-rater reliability (n = 39) 
Scale item Kappa ICC Mean (95% Cl) RC 
(95% Cl) (95% Cl) score difference 
Cognitive disability 0.43 0.75 -0.31 2 [0.24 to 0.62] [0.06 to 0.99] [-0.64 to 0.03] 
Mood disability 0.24 0.46 -0.18 2.1 [0.04 to 0.44] [0.01 to 0.99] [- 0.52 to 0.16] 
Visual disability 0.52 0.76 -0.10 1 [0.27 to 0.77] [0.33 to 0.99] [-0.27 to 0.06] 
Speech disability 0.37 0.56 - 0.08 1.4 [0.07 to 0.67] [0.03 to 0.99] [-0.30 to 0.13] 
Swallowing disability 0.72 0.91 - 0.03 0.4 [0.49 to 0.95] [0.70 to 0.99] [-0.12 to 0.07] 
Upper limb disability 0.66 0.75 - 0.21 1.8 [0.48 to 0.84] [0.19 to 0.99] [-0.50 to 0.09] 
Lower limb disability 0.60 0.87 0 1.6 
[0.42 to 0.78] [0.22 to 0.99] [-0.19 to 0.19] 
Bladder disability 0.58 0.79 -0.18 1.8 
[0.38 to 0.78] [0.20 to 0.99] [-0.49 to 0.09] 
Bowel disability 0.75 0.88 -0.10 1.3 
[0.57 to 0.93] [0.25 to 0.99] [-0.32 to 0.12] 
Fatigue disability 0.49 0.65 - 0.23 2.9 
[0.30 to 0.68] [0.05 to 0.99] [-0.71 to 0.25] 
Sexual disability 0.63 0.72 - 0.26 2.8 
[0.40 to 0.86] [0.17 to 0.99] [-0.71 to 0.20] 
Other disabilities 0.48 0.65 - 0.15 2. 
[0.18 to 0.68] [0.12 to 0.99] [-0.49 to 0.18] 
GNDS sum score 0.12 0.91 0 11.1 
[0.00 to 0.24] [0.21 to 0.99] [-1.28 to 1.28] 
ICC = intraclass correlation coefficient; RC = repeatability coefficient; CI = confidence intervals. 
These results suggest that the GNDS-R and many of its sub-scales are 
reliable when administered by a non-neurologist health care personnel, or by 
patients' relatives or carers. 
6.5.6 The reliability I validity of the GNDS-R when administered over the 
telephone or via a postal questionnaire 
The GNDS-R was originally designed for interview administration. 
However the feasibility of administering this scale over the telephone or via a 
postal questionnaire was tested since such applications could simplify the conduct 
of clinical trials and reduce their costs. 
I contacted all the patients who took part in the intra-rater reliability and 
responsiveness study by telephone within three days of their third three monthly 
visits and re-administered GNDS-R over the telephone. Records of the time 
needed to administer the scale were kept during these assessments. A postal 
127 
version of the GNDS-R was devised using the exact wording of the interview 
sections with a slightly modified layout to simplify their readability. This `postal 
questionnaire' was piloted on a group of five naive patients to assess its 
intelligibility and readability, and the layout, but not the questions, was modified 
accordingly (Appendix 2). Copies of this questionnaire were given to all patients 
who took part in the intra-rater reliability study during their fourth three monthly 
visits, and the patients were asked to complete the questionnaires and return them 
within three days. They were also asked to keep a record of the time needed to 
complete these questionnaires. All returned questionnaires were later scored by 
myself according to the patients' responses. 
A). Interview vs. telephone administration 
Forty-seven patients took part in this study. I was unable to contact the 
other three patients within the specified time frame. The median (range) of the 
GNDS-R sum and sub-scores of the interview and the telephone administrations 
were almost identical (Table 6.19). With the exemption of the mood disability 
sub-scale, the correlations between the scores obtained by administering the scale 
during an interview or over the telephone by the same rater were high with 
correlations coefficients ranging between 0.84 and 1. 
Table 6.19 Median (range) GNDS-R scores obtained during interview and 
telephone scale administration (n = 47) 





Cognitive disability 0 [0 to 4] 0 [0 to 4] 0.86 
Mood disability 0 [0 to 3] 0 [0 to 3] 0.67 
Visual disability 0 [0 to 3] 0 [0 to 3] 0.84 
Speech disability 0 [0 to 3] 0 [0 to 3] 1 
Swallowing disability 0 [0 to 2] 0 [0 to 2] 0.93 
Upper limb disability 1 [0 to 4] 1 [0 to 4] 0.95 
Lower limb disability 2 [0 to 5] 2 [0 to 5] 0.99 
Bladder disability 0 [0 to 5] 0 [0 to 5] 0.92 
Bowel disability 0 [0 to 5] 0 [0 to 5] 0.93 
Fatigue 2 [0 to 4] 2 [0 to 4] 0.91 
Sexual disability 0 [0 to 5] 0 [0 to 5] 1 
Other disabilities 1 [0 to 4] 0 [0 to 4] 0.84 
GNDS sum score 12 [0 to 28] 12 [0 to 29] 0.96 
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Inter-rater agreement on the different sub-scales was high, with kappa 
coefficients ranging between 0.69 and 1 (substantial to almost perfect), intraclass 
correlation coefficients ranging between 0.70 and 1 (substantial to almost perfect), 
and repeatability coefficients ranging between 0 and 1.4 points. Inter-rater 
agreement on the GNDS-R sum scores was equally high with intraclass 
correlation coefficient of 0.96 (almost perfect), and a repeatability coefficient of 
4.1 points (Table 6.20). The mean score differences between the two scale 
applications were small with relatively narrow 95% confidence intervals which 
included the `0' value indicating the absence of any raters' bias. The mean (SD) 
of the time needed for scale administration and scoring was 5 minutes and 12 
seconds (3 minutes and 50 second) for the interview application, and 5 minutes 
and 1 seconds (2 minutes and 30 seconds) for the telephone application. 
Table 6.20 GNDS-R interview / telephone scale administration inter-rater 
reliability (n = 47) 
Scale item Kappa ICC Mean (95% Cl) RC 
(95% CI) (95% CI) score difference 
Mental disability 0.81 0.85 0.09 1.4 
[0.64 to 0.98] [0.54 to 0.99] [-0.13 to 0.30] 
Mood disability 0.69 0.70 0 1.4 
[0.48 to 0.90] [0.39 to 0.99] [-0.21 to 0.21] 
Visual disability 0.76 0.87 -0.04 0.7 
[0.59 to 0.93] [0.58 to 0.99] [-0.15 to 0.06] 
Speech disability 1 1 0 0 
N/A N/A [N/A] 
Swallowing disability 0.79 0.87 -0.09 0.7 
[0.59 to 0.99] [0.59 to 0.99] [-0.19 to 0.02] 
Arm disability 0.86 0.97 0.11 0.6 
[0.74 to 0.98] [0.80 to 0.99] [0.01 to 0.19] 
Leg disability 0.97 0.99 0.02 0.3 
[0.95 to 0.99] [0.84 to 0.99] [-0.02 to 0.06] 
Bladder disability 0.77 0.91 0.13 1.1 
[0.63 to 0.911 [0.37 to 0.99] [-0.04 to 0.19] 
Bowel disability 0.91 0.96 -0.08 1.1 
[0.84 to 0.98] [0.47 to 0.99] [-0.26 to 0.08] 
Fatigue 0.79 0.92 0.11 1.4 
[0.65 to 0.93] [0.43 to 0.99] [-0.11 to 0.32] 
Sexual disability 1 1 0 0 
N/A N/A [N/A] 
Other disabilities 0.77 0.83 0 1.4 
[0.62 to 0.92] [0.45 to 0.99] [-0.15 to 0.15] 
GNDS sum score 0.26 0.96 0 4.1 
[0.09 to 0.42] [0.54 to 0.99] [-0.43 to 0.43] 
ICC = intraclass correlation coefficient; RC = repeatability coefficient; CI =confidence intervals. 
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B). Interview vs. postal questionnaire scale administration 
Forty-two patients took part in this study. Two patients did not complete 
the questionnaire in the specified time, and six questionnaires were lost in the 
post. The median (range) of the GNDS-R sum and sub-scores of the interview 
and the postal questionnaire scale administration were almost identical. The 
correlations between the scores obtained by administering the scale during an 
interview or via a postal questionnaire were high for the GNDS-R sum score and 
its speech, swallowing, upper limb, lower limb, bladder, bowel, fatigue, and 
sexual function disability sub-scales with correlations coefficients ranging 
between 0.81 and 1, and moderate for the cognition, mood, visual, and other 
disabilities sub-scales with correlations coefficients ranging between 0.66 and 
0.76 (Table 6.21). 
Table 6.21 Median (range) GNDS-R scores obtained during interview and postal 
questionnaire administration (n = 42) 
Scale items Interview application Postal questionnaire r 
Median (range) Median (range) 
Mental disability 0 [0 to 4] 0 [0 to 4] 0.66 
Mood disability 0 [0 to 3] 0 [0 to 3] 0.65 
Visual disability 0 [0 to 3] 0 [0 to 3] 0.76 
Speech disability 0 [0 to 3] 0 [0 to 3] 0.89 
Swallowing disability 0 [0 to 2] 0 [0 to 2] 0.94 
Upper limb disability 1 [0 to 4] 1 [0 to 4] 0.91 
Lower limb disability 2 [0 to 5] 2 [0 to 5] 0.92 
Bladder disability 0 [0 to 5] 1 [0 to 5] 0.86 
Bowel disability 0 [0 to 4] 0 [0 to 4] 0.93 
Fatigue 2 [0 to 4] 2 [0 to 4] 0.81 
Sexual disability 0 [0 to 5] 0 [0 to 5] 0.93 
Other disabilities 1 [0 to 3] 2 [0 to 3] 0.70 
GNDS sum score 12 [0 to 28] 13 [0 to 29] 0.93 
The reliability of the different GNDS-R sub-scales using the two scale 
administration methods was high, with kappa coefficients ranging between 0.49 
and 0.84 (moderate to almost perfect), intraclass correlation coefficients ranging 
between 0.761 and 0.92 (substantial to almost perfect), and repeatability 
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coefficients ranging between 0.5 and 1.7 points. The reliability of the GNDS-R 
sum score was equally high with an intraclass correlation coefficient of 0.93 
(almost perfect), and a repeatability coefficient of 6.2 points (Table 6.22). The 
mean score differences between the two scale applications were small with 
relatively narrow 95% confidence intervals which included the `0' value 
indicating the absence of any bias. The mean (SD) of the time needed for scale 
administration and scoring was 5 minutes and 23 seconds (3 minutes and 32 
second) for the interview application, and 6 minutes and 30 seconds (3 minutes 
and 54 seconds) for the postal questionnaire application (excluding the time 
needed for scoring the questionnaire). 
Table 6.22 GNDS-R interview-postal questionnaire scale administration inter- 
rater reliability (n = 42) 
Scale item Kappa ICC Mean (95% CI) RC 
(95% Cl) (95% Cl) score difference 
Cognitive disability 0.49 0.61 -0.05 2.6 
[0.27 to 0.77] [0.12 to 0.99] [-0.54 to 0.36] 
Mood disability 0.55 0.69 -0.02 1.5 
[0.31 to 0.79] [0.18 to 0.99] [-0.26 to 0.21 ] 
Visual disability 0.70 0.77 -0.14 0.5 
[0.51 to 0.89] [0.35 to 0.99] [-0.29 to 0.04] 
Speech disability 0.64 0.88 -0.05 0.7 
[0.53 to 0.75] [0.60 to 0.99] [-0.17 to 0.07] 
Swallowing disability 0.79 0.92 -0.02 0.5 
[0.59 to 0.99] [0.73 to 0.99] [-0.11 to 0.06] 
Upper limb disability 0.81 0.93 -0.02 0.9 
[0.67 to 0.95] [0.77 to 0.99] [-0.12 to 0.17] 
Lower limb disability 0.76 0.92 0.17 0.9 
[0.61 to 0.91] [0.73 to 0.99] [-0.04 to 0.37] 
Bladder disability 0.64 0.87 0 1.2 
[0.46 to 0.82] [0.58 to 0.99] [-0.24 to 0.24] 
Bowel disability 0.79 0.93 -0.02 1 
[0.62 to 0.95] [0.75 to 0.99] [-0.19 to 0.14] 
Fatigue 0.55 0.83 0.17 0.8 
[0.37 to 0.73] [0.48 to 0.99] [-0.16 to 0.49] 
Sexual disability 0.84 0.92 -0.07 1.4 
[0.67 to 0.99] [0.72 to 0.99] [-0.29 to 0.15] 
Other disabilities 0.56 0.69 0 1.7 
[0.36 to 0.76] [0.17 to 0.99] [-0.28 to 0.28] 
GNDS sum score 0.21 0.93 0.02 6.3 
[0.02 to 0.40] [0.75 to 0.99] [-1.02 to 0.97] 
ICC = intraclass correlation coefficient; RC = repeatability coefficient; CI = confidence intervals. 
These results suggest that the GNDS-R and many of its sub-scales are 
reliable when applied over the telephone or via a postal questionnaire. They also 
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suggest that the telephone and the postal questionnaire applications are valid 
methods of administering the GNDS-R. 
6.6 GNDS-R postal survey 
To evaluate the performance of the GNDS-R in a large community-based 
cohort of patients, and to assess its acceptability to patients, I conducted a study to 
test the postal version of the scale in a large cohort of naive patients. 
6.6.1 Study design 
Copies of the GNDS-R postal questionnaire (Appendix 2) were posted to a 
group of 400 randomly selected patients with multiple sclerosis whose names and 
addresses were retrieved from the Multiple Sclerosis Resource Centre (a 
charitable organisation) mailing list. The patients were invited to complete the 
questionnaires and to provide simple demographic information related to their 
age, sex, work status, and to indicate whether or not they required help to 
complete these questions. Participants were also asked to complete a face validity 
questionnaire identical to that used in the face and content validity studies 
discussed earlier. A single reminder was posted 6 weeks after the first mailing. 
All returned questionnaires were scored by a single rater. Uncompleted or 
incorrectly completed sub-scales were treated as missing values. Missing values 
were interpolated (mean of the other available scores) if >80% of the other sub- 
scores were available. 
6.6.2 Results 
One hundred and ninety four patients (48.5%) completed and returned 
their questionnaires. The median age of the respondents was 49 years (range 27- 
73), 78% were female, 12% were in full time and 15% were in part time 
employment. Eighty percent of the respondents were able to complete the 
questionnaires by themselves, whereas the rest needed some help in reading the 
questions (7%), working out the answers (8%), or writing them down (15%) 
(Table 6.23) 
132 
Table 6.23 Demographic characteristics of the GNDS-R postal survey 
respondents 
Number of patients surveyed 400 
Number of respondents 194 
Return rate 48.5 % 
Age: median (range) years 49 (27 to 73) 
Sex: female / male 151 / 43 
Work status: 
Full time 23(11.9%) 
Part time 29(14.9%) 
Not working 142(73.2%) 
Help needed in filling in the questionnaire 53(27.3%) 
Type of help required 
Reading the questions 14(7.2%) 
Writing in the answers 29(14.9%) 
Deciding on how to answer the questions 15(7.7%) 
Eighty-three percent of the respondents completed the GNDS-R 
questionnaire fully and correctly. The other 17% left parts of the questionnaires 
unanswered or incorrectly completed (Table 6.24). After interpolating for missing 
values, sum scores could be assigned to 97.9% of the returned questionnaires. 
The frequency of the GNDS-R sum scores was normally distributed with no 
`ceiling' or `floor' effects (Figure 6.3). 
Near normal frequency distribution was also observed in the cognitive, 
mood, upper limb, lower limb, bladder, bowel, fatigue, sexual function, and other 
disability sub-scales, whereas a skewed distribution to the `less disabled' end of 
the scale was noted in the vision, speech, and swallowing sub-scales reflecting the 
previously noted mild severity prevalence figures of these disabilities in 
population-based cohorts (Rodriguez et al., 1994; Midgard et al., 1996) (Table 
6.24). 
133 
Figure 6.3 The frequency distribution (with the superimposed normal curve) of 







GNDS-R sum score 
Table 6.24 Frequency distribution of the GNDS-R postal questionnaire (% of 
respondents scoring at each individual grade, n= 194) 
Grades 
Scale item 012345 Missing values (n) 
Cognitive disability 36.1 12.3 39.2 5.7 6.7 0 2 
Mood disability 27.3 28.4 12.9 26.3 4.6 0.5 2 
Visual disability 37.1 51.6 7.2 2.6 0 1.5 4 
Speech disability 73.6 13.9 8.2 3.6 0.5 0 7 
Swallowing disability 77.9 8.2 10.3 3.1 0 0.5 4 
Upper limb disability 27.8 5.7 25.3 30.9 7.2 3.1 1 
Lower limb disability 6.2 22.7 26.8 4.7 27.3 12.4 4 
Bladder disability 14.9 2.1 34.5 24.2 12.9 11.3 0 
Bowel disability 40.2 7.3 23.2 2.6 24.2 2.6 4 
Fatigue disability 2.6 4.6 15.4 49.5 6.7 17.5 1 
Sexual disability 35.1 5.2 8.8 7.7 30.9 12.4 17 
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The majority of the respondents (81.4%) completed the face validity 
questionnaire, whereas the rest (18.6%) left part of the questionnaire unanswered. 
Many respondents found the GNDS-R questionnaire not to be comprehensive 
enough and the `yes/no' answer options to be restrictive but the scale was 
otherwise perceived favourably. The majority (87.7%) of the respondents expressed 
their approval of the scale in general and only 4% disliked it. The majority of the 
responders also expressed their approval of the cognitive (87%), mood (83%), vision 
(84%), speech (83%), swallowing (84%), upper limb (82%), lower limb (84%), 
bladder (86%), bowel (85%), fatigue (86%), sexual function (89%) and the `others' 
(77%) sub-scales (Table 6.25). 
Table 6.25 Face validity of the GNDS-R postal questionnaire 
% of respondents (n = 194) 
Scale item Strongly Approve Tends to Tends to Disapprove Strongly Missing 
approve approve disapprove disapprove values 
Cognition 33 46.9 7.2 1.5 2.6 0 8.8 
Mood 34.4 41.2 7.2 4.6 2.1 0.5 10 
Vision 40.7 36.1 6.7 3.1 3.1 0 11 
Speech 33.5 42.3 7.2 3.6 2.1 0 11.3 
Swallowing 34 40.2 9.8 2.1 0.5 0.5 12.9 
Upper limb 38.1 34 10.3 3.1 2.6 2 9.9 
Lower limb 42.3 31.4 9.8 2.6 1 2.6 10.3 
Bladder 42.3 35.1 8.2 2.6 1.5 0.5 9.8 
Bowel 38.1 36.6 9.8 1.5 1.5 0.5 12 
Fatigue 46.4 32 7.2 2.1 2.1 0.5 9.7 
Sexual function 33.5 34.5 19.8 11 1 6.1 5.9 
Others 32.5 36.6 7.7 3.1 1 0.5 18.6 
Overall scale 
45.4 33.5 8.8 1.5 1.5 0 9.3 
Although the various GNDS-R items were not directly drawn from in-depth 
patient interviews (Thompson and Hobart, 1996b), these results support the face 
validity of the scale by indicating patients' approval of the scale and its various 
items 
(Sharrack and Hughes, 1999a). 
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6.7 Factor analysis 
Factor analysis was conducted to assess the underlying conceptual 
dimensions of the 12 GNDS-R sub-scales and investigate the presence of any 
redundant items. Data obtained during the postal survey met all the criteria 
required for an adequate factor analysis and these results will be discussed. Factor 
extraction by principal components, followed by orthogonal or oblique rotation 
gave comparable results. Factors which gained an eigenvalue of <1, and items 
which gained a loading of <0.35 on any factor so created were discarded. This 
analysis suggested a four factor solution which accounted for 58.7% of the total 
variance (cumulative percentage of 26.5%, 39.9%, 49.9%, and 58.7%; 
eigenvalues of 3.18,1.61,1.25,1.05 respectively). The rotated matrix suggested 
no redundant items. With a cut off loading value of 0.35, each GNDS-R sub-scale 
loaded on one factor only. 
The first factor of the rotated matrix (spinal factor) correlated with the 
lower limb, bladder, bowel, and sexual function sub-scales. The second factor 
(mental factor) correlated with the cognition, mood, and fatigue sub-scales. The 
third factor (bulbar factor) correlated with the speech and swallowing sub-scales. 
The fourth factor (upper limb / vision / other disabilities factor) correlated with 
the upper limb, vision, and other disabilities sub-scales (Table 6.26). These four 
factors segregated the 12 GNDS-R dimensions in a logical and predictable manner 
therefore strengthening the content validity of the scale. 
Factor analysis was also conducted on the inter-rater reliability data set 
with comparable results. The analysis suggested a four factor solution which 
accounted for 67.8% of the total variance (cumulative percentage of 31.7%, 
45.6%, 59.1%, and 67.8%; eigenvalues of 3.81,1.67,1.61,1.05 respectively). 
Compared with the factor analysis of the postal survey data set, the various 
GNDS-R sub-scales loaded on the four factors in an identical manner, although 
the individual contributions of the mental, mood and the upper limb/vision/other 
to the total variance were different in this sample (Table 6.27). 
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Table 6.26 GNDS-R factor analysis (postal survey data set): rotated components 
matrix 
Scale item Factor 1 Factor 2 Factor 3 Factor 4 
Cognitive disability 0.09 0.23 0.75 0.03 
Mood disability 0.30 -0.09 0.75 0.17 
Visual disability - 0.09 0.29 0.05 0.55 
Speech disability 0.07 0.82 0.21 -0.01 
Swallowing disability 0.12 0.77 -0.01 0.27 
Upper limb disability 0.29 0.35 0.12 0.66 
Lower limb disability 0.61 0.08 -0.21 0.31 
Bladder disability 0.81 -0.06 -0.03 -0.03 
Bowel disability 0.65 0.15 0.12 -0.02 
Fatigue -0.01 0.29 0.56 0.25 
Sexual disability 0.62 0.16 0.32 -0.05 
Other disabilities 0.06 -0.12 0.21 0.79 
Table 6.27 GNDS-R factor analysis (inter-rater reliability data set): rotated 
components matrix 
Scale item Factor 1 Factor 2 Factor 3 Factor 4 
Cognitive disability -0.03 0.17 0.34 0.57 
Mood disability 0.02 0.08 0.13 0.79 
Visual disability 0.01 0.72 0.21 0.06 
Speech disability 0.21 0.09 0.74 0.19 
Swallowing disability 0.04 0.02 0.88 -0.05 
Upper limb disability 0.25 0.71 0.22 0.31 
Lower limb disability 0.74 0.35 0.19 0.07 
Bladder disability 0.81 0.12 0.27 0.07 
Bowel disability 0.81 -0.26 -0.04 -0.25 
Fatigue 0.21 0.26 -0.05 0.77 
Sexual disability 0.67 0.34 -0.02 -0.02 
Other disabilities 0.19 0.72 -0.03 0.29 
137 
6.8 Validity 
In the absence of a gold standard to assess disability in multiple sclerosis, 
the validity of GNDS-R was established through the process of construct validity 
by assessing the degree to which this scale correlated with other existing measures 
of disability (convergent construct validity), impairment, handicap, and health 
related quality of life measures (discriminant construct validity), and other 
generated hypotheses (construct validity by hypothesis testing), and by testing its 
ability to differentiate between patient groups known to differ in the degree of 
their disability (construct validity by group differences). 
6.8.1 Study design 
The validity study was conducted on the same cohort of 50 patients who 
took part in the intra-rater and responsiveness study described above. During their 
third three monthly visit all patients were additionally assessed as follows: 
A). All patients underwent full neurological examinations including 
assessment of their visual acuity using a Snellen Chart, and were assigned scores 
on the SNRS, EDSS, FIM, Al, CMBS, time to walk 10 metres, and the Barthel 
Index. 
B). Patients were also asked to complete 12 separate visual analogue scales, 
adopted from the EuroQol VAS, to indicate the degree of disability as perceived 
by them in each of the 12 GNDS-R dimensions. 
Q. Upper limb function was assessed using the 9-hole peg test (time taken to 
place 9 pegs into a board and remove them) as an impairment measure 
(Mathiowetz et al., 1985). Three trials with each hand were performed and the 
mean of the results with the two hands was calculated. 
D). Swallowing was assessed using the timed swallowing test devised by 
Nathadwarawala and co-workers as an impairment test (Nathadwarawala et al., 
1992). The nature of the test was explained to the patients who were given 150 ml 
of cold water to drink from a standard cup. Patients were asked to drink the water 
as quickly as possible but to take care and to stop if difficulty arose. During the 
procedure, I sat at the side of the subjects to obtain an adequate view of the 
laryngeal movements during swallowing. The time taken from the beginning of 
the test to the last swallow recognised by return of the larynx to the rest position 
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was noted. The residual volume was measured in those who were unable to 
complete the test and the swallowing speed (ml/s) was calculated. 
E). Speech was assessed using the Frenchay Dysarthria assessment as an 
impairment measure (Enderby, 1988). This test was administered by giving 
patients specific tasks designed to assess the anatomical, physiological, and 
perceptual features of dysarthria in 8 separate sections: reflexes (3 items), 
respiration (2 items), lip movements (5 items), jaw movements (2 items), palatal 
movements (3 items), phonation (5 items), tongue movements (6 items), and 
intelligibility (3 items). A nine-point scoring system was used to record the 
patient's response in each sub-set, and the results were charted on a bar graph with 
a nine-point scale on the vertical axis, with eight sets and corresponding subsets 
on the horizontal axis giving a profile of the speech assessments. Sum scores of 
the eight sets were also calculated. 
F). All patients underwent a detailed battery of cognitive tests which were 
constructed following consultation with a neuropsychologist from the National 
Hospital for Neurology and Neurosurgery (Dr Luke Kartsounis). This battery was 
constructed as a comprehensive battery of impairment measures which included: 
1). The National Adult Reading Test (NART) as a measure of pre-morbid level of 
functioning (Nelson and Willison, 1992). 
This test consists of 50 single irregular words which do not obey the usual 
English letter-to-sound rules. The raw scores were transformed into IQ 
equivalents to provide an estimate of pre-morbid intelligence. 
2). Letter cancellation task as a measure of visual attention (Willison et al., 1980). 
This task was devised and used previously in a clinical study to assess the 
effect of high haematocrit on alertness. Patients were asked to stroke out at speed 
all the B's from a random array of 5 capital letters (A, B, C, D and E) arranged in 
a matrix of 11 rows by 8 columns on an A4 sheet. The time to complete the task 
and the number of errors were recorded. 
3). Paced Auditory Serial Addition Task (PASAT) version 2 and 4 seconds as a 
measure of auditory attention and speed of information processing (Gronwall, 
1977). 
Two pre-recorded lists of 61 numbers read at a rate of one digit every 2 or 
4 second intervals were played, and the patients were asked to add each number to 
the previous one and give their answers aloud. A demonstration with written 
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numbers and two practice auditory lists of 10 digits recorded at a rate of 2 and 4 
second intervals were given before the test was conducted. The total of the 
correct answers at each paced speed (ranging between 0 and 60) was recorded. 
4). Standard Progressive Matrices as a measure of non-verbal abstract reasoning 
and general intellectual function (Raven, 1994). 
The test consists of 60 problem (diagrammatic puzzles) divided into five 
sets (A, B, C, D, and E) each made up of 12 problems. In each set the first 
problem is self-evident, but the problems which follow build on the argument of 
those that have gone before and become progressively more difficult. A self- 
administered version was used. The test was explained to the patients who were 
asked to complete the task at their own pace up to a maximum of one hour. The 
final score was the total number of problems solved correctly. The consistency of 
the answers were checked as described in the operational manual, and the scores 
were transformed into percentiles and grades ranging between (I) indicating 
intellectual superiority, and (IV) indicating intellectual impairment. 
5). Similarities sub-set of the Wechsler Adult Intelligence Scale - Revised as a 
measure of verbal abstract reasoning (Wechsler, 1981). 
Patients were presented with a list of 14 two-item sets and were asked to 
indicate in what way the two items were alike. Raw scores were transformed into 
standard scores as described in the operational manual. 
6). Immediate and delayed story recall sub-set of the Adult Memory and 
Information Processing Battery as a measure of verbal memory (Coughlan and 
Hollows, 1985). 
Patients were read a standard story and were asked to repeat it 
immediately and 30 minutes afterwards. Raw scores were transformed into 
standard scores using the operational manual. 
7). Controlled Oral Word Association Test (COWAT) as a measure of verbal 
fluency and planning abilities (Benton and Hamsher, 1976; Miller, 1984). 
Patients were asked to say as many words as they could think of in 60 
seconds that begin with a given letter of the alphabet (F, A, S) excluding proper 
nouns, numbers, and the same word with a different suffix. A practice trial using 
the letter C was administered first to assure that the patient comprehended the 
task. The raw scores, the sum of all acceptable words produced in the three one- 
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minute trials, were adjusted for age, sex, and education and the adjusted scores 
were converted into percentiles. 
F). All patients were provided with booklets containing copies of the 
following self-administered scales: 
1). The London Handicap Scale (Harwood et al., 1994). 
This self-administered scale has six items each consisting of a question 
related to one of the ICIDH handicap dimensions (mobility, orientation, physical 
independence, occupation, social integration, and economic self-sufficiency), with 
a six-point scoring system from 1 to 6. Patients' responses are weighted and 
summed giving a total score ranging between 0 and 100. 
2). The Short Form 36 health survey questionnaire (SF-36) (Garratt et al., 1993). 
This is a 36 item self-administered questionnaire which addresses eight 
distinct quality of life dimensions including physical functioning (10 items), role 
limitation due to physical problems (4 items), role limitation due to emotional 
problems (3 items), social functioning (2 items), mental health (5 items), energy / 
vitality (4 items), pain (2 items), and general health perception (5 items), with a 
further single unscaled item related to health change over the last one year. Each 
item comprises a question requesting information about a certain aspect of 
perceived health. For each dimension, item scores are coded, summed, and 
transformed into a scale from 0 (worst possible health status) to 100 (best possible 
health status). 
3). The General Health Questionnaire (GHQ) (Goldberg and Williams, 1988). 
This is a self-administered screening test was designed to detect non- 
psychotic psychiatric symptoms among respondents in community settings or 
general medical outpatient departments, and can be considered to be an 
impairment measure. The 28-item scaled version is used mainly for research 
proposes. This questionnaire has four scales testing somatic symptoms, anxiety 
and insomnia, social dysfunction, and severe depression. Each scale has seven 
items which consist of questions asking whether the participant has recently 
experienced a particular symptom or certain behaviour. The answers were scored 
on the 4-point `Likert' scale between 0 (less than usual) and 3 (much more than 
usual) rather than the bimodal response (0-0-1-1) since the former is thought to 
produce less skewed distribution and offer marginal advantages if sub-scale scores 
were required. 
141 
4). The Beck Hopelessness Scale (Beck et al., 1974) 
This is a 20 true-false item self-administered scale which measures the 
extent of negative expectations about the immediate and long-range future 
(pessimism) as perceived by the patient, and is considered to be an impairment 
measure. The items scored are summed to yield a total score that can range from 0 
to 20 with the higher scores indicating greater hopelessness. 
5). The Chalder and Fatigue Scale (Chalder et al., 1993) 
This is a self-administered 14-item scale which was developed to measure 
the severity of physical and mental fatigue symptoms, and as such it is considered 
as an impairment scale. The scale items are answered on a 4-point scale and 
scored using the General Health Questionnaire bimodal response method (0-0-1- 
1) giving a total fatigue score which ranges from 0 to 28. The scale can also 
provide separate mental (ranging between 0 and 12) and physical (ranging 
between 0 and 16) fatigue scores. 
6). The Golombock Rust Inventory of Sexual Satisfaction (GRISS) (Rust and 
Golombok, 1985) 
This is a self-administered questionnaire which was developed to provide 
objective assessments of the quality of sexual relationships and the function of 
individuals within them, and can be considered as a sexual disability scale. It has 
28 items on a single sheet all answered on a 5-point scale. The scale gives a 
transformed overall sexual dysfunction score on a 10 point scale between 0 and 9 
with scores 5 and above indicating a problem. It also gives a sexual profile using 
similar 10-point scales on 12 sub-scales comprising impotence and premature 
ejaculation in males, anorgasmia and vaginismus in females, infrequency, non- 
communication, non-sensuality, avoidance, and dissatisfaction of both sexes. 
Patients were asked to compete these 6 questionnaires and return them 
within three days of their third three monthly clinical assessment. 
H). All patients were also ranked by myself according to their ability to work, 
do their housework, and look after themselves. They were also ranked 
independently by myself and a research nurse according to their subjectively 
perceived degree of disability. 
I). Patients' close relatives or carers were asked to complete a copy of the 
GNDS-R questionnaire to reflect their independent assessment of the patients' 
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various disabilities as they observed or perceived them without referring to the 
patients. 
Convergent and discriminant construct validity were tested by assessing 
the degree to which the GNDS-R and its 12 sub-scales correlated with other 
measures of impairment (SNRS, EDSS, cognitive assessment, General Health 
Questionnaire, Beck Depression Inventory, visual acuity, Frenchay Dysarthria 
Assessment, swallowing test, 9-hole peg test, time to walk 10 metres, and Chalder 
Fatigue Scale), disability (EDSS, FIM, Barthel Index, the disability domain of the 
CAMBS, the various visual analogue scales, GRISS sexual dysfunction scale), 
handicap (the London Handicap Scale, the handicap domain of the CAMBS), and 
health related quality of life (EuroQol, and SF-36). Group differences construct 
validity was assessed by testing the extent to which the GNDS-R scores correlated 
with the severity of disability as judged by the two raters. Hypothesis testing 
construct validity was assessed by testing the hypothesis that GNDS-R scores 
should be more abnormal in patients who are unable to work or do their 
housework because of multiple sclerosis, and in patients who are dependent on 
others for some or all of their activities of daily living. The objectivity of the 
GNDS-R was also assessed by testing the hypothesis that GNDS-R scores should 
correlate with scores obtained when the scale is completed by patients' close 
relatives or carers independently of patients' own assessments of their disability. 
As indicated above, 50 patients were included in this study. The group 
consisted of 31 women and 19 men with a median age 36 years (range 24-51), 
and a median disease duration of 12 years (range 2-17). The patients had mild to 
moderate disability with a median EDSS score of 4.5 (range 0-7.5), and median 
(range) GNDS-R score was 12 (0-28). 
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6.8.2 Convergent and discriminant validity 
A). Cognitive disability sub-scale 
The distribution of pre-morbid IQ, estimated from the NART, showed a 
mean of 108 and a standard deviation of 13 indicating that the patients constituted 
a relatively unbiased sample from the general population (a perfect normal sample 
would have a mean of 100 and a standard deviation of 15). One patient was not 
able to perform the letter cancellation task due to severe tremor of both arms. 
Two other patients claimed that their performance was affected by loss of 
dexterity. Statistical analysis with or without their data revealed similar results. 
The GNDS-R cognitive disability sub-scale correlated weakly with the speed of 
letter cancellation (r = 0.31), and the mentation and mood domain of the SNRS (r 
= -0.54), and moderately with the mental Functional System of the EDSS (r = 
0.62) but not with any other impairment measure. It also correlated highly with 
the memory domain of the FIM (r = -0.80), moderately with perceived degree of 
cognitive disability (r = -0.70), and weakly with the problem solving domains of 
the FIM (r = -0.33). It also correlated weakly with the orientation domain of the 
London Handicap scale (r = -0.36), but not with any aspects of Health Related 
Quality of life (Table 6.28). 
As the strongest correlations were established with other disability rather 
than impairment, handicap, or heath related quality of life measures, these results 
support the validity of the cognitive disability sub-scale as a measure of disability. 
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Table 6.28 The correlation between the GNDS-R cognitive disability sub-scale 
and other disablement and health related quality of life measures (n = 50) 
Score r p 
Cognitive disability sub-scale * 0 (0 to 3) - - 
Pre-morbid IQ (NART) ** 108 (13) - - 
Impairment measures 
Speed of letter cancellation (seconds) ** # 23.7 (7.8) 0.31 0.027 
PASAT 2" (correct answers) * 34 (4 to 59) -0.09 NS 
PASAT 4" (correct answers) * 51 (20 to 60) -0.26 0.057 
Standard progressive matrices (grades) * 3 (0 to 5) 0.13 NS 
Similarities (standard scores) * 10 (6 to 15) 0.08 NS 
Immediate story recall (percentiles) ** 58 (27) 0.18 NS 
Delayed story recall (percentiles) ** 56 (27) 0.20 NS 
COWAT (adjusted scores) * 42 (15 to 62) 0.03 NS 
SNRS - Mentation and Mood * 10 (4 to 10) -0.54 0.002 
EDSS - Mental Functional System * 0 (0 to 3) 0.62 <0.001 
Disability measures 
FIM- Problem solving * 7 (3 to 7) -0.33 0.047 
FIM -Memory * 7 (0 to 7) -0.80 <0.001 
Perceived cognitive disability (VAS) ** 86 (20) -0.70 <0.001 
Handicap measures 
London Handicap Scale -Orientation ** 1.4 (1.3) -0.36 0.013 
Health Related Quality of Life measures 
SF 36- Mental health ** 72(9) -0.12 NS 
* Median (range); ** Mean (SD); #n= 47 patients 
B). Mood disability sub-scale 
The GNDS-R mood disability sub-scale correlated moderately with the 
mentation and mood item of the SNRS (r = -0.59), and the mental Functional 
System of the EDSS (0.40), and weakly with overall score of the General Health 
Questionnaire (r = 0.34), but not with any of its four domains, nor with the Beck 
Hopelessness Scale. It also correlated moderately with the perceived degree of 
mood disability (r = -0.74), and weakly with the emotional role limitation of the 
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SF-36 (r = -0.45). No handicap measures were available for this study (Table 
6.29). 
Table 6.29 The correlation between the GNDS-R mood disability sub-scale and 
other disablement and health related quality of life measures (n = 50) 
Score rp 
Mood disability sub-scale *0 (0 to 4) -- 
Impairment measures 
SNRS - Mentation and Mood * 10 (4 to 10) -0.59 <0.001 
EDSS - Mental Functional System *0 (0 to 3) 0.40 <0.001 
General Health Questionnaire * 
GHQ - overall score 22 (19 to 32) 0.34 0.02 
GHQ - Somatic symptoms 1 (0 to 5) 0.11 NS 
GHQ - Anxiety and insomnia 0 (0 to 4) 0.20 NS 
GHQ - Social dysfunction 1 (0 to 5) 0.06 NS 
GHQ - Severe depression 7 (7 to 10) 0.19 NS 
Beck Depression Scale * 6 (6 to 16) 0.37 NS 
Disability Measures 
Perceived mood disability (VAS) ** 82 (19) -0.74 0.001 
Handicap measures 
NA --- 
Health Related Quality of Life 
SF 36 -Emotional Role Limitation ** 50 (42) -0.45 0.001 
* Median (range); ** Mean (SD) 
As the strongest correlations were established with other disability rather 
than impairment, or heath related quality of life measures, these results support 
the validity of the mood disability sub-scale as a measure of disability. 
C). Visual disability sub-scale 
The GNDS-R visual disability sub-scale correlated moderately with the 
upper cranial nerves (visual acuity, fields, discs, pupils, eye movements, and 
nystagmus) components of the SNRS (r = -0.61), the visual EDSS Functional 
Systems (r = 0.60), and with the visual acuity of the worse (r = 0.51) and the 
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better eyes (r = 0.49). It also correlated moderately the perceived degree of visual 
disability (r = -0.79). There were no handicap and health related quality of life 
measures available for this study (Table 6.30). 
Table 6.30 The correlation between the GNDS-R visual disability sub-scale and 
other disablement and health related quality of life measures (n = 50) 
Score rp 
Visual disability sub-scale *0 (0 to 3) 
Impairment measures 
SNRS - Upper cranial nerves (items 1 to 4) * 17 (0 to 19) -0.61 <0.001 
EDSS - Visual Functional System *0 (0 to 6) 0.60 <0.001 
Visual acuity - better eye * 6/6 (5/6 to 36/6) 0.49 <0.001 
Visual acuity - worse eye * 6/6 (5/6 to 60/6) 0.51 <0.001 
Disability Measures 
Perceived visual disability (VAS) ** 83 (21) -0.79 <0.001 
Handicap measures 
NA --- 
Health Related Quality of Life 
NA --- 
* Median (range); ** Mean (SD) 
As the strongest correlations were established with other disability rather 
than impairment measures, these results support the validity of the visual 
disability sub-scale as a measure of disability. 
D). Speech disability sub-scale 
The GNDS-R speech disability sub-scale correlated moderately with the 
lower cranial nerves domain of the SNRS (r = -0.72), and weakly with the brain 
stem Functional System of the EDSS (r = 0.52). It also correlated weakly with 
the Frenchay Dysarthria Assessment sum score (r = -0.46), and its reflex (r =- 
0.50), respiration (r = -0.44), lips (r = -0.50), soft palate (r = -0.40), tongue (r =- 
0.43), and intelligibility (r = -0.58) domains sum scores. The GNDS-R speech 
disability sub-scale also correlated moderately with the perceived degree speech 
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disability (r = -0.75). There were no handicap or quality of life measures for 
comparisons (Table 6.31). 
Table 6.31 The correlation between the GNDS-R speech disability sub-scale and 
other disablement and health related quality of life measures (n = 50) 
Score r p 
Speech disability sub-scale * 0 (0 to 3) - - 
Impairment measures 
SNRS - Lower cranial nerves * 0 (0 to 5) -0.72 <0.001 
EDSS - Brain stem Functional System * 0 (0 to 4) 0.52 0.002 
Frenchay Dysarthria Assessment ** 
Sum score 246.6 (10.4) -0.46 0.001 
Reflex 25.6 (2.4) -0.50 <0.001 
Respiration 17.5 (1.2) -0.44 0.002 
Lips 44.5 (1.1) -0.50 <0.001 
Jaw 18 (0) -0.28 NS 
Soft palate 26.8 (0.9) -0.40 0.004 
Larynx 35.4 (1.4) -0.26 NS 
Tongue 52.4 (3.2) -0.43 0.002 
Intelligibility 26.3 (2) -0.58 <0.001 
Disability Measures 
Perceived speech disability (VAS) ** 93 (15) -0.75 <0.001 
Handicap measures 
NA - - - 
Health Related Quality of Life 
NA --- 
* Median (range); ** Mean (SD) 
The high correlation between this sub-scale and the lower cranial nerves 
domain of the SNRS is likely to reflect the mild degree of speech disability of this 
cohort since this sub-scale concentrates on the symptomatic aspects of the speech 
disturbance in its lower grades. However the high correlation with the perceived 
degree of speech disability support the validity of this sub-scale as a measure of 
disability. 
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E). Swallowing disability sub-scale 
The GNDS swallowing disability sub-scale correlated weakly with the 
lower cranial nerves domain of the SNRS (r = -0.40), and the timed swallowing 
test (r = 0.33), but moderately with the brain stem Functional System of the EDSS 
(r = 0.54). It also correlated moderately with the perceived degree of swallowing 
disability (r = -0.75). There were no other disability, handicap, or quality of life 
measures available for comparison (Table 6.32). 
Table 6.32 The correlation between the GNDS-R swallowing disability sub-scale 
and other disablement and health related quality of life measures (n = 50) 
Score rp 
Swallowing disability sub-score *0 (0 to 2) 
Impairment measures 
SNRS - Lower cranial nerves * 0 (0 to 5) -0.40 0.004 
EDSS - Brain stem Functional System * 0 (0 to 4) 0.54 <0.001 
Timed swallowing test (Seconds) ** 16 (10) 0.33 0.020 
Disability Measures 
Perceived disability (VAS) * 94 (11) -0.75 <0.001 
Handicap measures 
NA --- 
Health Related Quality of Life 
NA --- 
* Median (range); ** Mean (SD) 
As the strongest correlation was established with disability rather than 
impairment measures, these results support the validity of this sub-scale as a 
measure of disability. 
F). Upper limb disability sub-scale 
Three patients were unable to perform the 9-hole peg test due to severe 
tremor or impaired proprioception. The GNDS-R upper limb disability sub-scale 
correlated moderately with the upper limb items (motor, sensory, cerebellar, and 
reflexes) of the SNRS (r = -0.53), and the pyramidal Functional 
System of the 
EDSS (r = 0.52), but weakly with the cerebellar (r = 0.30) and the sensory (r = 
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0.41) EDSS Functional Systems, and with the 9-hole peg test time (0.46). It also 
correlated moderately with the self-care item (items A to E) of the FIM (r =- 
0.66), the perceived degree of upper limb disability (r = -0.79), the independence 
domain of the London Handicap Scale (r = -0.63), and with the physical 
functioning domain of the SF-36 (r = -0.58) (Table 6.33). 
Table 6.33 The correlation between the GNDS-R upper limb disability sub-scale 
and other disablement and health related quality of life measures (n = 50) 
Score r p 
Upper limb disability sub-scale * 1 (0 to 4) - - 
Impairment measures 
SNRS - Upper limb items (motor, sensory, 24 (6 to 26) -0.53 <0.001 
cerebellar, reflexes) * 
EDSS - Pyramidal Functional System * 3 (0 to 5) 0.52 <0.001 
EDSS - Cerebellar Functional System * 2 (0 to 5) 0.30 0.038 
EDSS - Sensory Functional System * 0 (0 to 5) 0.41 0.003 
Nine-peg-hole time (mean of right and left 28 (13) 0.46 0.001 
hands) (Seconds) ** # 
Disability Measures 
FIM- Self care items(A to E) * 42 (26 to 42) -0.66 <0.001 
Perceived upper limb disability (VAS) ** 90 (17) -0.76 <0.001 
Handicap measures 
London Handicap Scale - Independence ** 3 (3.6) -0.63 <0.000 
Health Related Quality of Life 
SF 36 - Physical Functioning ** 20(6) -0.58 <0.001 
* Median (range); ** Mean (SD); # Number = 47 patients 
As the strongest correlations were established with other disability rather 
than impairment, handicap, or heath related quality of life measures, these results 
support the validity of the upper limb disability sub-scale as a measure of 
disability. 
G). Lower limb disability sub-scale 
Six patients were unable to perform the 10-metre walk. The GNDS-R 
lower limb disability sub-scale correlated highly with the lower limb items 
(motor, sensory, cerebellar, reflexes, and gait) of the SNRS (r = -0.87), the 
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pyramidal EDSS Functional System (r = 0.81), and the 10-metre walk (r = 0.87), 
and moderately with the cerebellar EDSS Functional Systems (r = 0.67), and 
weakly with sensory EDSS Functional System (r = 0.45). It also correlated 
moderately with the transfer (items I to K) (r = -0.72) and locomotion (items L 
and M) (r = -0.73) items of the FIM, and highly with the Ambulation Index (r = 
0.90), and the perceived severity of lower limb visual disability (r = -0.80). The 
lower limb disability sub-scale also correlated weakly with the mobility domain of 
the London Handicap Scale (r = -0.43), but strongly with the physical functioning 
domain of the SF-36 (r = -0.87) (Table 6.34). 
Table 6.34 The correlation between the GNDS-R lower limb disability sub-scale 
and other disablement and health related quality of life measures (n = 50) 
Score rp 
Lower limb disability sub-scale *2 (0 to 4) -- 
Impairment measures 
SNRS - Lower limb items (motor, sensory, 
21 (0 to 39) -0.87 <0.001 
cerebellar, reflexes, gait) * 
EDSS - Pyramidal Functional System 
* 3 (0 to 5) 0.81 <0.001 
EDSS - Cerebellar Functional System 
* 2 (0 to 5) 0.67 <0.001 
EDSS - Sensory Functional System * 
0 (0 to 5) 0.45 0.001 
10 metre walk (seconds) **# 13 (14) 0.87 <0.001 
Disability Measures 
FIM - Transfer (Items Ito K) * 
20 (12 to 21) -0.72 <0.001 
FIM - Locomotion (Items L and M) 
* 12 (2 to 14) -0.73 <0.001 
Ambulation Index 2 (0 to 9) 0.90 <0.001 
Perceived lower limb disability (VAS) ** 65 (28) -0.80 <0.001 
Handicap measures 
London Handicap Scale - Mobility ** 3 (2.7) -0.43 
0.002 
Health Related Quality of Life 
SF 36 -Physical Functioning ** 
20(6) -0.87 <0.001 
* Median (range); ** Mean (SD); # Number = 44 patients 
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As the strongest correlations were established with other disability rather 
than impairment, handicap, or heath related quality of life measures, these results 
support the validity of the lower limb disability sub-scale as a measure disability. 
H). Bladder disability sub-scale 
The GNDS-R bladder disability sub-scale correlated moderately with the 
special category items of the SNRS (r = -0.76), and highly with the bladder and 
bowel EDSS Functional System (r = 0.82). It also correlated moderately with the 
bladder management item of the FIM (r = -0.70), and with the perceived degree of 
bladder disability (r = -0.73). No handicap or quality of life measures were 
available for comparison (Table 6.35). 
Table 6.35 The correlation between the GNDS-R bladder disability sub-scale and 
other disablement and health related quality of life measures (n = 50) 
Score rp 
Bladder disability sub-scale *2 (0 to 4) 
Impairment measures 
SNRS - Special category * -3 (-7 to 0) -0.76 <0.001 
EDSS - Bladder and Bowel Functional System * 1 (0 to 4) 0.82 <0.001 
Disability Measures 
FIM- Bladder management * 6 (1 to 7) -0.70 <0.001 
Perceived disability (VAS) ** 73 (27) -0.73 <0.001 
Handicap measures 
NA --- 
Health Related Quality of Life 
NA --- 
* Median (range); ** Mean (SD) 
The high correlation between this sub-scale and the bladder and bowel 
EDSS Functional System and the special category of the SNRS is likely to reflect 
the relatively mild degree of bladder disability in this cohort and the nature of this 
sub-scale which concentrates on the symptomatic aspects of bladder dysfunction 
in its lower grades. However, its high correlation with other disability measures 
lends support to its validity as a disability measure. 
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I). Bowel disability sub-scale 
The GNDS-R bowel disability sub-scale correlated moderately with the 
special category items of the SNRS (r = -0.53), and the bladder and bowel EDSS 
Functional System (r = 0.65), and highly with bowel management item of the FIM 
(r = -0.84), and the perceived degree of bowel disability (r = -0.78). No handicap 
or quality of life measures were available for comparison (Table 6.36). 
Table 6.36 The correlation between the GNDS-R bowel disability sub-scale and 
other disablement and health related quality of life measures (n = 50) 
Bowel disability sub-scale * 
Impairment measures 
SNRS - Special category * 
EDSS - Bladder and Bowel Functional System * 
Disability Measures 
FIM- Bowel management * 
Perceived bowel disability (VAS) ** 
Handicap measures 
NA 




-3 (-7 to 0) -0.53 <0.001 
1 (0 to 4) 0.65 <0.001 
7 (6 to 7) -0.84 <0.001 
84 (23) -0.78 <0.001 
* Median (range); ** Mean (S D) 
As the strongest correlation was established with disability rather then 
impairment measures, these results support the validity of this sub-scale as a 
measure of disability. 
J). Fatigue disability sub-scale 
The GNDS-R fatigue disability sub-scale correlated moderately with the 
overall score of the Chalder fatigue scale (r = 0.57), and with its physical fatigue 
domain (r = 0.54), but weakly with its mental fatigue domain (r = 0.36). It also 
correlated moderately with the perceived degree of fatigue disability (r = -0.70), 
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but weakly with the vitality domain of the SF-36 (r = -0.46). 
measures were available for comparison (Table 6.37). 
No handicap 
Table 6.37 The correlation between the GNDS-R fatigue disability sub-scale and 
other disablement and health related quality of life measures (n = 50) 
Score r P 
Fatigue disability sub-scale *2 (0 to 4) -- 
Impairment measures 
Chalder Fatigue Scale * 
Total score 0 (0 to 13) 0.57 <0.001 
Physical fatigue 0 (0 to 8) 0.54 <0.00 1 
Mental fatigue 0 (0 to 6) 0.36 0.029 
Disability Measures 
Perceived fatigue disability (VAS) ** 71(25) -0.70 <0.001 
Handicap measures 
NA --- 
Health Related Quality of Life 
SF 36 Vitality ** 42(21) -0.46 0.001 
* Median (range); ** Mean (SD) 
As the strongest correlation was established with disability rather than 
impairment or health related quality of life measures, these results support the 
validity of the GNDS fatigue disability sub-scale as a disability measure, and 
indicate that it is tapping physical rather than mental fatigue. 
K). Sexual disability sub-scale 
1). Male patients 
Only 11 male patient (57.9% of the total male population) consented to 
completing the GRISS questionnaire. Other patients felt that the questionnaire 
was too detailed and too personal to be completed. The median (range) of the 
sexual disability sub-scale scores and of the GNDS-R sum scores of the 
respondents and the non-respondents were identical at 3 (0 to 5) and 17 (0 to 28) 
respectively. The GNDS-R sexual disability sub-scale correlated moderately with 
the special category items of the SNRS (r = -0.54), and highly with the GRISS 
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questionnaire overall score (r = 0.85), and its impotence (r = 0.89) and non- 
communication (r = 0.87) domains, and moderately with its premature ejaculation 
(r = 0.63), avoidance (r = 0.62), dissatisfaction (r = 0.72) and infrequency (r = 
0.61) domains. It also correlated moderately with the perceived degree of sexual 
function disability (r = -0.62). No other handicap or quality of life measures were 
available for comparison (Table 6.38). 
Table 6.38 The correlation between the GNDS-R sexual disability sub-scale of 
male patients and other disablement and health related quality of life measures 
Score r p 
Sexual disability sub-scale *# 3 (0 to 5) - - 
Impairment measures 
SNRS - Special category *# -3 (-7 to 0) -0.54 0.018 
Disability Measures 
GRISS questionnaire *## 
Overall score 5 (1 to 9) 0.85 0.004 
Impotence 6 (2 to 9) 0.89 0.004 
Premature ejaculation 6 (1 to 9) 0.63 0.070 
Non-sensuality 3 (1 to 7) 0.39 NS 
Avoidance 1 (1 to 7) 0.62 0.078 
Dissatisfaction 2 (1 to 7) 0.72 0.001 
Infrequency 6 (1 to 9) 0.61 0.083 
Non-communication 4 (1 to 7) 0.87 0.003 
Perceived sexual disability (VAS) ** # 68.1 (29.3) -0.62 0.007 
Handicap measures 
NA 
Health Related Quality of Life 
NA 
* Median (range); ** Mean (SD); #n= 19 patients; ## n= 11 patients 
As the strongest correlations were established with other disability rather 
than impairment measures, these results support the validity of this sub-scale as a 
measure of disability. 
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2). Female patients 
Only 19 female patient (61% of the total female population) completed the 
GRISS questionnaire. Other patients felt that the questionnaire was too detailed 
and too personal to be completed. The median (range) of the sexual disability 
sub-scale scores and of the GNDS-R sum scores of the respondents and the non- 
respondents were identical at 0 (0 to 4) and 9 (0 to 26) respectively. The GNDS-R 
sexual disability sub-scale correlated moderately with GRISS questionnaire 
infrequency (r = 0.56) and anorgasmia (r = 0.59) domains, and with the perceived 
degree of sexual function disability (r = -0.51), but weakly with the special 
category items of the SNRS (r = -0.42), and with the GRISS questionnaire overall 
score (r = 0.37) and its vaginismus domain (r = 0.35). No other handicap or 
quality of life measures were available for comparison (Table 6.39). 
Table 6.39 The correlation between the GNDS-R sexual disability sub-scale of 
female patients and other disablement and health related quality of life measures 
Score rp 
Sexual disability sub-scale *#0 (0 to 4) -- 
Impairment measures 
SNRS - Special category *# -3 (-7 to 0) -0.42 0.022 
Disability Measures 
GRISS questionnaire *## 
Overall score 3 (1 to 3) 0.37 0.040 
Infrequency 5 (3 to 9) 0.56 0.024 
Non-communication 4 (1 to 9) 0.06 NS 
Dissatisfaction 3 (1 to 4) 0.16 NS 
Avoidance 2 (1 to 6) 0.35 NS 
Non-sensuality 3 (1 to 7) 0.22 NS 
Vaginismus 1 (1 to 6) 0.35 0.040 
Anorgasmia 7 (2 to 9) 0.59 0.017 
Perceived sexual disability (VAS) ** # 89.2 (17.4) -0.51 0.011 
Handicap measures 
NA -- 
Health Related Quality of Life 
NA --- 
* Median (range); ** Mean (SD); #n= 31 patients; ## n= 19 patients 
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Although female patients recruited for this study had relatively low sexual 
disability grades in comparison to male patients, these results support the validity 
of this sub-scale as a measure of sexual disability as the strongest correlation was 
established with other measures of disability rather than impairment, handicap, or 
quality of life. 
L). Other disabilities sub-scales 
The GNDS-R other disability sub-scale correlated moderately with the 
perceived degree of other disabilities (r = -0.72), but only weakly with the pain 
item of the SF 36 (r = -0.35). No other impairment or handicap measures were 
available for comparison (Table 6.40). 
Table 6.40 The correlation between the GNDS-R other disabilities sub-scale and 
other disablement and health related quality of life measures (n = 50) 
Score pr 




Perceived other disability (VAS)** 83.5 (24.1) -0.76 <0.001 
Handicap measures 
NA --- 
Health Related Quality of Life 
SF 36 -Bodily pain ** 76(25) 0.35 0.014 
* Median (range); ** Mean (SD) 
As the strongest correlation was established with disability rather than 
health related quality of life measures, these results support the validity of this 
sub-scale as a disability measure. 
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M). GNDS-R sum score 
The GNDS-R sum score correlated moderately with the SNRS (r = -0.75) 
and the EDSS (r = 0.78) as impairment measures. The GNDS-R also correlated 
highly with the FIM (r = -0.84), and moderately with the disability domain of the 
CAMBS (r = 0.73), the Barthel Index (r = -0.76), Ambulation Index (r = 0.74), 
and patients' perceived degree of disability (r = 0.75) as disability measures, and 
moderately with handicap domain of the CAMBS (r = 0.65) and with the London 
Handicap Scale (r = -0.52) as handicap measures. The GNDS-R sum score also 
correlated highly with the physical functioning domain of the SF-36 (r = -0.81), 
and moderately with the physical role limitation (r = -0.57) and the vitality 
domains (r = -0.58) of the SF-36 and with the overall quality of life as assessed by 
the EuroQol (r = -0.61), but weakly with the other domains of the SF-36 as 
health-related Quality of life measures (Table 6.41). 
As the strongest correlations were established with other disability rather 
than impairment, handicap, or heath related quality of life measures, these results 
support the validity of the GNDS-R as a measure of disability. 
6.8.3 Group differences and hypothesis testing 
The two disability rank lists, which were compiled by myself and the 
research nurse, were almost identical (r = 0.99, p= <0.001). The GNDS-R sum 
score correlated highly with the mean ranks of disability (r = 0.91), moderately 
with the patients' ability to work (r = 0.71) and do their house work (r = 0.59), 
and weakly with the degree of patient's independence (r = 0.43) (Table 6.42). 
Thirty-seven patients had close relatives or carers able to complete the 
GNDS-R within three days of patients' clinical assessments. The correlation 
between the GNDS-R scores obtained by interview scale administration and the 
scores obtained when the scale was completed by patients' close relatives or 
carers to reflect their observed or perceived degree of disability independently of 
patients' own assessments of their disability was very high for the sum score and 
the majority of its sub-scales (r = 0.82 to 0.94) but moderate for the mood (r = 
0.77), fatigue (r = 0.77), and other disabilities (r = 0.72) sub-scales (Table 6.43). 
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Table 6.41 The correlation between the GNDS-R sum score and other 
disablement and health related quality of life measures 
Score r p 
GNDS sum score * 12 (1 to 29) - - 
Impairment measures 
SNRS * 69 (25 to 98) -0.75 <0.001 
EDSS * 4.5 (0 to 7.5) 0.78 <0.001 
Disability measures 
FIM * 121 (91 to 126) -0.84 <0.001 
Barthel * 20 (9 to 20) -0.76 <0.001 
CAMBS - disability * 2 (1 to 4) 0.73 <0.001 
Ambulation Index * 2 (0 to 9) 0.74 <0.001 
Perceived disability (VAS) ** 75 (21) 0.75 <0.001 
Handicap measures 
CAMBS -Handicap * 2 (1 to 4) 0.65 <0.001 
London Handicap Scale ** 60(16) -0.52 0.001 
Quality of Life measures 
EuroQol VAS ** 72 (22) -0.61 <0.001 
SF36: ** 
Physical functioning 20 (6) -0.81 <0.001 
Physical role limitation 50 (42) -0.57 <0.001 
Emotional role limitation 69 (42) -0.35 0.02 
Social functioning 62 (25) -0.49 <0.001 
Mental health 72 (19) -0.39 0.007 
Vitality 42 (22) -0.58 <0.001 
Bodily pain 76 (25) -0.43 0.002 
General health perception 48 (25) -0.47 0.001 
* Median (range); ** Mean (SD) 
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Table 6.42 GNDS-R group difference and hypothesis testing construct validity 
rp 
Work 0.71 <0.001 
House work 0.59 <0.001 
Independence 0.43 0.001 
Disability rank 0.91 <0.001 
Although patients' close relatives or carers overestimated overall, fatigue, 
and other disabilities and underestimated lower limb disability compared with the 
GNDS-R disability scores, these results suggest that the interview administration 
of the GNDS-R, which is based on patients' reports, is a valid method of applying 
this scale as it is capable of reflecting the degree of patients' disability as 
perceived by their close relatives or carers. These results therefore support the 
objectivity of the GNDS-R as a disability measure. 
Table 6.43 The correlation between close relative or carers independent disability 
assessment and disability scores obtained through interview administration of the 
GNDS-R (n = 37) 





Cognitive disability 0 [0 to 4] 0 [0 to 5] 0.83 
Mood disability 0 [0 to 3] 0 [0 to 3] 0.77 
Visual disability 0 [0 to 3] 0 [0 to 3] 0.83 
Speech disability 0 [0 to 3] 0 [0 to 3] 0.82 
Swallowing disability 0 [0 to 2] 0 [0 to 2] 0.94 
Upper limb disability 1 [0 to 4] 1 [0 to 4] 0.93 
Lower limb disability 3 [0 to 5] 2 [0 to 5] 0.92 
Bladder disability 0 [0 to 5] 0 [0 to 5] 0.83 
Bowel disability 0 [0 to 4] 0 [0 to 5] 0.89 
Fatigue 2 [0 to 4] 3 [0 to 4] 0.77 
Sexual disability 0 [0 to 5] 0 [0 to 5] 0.89 
Other disabilities 0 [0 to 4] 1 [0 to 3] 0.72 
GNDS-R sum score 12 [0 to 28] 15 [0 to 29] 0.92 
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6.9 The validity of the GNDS-R sum score 
A sum score is a desirable attribute for any outcome measure. It simplifies 
statistical analysis and allows direct comparison between different patients. The 
validity of summing the GNDS-R sub-scales to obtain a sum score and the need 
for a weighting system was therefore assessed using two methods: regression 
analysis and factor analysis. 
6.9.1 Regression analysis 
In multiple regression, the values of one variable (the dependent variable: 
y) are estimated from those of two or more other variables (the independent 
variables: x1, x2, ...., xp) 
(Norman and Streiner, 1993c). This is achieved by the 
construction of a linear equation (the multiple linear regression equation) of the 
general form: 
Y= bi (x, ) + b2 (x2) + ..... + bp (xp) + bo 
where the parameters b1, b2, .., 
bp are the partial regression coefficients and the 
intercept bo is the regression constant. 
Using the inter-rater reliability data-set, the 12 GNDS-R sub-scales were 
regressed against the patients' perception of the degree of their disability as 
assessed by the 100-point visual analogue scales adopted from the EuroQol, and 
the patients' disability ranks which were compiled by myself as described in the 
validity study. The analysis suggested variable beta values for the different sub- 
scales (Table 6.44) which were used to obtain weighted sum scores using the 
multiple regression equation. The correlation between the raw and the weighted 
scores were high (r = 0.95 to 0.97, p= <0.001) suggesting that a weighting system 
was not needed. 
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Table 6.44 GNDS-R regression analysis 
Disability ranks Perception of disability 
(doctor) (patient) 
Regression sum square 16235.90 16681.54 
Residuals sum square 2332.09 5110.29 
Multiple regression coefficient 0.95 0.88 
Regression constant 98.57 98.36 
Independent variables 
Beta- Cognitive disability 0.04 0.04 
Beta-Mood disability 0.08 0.22 
Beta-Visual disability 0.23 0.28 
Beta-Speech disability 0.11 0.37 
Beta-Swallowing disability 0.22 0.34 
Beta-Upper limb disability 0.18 0.05 
Beta-Lower limb disability 0.48 0.29 
Beta-Bladder disability 0.10 0.06 
Beta-Bowel disability 0.14 0.08 
Beta-Fatigue 0.07 0.22 
Beta-Sexual disability 0.13 0.04 
Beta-Other disabilities 0.01 0.05 
Correlation between raw and 0.96 0.97 
weighted scores 
6.9.2 Factor analysis 
Vickrey and co-workers (1993) suggested a statistical method for reaching 
an overall score in multidimensional scales, which takes into account the 
possibility that different domains may contribute unequally to the construct being 
assessed. The suggested method was applied to the inter-rater reliability data set 
as follows: 
1). Based on the oblique four factor rotated solution for the GNDS-R, four 
composite scores were created by weighting and summing the appropriate sub- 
scores. The specific weights contributing to each composite score were derived 
from dividing each sub-scale's factor loading by the sum of the factor loading of 
all the sub-scales selected as contributing to that factor's composite score. 
2). These four composite scores were averaged to obtain a summary score. 
3). The summary score was regressed onto the 12 GNDS-R sub-scores, and the 
standardised beta coefficients of this regression analysis were adjusted for a 
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theoretical maximum GNDS-R score of 100, and were used to assign relative 
weights to each GNDS sub-scale. 
4). The sum of each sub-scale score times its weight yielded a weighted GNDS-R 
sum score (Table 6.45). 
Table 6.45 The GNDS-R Vickrey weighting system 
Composite Formula 
(Using the 12 GNDS-R sub-scales and the suggested weights) 
Spinal disability = 1.5 Lower limb disability score 
+ 1.8 Bladder disability score 
+ 1.8 Bowel disability score 
+ 1.5 Sexual disability score 
Mental disability = 2.2 Cognitive disability score 
+ 2.1 Mood disability score 
+ 2.2 Fatigue disability score 
Bulbar disability = 1.4 Speech disability score 
+1.3 Swallowing disability score 
Arm/vision/other disabilities = 1.6 Upper limb disability score 
+ 1.0 Vision disability score 
+ 1.6 Other disabilities score 
Overall score = Sum of all 12 weighted sub-scales (0 - 100 point scale) 
The correlation between the raw and the weighted sum scores was very 
high (r = 0.99, p= <0.00 1) suggesting that this weighting system has complicated 
the calculation process but not added to the validity of the final score. 
6.10 Discussion 
Multiple sclerosis is a multidimensional disease characterised by a wide 
variability of clinical manifestations and natural history. Clinical outcome 
measures used in this illness should therefore have relevant scale items, 
be able to 
embrace all its clinical manifestations, and have high levels of reliability, validity, 
and responsiveness. The GNDS was devised as a comprehensive clinical 
disability scale capable of fulfilling the need for a new outcome measure which is 
meaningful, relevant to patients' disability experiences, practical to administer, 
cost effective, and psychometrically sound. 
At a conceptual level, the GNDS was devised as a disability scale, to 
complement rather than replace other impairment, handicap, and health-related 
163 
quality of life scales. Disability was thought to be particularly important due to its 
direct and practical relevance to the patients' ability to perform their various 
activities of daily living, and its indirect repercussion on health care resources and 
society at large. 
A detailed review of the literature, supplemented by open interviews with 
5 patients with multiple sclerosis and advice from a panel of experts, suggested 
that disability in multiple sclerosis is a multidimensional construct that can be 
categorised in 12 mutually exclusive dimensions which included cognition, mood, 
vision, speech, swallowing, upper limb, lower limb, bladder, bowel, fatigue, 
sexual function, and other disabilities to include pain, vertigo, and spasms. The 
severity of disability in each of these 12 dimensions was graded according to its 
impact on this particular function and the need for assistance according to 7-point 
severity scale. This process resulted in a comprehensive 12-category disability 
scale, capable of embracing the wide range of possible disabilities that could be 
experienced by patients with multiple sclerosis through the various stages of its 
natural history. To facilitate the application of the GNDS and to improve its 
reproducibility, an additional set of 12 interview sections was devised to 
complement the scoring sections. The interview sections contained sets of 
standard questions designed to ascertain the presence and the severity of disability 
according to the relevant disability sub-scales. This process created a 12- item 
comprehensive disability scale which could be administered by patient interview. 
The face and content validity of this pilot scale were assessed by asking a 
cohort of 49 international experts to review the scale and indicate the degree of 
their approval or disapproval using a standard questionnaire. The majority of the 
referees approved the scale confirming its face validity. Their critical comments 
in relation to the scale contents were utilised to modify the scale as discussed 
later. The GNDS was piloted on a cohort of 64 patients with a wide rage of 
disabilities to assess its inter-rater reliability and construct validity, and a sub- 
group of 50 were followed up for 6 months to assess its intra-rater reliability and 
responsiveness. This study showed the GNDS to be internally consistent, have 
high inter- and intra-rater reliability, and to be moderately responsive to clinical 
change. However the frequency distribution of the scale was skewed to the `less 
disabled' end of the scale suggesting a `floor' effect. 
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This pilot scale therefore needed to be revised, and this process was 
achieved by utilising the critical comments of the referees which were collected in 
the face and content validity study. The revisions included reducing the number 
of the grades in each sub-scale from 7 to 6 (between 0 and 5) and modifying the 
disability grades of all 12 sub-scales to create the Revised Guy's Neurological 
Disability Scale (GNDS-R). Such a major revision meant that the psychometric 
data already collected were no longer applicable and that the scale's psychometric 
properties needed to be evaluated again. Ideally, such an evaluation needed to be 
done on a naive cohort of patients to avoid any bias resulting from training effects. 
However, due to administrative difficulties in recruiting and following a further 
cohort of patients, the second evaluation was done on the group of 50 patients 
with mild to moderate disability who had participated in the intra-rater reliability 
and responsiveness assessment of the GNDS. These patients were followed up 
for 9 months with three monthly assessments. Such a strategy was felt to be 
acceptable because the revisions were of such magnitude as to have effectively 
resulted in a new scale. Furthermore the previous administrations of the GNDS 
had been separated by three monthly intervals which minimised any subject or 
rater bias resulting from the effect of training or recall of previous answers. My 
previous study of the psychometric properties of other clinical scales used for 
multiple sclerosis suggested that raters' and patients' bias was insignificant when 
these scales were applied at three monthly intervals (Sharrack et al., 1999c). 
The face validity of the revised scale was reassessed by inviting the same 
group of 49 international experts who took part in the first face and content study to 
examine the GNDS-R critically and indicate the degree of their approval or 
disapproval of the scale and its 12 categories. Compared with the first face validity 
study, more referees approved the revised scale. Eighty two percent of the 
respondents expressed their approval of the scale in general, and the majority also 
approved the various sub-scales therefore supporting the validity of this scale as a 
disability measure for multiple sclerosis. 
Internal consistency of the GNDS-R was high with a Cronbach's alpha of 
0.79 indication that the 12 sub-scales were internally consistent. Factor analysis 
suggested four meaningful factors which accounted for 58.7% of the total 
variance. The rotated matrix suggested no redundant items as each sub-scale 
loaded on one factor only suggesting that that the 12 GNDS categories are tapping 
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separate and mutually exclusive domains of human function. The first factor of 
the rotated matrix (spinal factor) correlated with the lower limb, bladder, bowel, 
and sexual function sub-scales. The second factor (mental factor) correlated with 
the cognition, mood, and fatigue sub-scales. The third factor (bulbar factor) 
correlated with the speech and swallowing sub-scales. The fourth factor (upper 
limb / vision / other disabilities factor) correlated with the upper limb, vision, and 
other disabilities sub-scales. 
Inter-rater reliability of the different GNDS-R sub-scales was high with 
kappa coefficients ranging between 0.54 and 1 (moderate to perfect), and 
intraclass correlations coefficients ranging between 0.82 and 1 (almost perfect to 
perfect). Intra-rater reliability was also high with kappa coefficients ranging 
between 0.46 and 0.87 (moderate to almost perfect), and intraclass correlation 
coefficients ranging between 0.77 and 0.96 (substantial to almost perfect). 
Reliability of the GNDS-R sum scores was also very high with inter- and intra- 
rater intraclass correlation coefficients of 0.98 and 0.96 (almost perfect) 
respectively. Complete inter- and intra-rater agreement were obtained by 
allowing a difference of 3 and 5 points respectively. 
The GNDS-R sum score was sensitive to clinical change with an effect 
size of 0.58 (moderate). In addition, the mood, vision, upper limb, lower limb, 
bladder, fatigue, and other disabilities sub-scales were also responsive with effect 
size values ranging between 0.23 (small) to 0.92 (large). The other sub-scales, 
cognition, speech, swallowing, bowel, and sexual, were unresponsive in this 
cohort reflecting the relatively static nature of these disabilities. 
The frequency distribution of the GNDS-R sum scores in the studied 
cohort was slightly skewed to the normal end of the scale reflecting the range of 
disability (mild to moderate, EDSS: 0 to 7.5) of the patients in this study. The 
frequency distribution therefore needed to be reassessed in a more representative 
cohort. 
The GNDS-R was designed as a simple instrument which could be applied 
by any health care personnel during an interview, over the telephone, or via a 
postal questionnaire so as to simplify the conduct and reduce the cost of clinical 
trials. Inter-rater reliability of the scale when applied by a neurologist and a 
nurse, or by a neurologist and a patient's relative or carer was therefore tested and 
found to be very high. The GNDS-R sum score interclass correlation coefficients 
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of the neurologist - nurse scale administration was 0.96 (almost perfect) with sub- 
scales kappa coefficients ranging between 0.58 and 0.95 (moderate to almost 
perfect). The GNDS-R sum-score intraclass correlation coefficient of the 
neurologist - relative scale administration was equally high at 0.91 (almost 
perfect) with sub-scales kappa coefficients ranging between 0.24-0.72 (fair to 
substantial). The GNDS-R was also found to be valid and reliable when 
administered over the telephone or via a postal questionnaire. With the exception 
of the mood disability sub-scale, the correlations between the scores obtained by 
administering the scale during an interview or over the telephone by the same 
rater were high with Spearman rank correlation coefficients ranging between 0.84 
and 1. The correlations between the scores obtained by administering the scale 
during an interview or via a postal questionnaire were equally high for the GNDS- 
R sum scores and the majority of the sub-scales (speech, swallowing, upper limb, 
lower limb, bladder, bowel, fatigue, and sexual function) with Spearman rank 
correlation coefficients ranging between 0.81 and 1, but moderate for the 
cognition, mood, visual, and other disabilities sub-scales with Spearman Rank 
correlation coefficients ranging between 0.66 and 0.76. When compared with the 
interview administration, the GNDS-R telephone scale administration was very 
reliable with sum score interclass correlation coefficients of 0.96 (almost perfect) 
and sub-scales kappa coefficients ranging between 0.69 and 1 (substantial to 
almost perfect). GNDS-R sum score intraclass correlation coefficient of the 
postal questionnaire administration was equally high at 0.93 (almost perfect) with 
sub-scales kappa coefficients ranging between 0.49 and 0.84 (substantial to almost 
perfect). 
Records of the time needed to administer the GNDS-R by various raters 
(neurologist, nurse, patient, patient's relative) and by various methods (interview, 
over the telephone, via a postal questionnaire) showed that the scale could be 
applied on average in <10 minutes suggesting that the scale constitute a minor 
burden for patients and raters. 
The validity of summing the GNDS-R sub-scales to obtain a sum score 
and the need for a weighting system was assessed using regression analysis and 
factor analysis. Both methods showed high correlations between the raw and the 
weighted sum scores suggesting that a weighting system was an unnecessary 
complication. 
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The postal version of the GNDS-R was later tested on 194 naive patients 
to evaluate the performance of this scale in such large community based cohorts 
and to assess its acceptability to patients. Eighty three percent of the returned 
questionnaires were fully and correctly completed and an additional 15% 
contained enough data to allow assigning sum scores, suggesting that the scale's 
layout was simple, user friendly and acceptable to patients. The frequency 
distribution of the GNDS-R sum scores was Normal with no ceiling or floor 
effects. Eighty eight percent of the respondents expressed their approval of the 
scale in general and the majority expressed their approval of the different sub-scales 
supporting the face validity of this scale from the patients' perspective. 
The face validity of the GNDS-R as a measure of disability was confirmed 
by demonstrating its high correlation with another disability measures including 
the FIM, patients disability ranks, and patients' self-assessment of disability using 
the physical functioning domain of the SF-36, and its moderate correlation with 
the EDSS, the disability domain of the CAMBS, the Ambulation Index, and the 
degree of disability as perceived by the patients. The moderate correlation 
between the GNDS-R and the Barthel Index is likely to be due to generic 
differences between these two scales. The Barthel Index is not a disease specific 
scale. It addresses disability in a limited range of activities of daily living (Table 
5.3), and is known to have `floor' and `ceiling' effects (Applegate et al., 1990; 
Wade, 1995b). The GNDS-R, on the other hand, is a comprehensive disease 
specific scale with no `floor' or `ceiling' effects as demonstrated in the postal 
survey study. As expected in any disability scale, the GNDS-R correlated 
moderately with other measures of impairment (SNRS), handicap (the London 
Handicap Scale) and quality of life (the EuroQol and the SF-36), and with 
patients' ability to work and do their housework. Interestingly, the correlation 
between the GNDS-R sum score and the handicap domain of the CAMBS was of 
a magnitude similar to its correlation with the EuroQol rather tan the London 
Handicap Scale suggesting that the handicap domain of the CAMBS is tapping 
health related quality of life rather than handicap. 
The validity of the GNDS-R interview format, which depends on patients' 
level of reporting, was supported by the high correlation between the scores 
obtained during interview administration and patients' relatives or carers' 
independent perception of the degree of their disabilities. This correlation was 
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very high for the GNDS-R sum score (r = 0.92) and the cognitive, visual, speech, 
swallowing, upper limb, lower limb, bladder, bowel, and sexual disability sub- 
scales (r = 0.82 to 0.94) and moderate for the mood, fatigue, and other disabilities 
sub-scales (r = 0.72 to 0.77). The `objectivity' of the GNDS-R is not surprising 
because its self-reporting elements are not based on any value judgements (as in 
the case of health related quality of life measures) but on directly observable or 
easily ascertainable dimensions which can be verified against a detailed history 
obtained from the patients, their families, close friends or carers. 
The validity of the various GNDS-R sub-scales was also established by 
demonstrating high correlations between these sub-scales and other relevant 
measures of disability, and moderate correlations between them and other relevant 
measures of impairment, handicap, and health related quality of life. 
The cognitive sub-scale correlated highly with the memory domain of the 
FIM and moderately with the perceived degree of cognitive disability. Rudick 
and co-workers advocated the use the 3 or the 2 second version of the PASAT as 
part of a composite outcome measure (Rudick et al., 1996b). In my study, the 4 
second (but not the 2 second) version of the PASAT correlated weakly with the 
GNDS-R cognitive sub-scale confirming my earlier impression (chapter 3) that 
such composite outcomes are likely to be of limited value as they comprise 
impairment measures which do not adequately reflect patients' functional status. 
The highest correlation in the mood disability sub-scale was demonstrated 
with the perceived degree of mood disability. Weaker correlations were 
established between this sub-scale and other impairment (including the General 
Health Questionnaire) and health related quality of life measures. 
The highest correlation in the visual disability sub-scale was demonstrated 
with the perceived degree of visual disability. Weaker correlations were 
established between this sub-scale and other impairment measures including 
visual acuity, and the relevant items of the SNRS and the visual Functional 
System of the EDSS. 
The speech disability sub-scale correlated moderately with the perceived 
degree of speech disability, and the lower cranial nerves domain of the SNRS, but 
weakly with other impairment measures including the Frenchay Dysarthria 
Assessment. The high correlation between this sub-scale and the lower cranial 
nerves domain of the SNRS is likely to reflect the mild degree of speech disability 
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in the cohort studied as this sub-scale concentrates on the symptomatic aspects of 
the speech disturbance in its less severe grades. 
The highest correlation in the swallowing disability sub-scale was 
demonstrated with the perceived degree of speech disability. Weaker correlations 
were established between this sub-scale and other impairment measures including 
the timed swallowing test and the relevant items of the SNRS and the EDSS brain 
stem Functional System. 
The upper limb disability sub-scale correlated moderately with the 
perceived degree of upper limb disability and the self-care items of the FIM. 
Weaker correlations were also established between this sub-scale and other 
impairment measures including the 9-peg hole test and the relevant items of the 
SNRS and the Functional Systems of the EDSS. Three patients were unable to 
perform the 9-peg hole test, the second component of the composite outcome 
measure advocated by Rudick and co-workers, suggesting a `ceiling' effect and 
throwing doubt on its usefulness in clinical trials. 
The lower limb disability sub-scale correlated highly with the 
Ambulation Index, patients' self-assessment of disability using the physical 
functioning domain of the SF-36, and the perceived degree of lower limb 
disability. It also correlated highly with the 10 metre walk, the relevant items of 
the SNRS, and the pyramidal Function System of the EDSS, and moderately with 
the transfer and locomotion items of the FIM. Six patients were unable to 
perform the 10 metre walk, which is very similar to the 25-foot walk suggested by 
Rudick and co-workers as the third component of the composite outcome 
measure, suggesting a `ceiling' effect and rendering this measure inappropriate for 
clinical trials of multiple sclerosis. 
The bladder disability sub-scale correlated moderately with the special 
category item of the SNRS, and highly with the EDSS bladder and bowel 
Functional System, the bladder management item of the FIM, and the perceived 
degree of bladder disability. The high correlation between this sub-scale and the 
relevant EDSS and SNRS items is likely to reflect the nature of this sub-scale 
which concentrates on the symptomatic aspects of bladder dysfunction as well as 
its consequences suggesting that it may be assessing both impairment and 
disability. However, its high correlation with other disability measures lends 
strong support to its validity as a measure of disability. 
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The bowel disability sub-scale correlated highly with the bowel 
management item of the FIM and moderately with the perceived degree of bowel 
disability. Weaker correlations were also noted with the SNRS and the EDSS 
related items. 
The highest correlation in the fatigue disability sub-scale was 
demonstrated with the perceived degree of fatigue disability. Weaker correlation 
was also established between this sub-scale and Chalder Fatigue scale. Factor 
analysis showed this sub-scale to have loaded on the second factor along with the 
cognitive and the mood sub-scales, however its correlation with the physical 
domain of the Chalder Fatigue scale was higher than its correlation with the 
mental domain suggesting that its is tapping physical rather than mental fatigue. 
Although 42% of male patients and 39% of female patients in this cohort 
did not complete the validity assessment of the sexual disability sub-scale, the 
median GNDS-R sum scores and sexual disability sub-scale scores of the 
participants and the non participants were identical indicating comparable degrees 
of disability. Among male patients, this sub-scale correlated highly with the 
GRISS questionnaire sum score and many of its items and moderately with the 
perceived degree of disability. However the correlation between this sub-scale 
and the GRISS questionnaire sum score and many of its items was weak for 
female patients, which is likely to be related to the previously reported low degree 
of sexual disability in this sub-group of patients (Valleroy and Kraft, 1984). 
Similar low correlation figures were obtained by using the self-administered 
version of the sub-scale (data from the postal questionnaire study) indicating that 
female patients did not underreport their sexual disabilities during the interview 
administration of the scale. 
Finally the correlation between the other disability sub-scale and the 
perceived degree of disability was moderate supporting the validity of this sub- 
scale as a disability measure. 
6.11 Raters' and patients' bias 
As discussed in chapter 5, this study was designed to minimise the effect 
of raters' and patients' bias on the assessment of reliability and responsiveness. 
All the raters were blinded to their own and other raters' previous scores, and 
open discussions about patients' clinical conditions were avoided amongst 
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themselves. In the inter-rater reliability study, patients were assessed 
independently by the two raters and no fixed order for the examination was 
observed so as to reduce the effect of patients' bias which may result from 
practice effect or fatigue. Data for the intra-rater reliability and responsiveness 
study were collected at three monthly intervals so as to reduce raters' and patients' 
bias which may result from recall of the previous assessments. The effect of this 
potential source of bias is unlikely to have been significant since the inter-rater 
reliability figures were often higher than the intra-rater reliability figures. It is also 
unlikely that the familiarity of the patients to the assessors or the frequent 
administrations of the GNDS-R have biased the results since the reliability figures 
of the various methods of scale administration were often lower then the initial 
inter-rater reliability figures which were obtained when the scale was 
administered by the two raters for the first time. A noticeable deficiency in this 
study is the lack of supportive psychometric data by independent investigators on 
naive cohorts of patients. Such a study in now underway in six centres throughout 
the UK. 
6.12 Conclusion 
The Guy's Neurological Disability Scale goes a long way towards meeting 
the need for a new clinical disability scale for multiple sclerosis. It is a 
comprehensive multidimensional clinical rating scale capable of embracing the 
whole range of disabilities likely to be encountered in this illness. It is simple and 
user-friendly, acceptable to neurologists and patients, and can be applied by non- 
medically qualified health care staff or by the carers of patients without prior 
training. In our hands, this scale is reliable, responsive, and valid as a disability 
scale. As a clinical outcome measure for multiple sclerosis, this scale is capable 
of providing relevant information on the degree of disability as experienced by the 
affected patients. Additional assessment of impairment, handicap, and health 
related quality of life could be necessary to provide a more comprehensive 
appraisal of patients' health status. 
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Chapter 7 
MAGNETIC RESONANCE IMAGING IN MULTIPLE SCLEROSIS 
7.1 Introduction 
The increasing use of Magnetic Resonance Imaging (MRI) over the last 10 
to 15 years as a diagnostic and research tool has had a major impact on our 
understanding of the pathogenesis and the natural history of multiple sclerosis. 
MRI has greatly improved the diagnostic yields in patients with inconclusive 
clinical features, and has allowed the dynamic disease processes to be visualised 
as never before. The difficulty in developing satisfactory measures of clinical 
outcome in multiple sclerosis and the sensitivity of MRI in detecting disease 
activity compared with clinical relapse rate (Paty, 1988) has also led to its 
increasing use as a primary and secondary outcome measure in many phase II and 
III therapeutic clinical trials. However the lack of a consistent association 
between clinical outcome measures and conventional MRI parameters has been a 
major concern. T2-weighted brain imaging complimented with gadolinium 
enhanced T 1-weighted imaging have traditionally been used for the diagnosis and 
the monitoring of disease activity, whereas unenhanced TI-weighted imaging has 
been of limited use. 
7.1.1 T2 weighted imaging 
Conventional T2-weighted spin echo pulse sequence has been used in 
most clinical trials of multiple sclerosis (Miller et al., 1998). On this sequence 
multiple sclerosis lesions demonstrate high intensity while background white 
matter appears generally dark. The introduction of fast spin echo imaging allowed 
the acquisition of qualitatively equivalent thin contiguous imaging sections in 
times similar to those used for thicker sections on conventional spin echo images 
(Thorpe et al., 1994). Earlier studies of post-mortem cadaver MRI scans and 
subsequent pathological examination have provided support for using T2- 
weighted imaging as a measure of the extent of demyelination (Paty and Moor, 
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1997). However the pathological specificity of T2-weighted signals is very low. 
Standard T2-weighted MRI simply reflects the extent of `water protons' in the 
various tissues and all the pathological processes in multiple sclerosis lesions 
(oedema, inflammation, demyelination, axonal loss, and gliosis) are therefore 
represented as hyperintense areas on this sequence (McDonald et al., 1994). 
7.1.2 TI-weighted imaging 
TI-weighted spin echo imaging shows multiple sclerosis lesions as areas 
of low signal intensity, or black holes, in contrast to the background isointense 
white and grey matter. Acute black holes develop and resolve in parallel with 
onset and recovery from relapses (van Waesberghe et al., 1997), but some may 
persist and become chronic. Histopathological studies of chronic hypointense 
lesions revealed a strong correlation between the degree of hypointensity on post- 
mortem T 1-weighted images and both axonal density (r = -0.72) and the degree of 
matrix destruction and widening of the extracellular space (r = 0.45) (van 
Walderveen et al., 1996). Additionally, changes on T2-weighted images in 
patients with secondary progressive multiple sclerosis were more frequently 
accompanied by changes on TI-weighted images compared with relapsing 
remitting patients suggesting that T 1-weighted hypointense lesion load is the MRI 
equivalent of failure of remission (Truyen et al., 1996). Chronic hypointense T1- 
weighted lesions therefore represent the more disabling lesions compared with 
lesions which are only noted on T2-weighted images. 
7.1.3 Other MRI parameters 
The nature of the pathological process in multiple sclerosis can also be 
assessed using Gadolinium-enhanced T1-weighted imaging to examine the degree 
of inflammation and blood brain barrier breakdown (Stone et al., 1995), 
magnetization transfer imaging to assess the degree of demyelination and axonal 
degeneration (McGowan et al., 1997), diffusion weighted imaging to examine the 
integrity of myelin and fiber pathways (Horsfield et al., 1997), proton 
spectroscopy to assess the biochemical changes associated with myelin 
destruction (Arnold et al., 1997), and cerebral and spinal cord atrophy as a marker 
of tissue loss (Losseff et al., 1996a; Losseff et al., 1996b). 
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7.2 Correlation between MRI and clinical rating scales 
Two main MRI methods have been used to evaluate disease activity in 
multiple sclerosis and to monitor treatment efficacy: counting the number of new 
or active brain lesions and measuring total brain lesion load. 
Weak correlations (r = 0.19-0.23) have been reported between the number 
of new and active MRI lesions and the frequency of clinical relapses (Simon et al., 
1998). The correlation between the presence of active lesions and long-term 
clinical evolution is less clear (Morrissey et al., 1993). 
The presence and the extent of T2-weighted MRI abnormalities at first 
presentation with clinically isolated syndromes suggestive of multiple sclerosis 
correlate moderately with the degree of disability after 5 and 10 years (r = 0.75 
and 0.45 respectively) (Morrissey et al., 1993; O'Riordan et al., 1997). However 
in established multiple sclerosis, the correlation between T2-weighted 
abnormalities and clinical disablement remains modest (Table 7.1). Cross- 
sectional studies have shown no (Thompson et al., 1990), or only modest 
correlations (r = 0.22-0.28) (The IFNB Multiple Sclerosis Study Group and The 
University of British Columbia MS/MRI Analysis Group, 1995) between T2- 
weighted lesion loads and clinical outcome measures of impairment and disability. 
However when the association between lesion load at specific anatomical sites 
and relevant clinical presentations is examined, higher correlations (r = 0.33-0.52) 
are found between cerebral and brain stem lesion load and the EDSS and its brain 
stem Functional System scores, the Ambulation Index, and other tests of upper 
extremity function (Baumhefner et al., 1990), and between cerebral lesion load 
and corpus callosum atrophy and cognitive dysfunction (Franklin et al., 1988; Rao 
et al., 1989). Many longitudinal studies have shown only modest correlation 
between the change in T2-weighted MRI lesion load and the sustained change in 
clinical disablement measures (r = 0.13-0.23) (The IFNB Multiple Sclerosis Study 
Group and The University of British Columbia MS/MRI Analysis Group, 1995; 
Filippi et al., 1995). 
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Table 7.1 Correlation between T2-weighted lesion load and clinical outcomes 
Study Correlation r (p) 
Gass (1994) T2 lesion load and EDSS 
IFNB MS Study T2 lesion load and EDSS at entry 
Group (1995) T2 lesion load and EDSS at exit 
T2 lesion load and SNRS at entry 
T2 lesion load and SNRS at exit 
Change in T2 lesion load and change in EDSS 
Change in T2 lesion load and change in SNRS 
Van Walderveen (1995) T2 lesion load and EDSS 
Change in T2 lesion load and change in EDSS 











Enlarging T2 lesions and change in EDSS 0.18 (0.02) 
Similar to T2-weighted lesion load, cross sectional analysis of Ti- 
weighted lesion load showed no (Truyen et al., 1996) or only moderate correlation 
(r = 0.46) (van Walderveen et al., 1995) with the EDSS. However in longitudinal 
studies, the relative increase in TI-weighted lesion load correlated more strongly 
with disease progression as assessed by sustained change in the EDSS scores (r = 
0.74-0.80) (van Walderveen et al., 1995; Truyen et al., 1996). 
The use of new imaging techniques has also provided stronger correlations 
with clinical outcome measures. For example significant correlation (r = 0.70) 
has been found between EDSS and the diameter of the spinal cord at the level of 
C2 reflecting the importance of axonal damage on the progression of disability 
(Losseff et al., 1996b). Progressive cerebral atrophy has also been reported to 
correlate with increasing disability (Losseff et al., 1996a). Several other non- 
conventional MR putative markers of demyelination and axonal degeneration 
have been correlated more strongly with disability. Cross-sectional studies found 
moderate correlations between the degree of disability and average lesion 
Magnetisation Transfer ratio (r = -0.44) (Gass et al., 1994), and between 
decreased N-acetyle-aspartate resonance intensities in and around MS lesions and 
the degree of disability (r = -0.73) (De Stefano et al., 1995). The use of these 
non-conventional MR techniques in clinical trials requires further clinical 
validation in large longitudinal studies to confirm these encouraging initial results. 
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7.3 Quantitative MRI analysis techniques 
Data obtained by quantitative MRI analysis are critical both for 
understanding the natural history of the disease and for monitoring the effects of 
the therapeutic interventions. The reliability of such data depends on the accuracy 
of two distinct processes: recognition (the identification of multiple sclerosis 
lesions), and delineation (defining the boundaries of such lesions). Human 
experts appear to be better than computers at recognition, whereas computers are 
better and faster at delineation (Miller et al., 1998). However both processes can 
be problematic. Multiple sclerosis lesions are often small in size and large in 
number, and have a `lumpy-bumpy' appearance with irregular and fuzzy 
boundaries causing significant variation in their conspicuity and considerable 
difficulties in their delineation. There may also be many artefacts from scanners, 
patient motion, and other sources such as blood and CSF flow which could 
compromise the accuracy of lesion identification. 
Many segmentation techniques have been devised and used in quantifying 
lesion load. Manual outlining is the current standard for lesion segmentation in 
almost all clinical trials (Miller et al., 1996). The accuracy of this technique is 
operator dependent with intra-rater variability as low as 6% and inter-rater 
variability as high as 14-40% (Paty and Li, 1993; Paty et al., 1994). Threshold- 
based segmentation methods substantially improve the reliability of volume 
measurement compared with manual tracing but they require considerable 
operator assistance to correct for false positives and negatives (Grimaud et al., 
1996). Local (lesion-by-lesion) thresholding techniques, which use the advantage 
of expert recognition and computer delineation, offer a better precision but they 
take about as long as manual outlining to perform (Grimaud et al., 1996). Many 
other techniques with reduced human input have been developed in the past few 
years (Filippi et al., 1998). The main potential advantage of these techniques is to 
reduce the time and effort needed for the operator to assess the images and to 
improve reproducibility. 
7.4 Rational for this study 
The WHO ICIDH model predicts a close relation between pathology and 
impairment, but a weak relation between pathology and disability, and between 
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pathology and handicap (Wade, 1996). There are no published reports in the 
literature addressing the relation between pathology and the three ICIDH 
components in a single cohort of patients, or the relation between pathology and 
health related quality of life. This study was therefore designed to assess 
comprehensively the correlation between MRI lesion load in multiple sclerosis on 
two of the most commonly used acquisitions as a measure of pathology and 
various impairment, disability, handicap, and health relater quality of life outcome 
measures. 
7.5 Patients and methods 
Forty-eight patients with clinically or laboratory supported definite 
relapsing remitting or secondary progressive multiple sclerosis attending a 
multiple sclerosis outpatient research clinic were recruited for this study. The 
cohort consisted of 30 women and 18 men with a median age of 36 years (range 
24-5 1), a median EDSS of 4.5 (range 0-7.5), and a median disease duration of 12 
years (range 2-17). High resolution (slice thickness 2.4 mm, in plane resolution 
0.89 by 0.89 mm) contiguous T1- (TR 28.3 ms, TE 6.9 ms) and T2-weighted (TR 
3300 ms, TE 120 ms) MRI scans were performed on all patients using a 
standardised protocol on a 1.5 T Phillips ACS scanner at Guy's Hospital, London. 
All patients were assessed clinically on the same day as their scans and were 
assigned scores on the EDSS and the SNRS as impairment measures, the GNDS- 
R, the Al, the FIM, the disability components of the CAMBS and the Barthel 
Index as disability measures. Patients were also invited to complete the London 
Handicap Scale and the handicap components of the CAMBS as handicap 
measures, and the EuroQol and the Short Form 36 health survey questionnaire as 
health related quality of life measures within three days of their clinical 
assessment. 
7.6 MRI analysis 
Quantitative MRI analysis was done in a blinded fashion on a standard 
graphic workstation (Hewlett Backard 735), using a novel semi-automated 
integrated software package designed for the segmentation and analysis of 
multiple sclerosis lesions, Analysis Tool for MS (ATOMS), which was developed 
by Dr. Alan Colchester's research group at the United Medical and Dental 
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Schools, University of London. MRI images were stored on a local hard disc to 
allow rapid access while using ATOMS. A standard screen arrangement was 
employed in which three quarters were used to display slices of the image data 
while the fourth was used to select the method of segmentation, image display 
mode, image orientation (axial, coronal, sagital), zooming facility, slice 
numbering, and saving facilities. Alternative slice display could be selected to 
allow either a single image display or orthogonal display in the three cardinal 
anatomical planes of the anatomically corresponding levels. Several segmentation 
techniques are supported by ATOMS, including manual outlining, intensity based 
threshholding, and hierarchical segmentation. The latter method was used for this 
study. The hierarchical segmentation method is a novel clustering algorithm 
developed at the United Medical and Dental Schools by L. D. Griffin (Griffin et 
al., 1996) in which the user makes points inside and outside a lesion and the 
computer searches to find the largest object containing all the inside and none of 
the outside points. It works by grouping adjacent pixels which have low edge 
strength based on local grey level differences. Boundaries, which correspond to 
ridges of locally high edge strength, are established between pixels that belong to 
different clusters. The grouping is computed to produce a finely detailed 
segmentation. The hierarchical segmentation is fully automated and requires no 
thresholds or other adjustable parameters. Compared with manual editing and 
intensity based threshholding, the hierarchical segmentation method was found to 
shorten the time needed for interactive segmentation by at least 25% whilst 
providing comparable volumetric assessments (Colchester et al., 1996). 
Five training sessions supervised by an experienced neuroradiologist (Dr. 
Tim Cox, Guy's Hospital) were arranged in which high-resolution T l- and T2- 
weighted scans of five patients with multiple sclerosis obtained using the same 
study protocol were segmented. All MRI analysis was done thereafter by myself 
in a blinded fashion. Multiple sclerosis lesions were identified and segmented 
using ATOMS, and each lesion was assigned one of three anatomical locations 
(cerebral, cerebellar, and brain stem) according to a reference atlas (Kretschmann 
and Weinrich, 1992). At the end of the analysis, six randomly selected T l- and 
T2-weighted scans were re-segmented (some three months after the initial 
segmentation) to assess intra-rater reliability. 
assessed because this study involved a single rater. 
Inter-rater reliability was not 
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7.7 Statistical analysis 
Data were tabulated and analysed using SPSS 7.5 for windows. The 
EDSS, SNRS, FIM, Al, CAMBS, and Barthel Index were treated as ordinal data. 
The London Handicap scale, EuroQol, Short Form 36 health survey questionnaire 
and MRI lesion loads were treated as interval data. Intra-rater reliability was 
expressed as the mean and 95% confidence intervals of the difference between the 
two observations to assess rater bias, and the repeatability coefficient as an 
indication of the maximum difference required to achieve 95% rater agreement. 
Intra-rater reliability was also assessed using intra-rater variability calculated as 
the percentage difference between the first and the second observations divided by 
the first observation (van Walderveen et al., 1995). Correlation between lesion 
load and the various clinical scales was assessed using Pearson's and Spearman 
rank correlation coefficients for interval and ordinal data respectively. 
7.8 Results 
Depending on the extent of the MRI abnormalities, the analysis of each set 
of the T2-weighted images required on average 90 to 120 minutes, whereas the 
analysis of each set of the TI-weighted images required on average 60 to 90 
minutes. Mean T2-weighted lesion loads were substantially higher than mean T 1- 
weighted lesion loads in all three anatomical sites (Table 7.2). Ninety five percent 
of the total T2- and TI-weighted lesion loads was due to lesions in the cerebrum. 
Brain stem lesion load was higher than cerebellar lesion load on the T2-weighted 
images, whereas cerebellar lesion load was higher than brain stem lesion load on 
the T 1-weighted images. 
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Table 7.2 Distribution of MRI lesion loads (cm) 
Site Mean SD 
T2-weighted imaging 
Total lesion load 14.37 18.66 
Cerebral 13.59 18.31 
Brain stem 0.67 0.96 
Cerebellar 0.23 0.27 
T1-weighted imaging 
Total lesion load 5.87 8.51 
Cerebral 5.62 6.35 
Brain stem 0.03 0.05 
Cerebellar 0.16 0.21 
7.8.1 Intra-rater reliability of lesion load analysis 
Lesion loads in the six randomly selected scans analysed in this study were 
higher than mean lesion loads of the cohort as a whole (Table 7.3). Intra-rater 
reliability of the T2-weighted total, cerebral, brain stem, and cerebellar lesion 
loads was very high with intra-rater variability of 3.1% - 3.4%. Mean volume 
differences between the two assessments were small with narrow 95% confidence 
intervals which included the "0" value indicating the absence of rater bias. 
Repeatability coefficients of the total and cerebral lesion loads were small (11.8% 
and 13.2% of the first observation values respectively), but relatively high for the 
brain stem and cerebellar lesion loads (59.2% and 40.7% of the first observation 
values respectively). 
By contrast, intra-rater reliability of the T 1-weighted total and cerebral 
lesion loads was slightly lower with intra-rater variability of 14.5% and 14.1% 
respectively. Intra-rater reliability of the TI-weighted brain stem and cerebellar 
lesion loads was low with intra-rater variability of 52.5% and 35.6% respectively. 
Mean volume differences between the two assessments were slightly high with 
wide 95% confidence intervals suggesting a partial bias towards the second 
observation. Repeatability coefficients of the total and cerebral lesion loads were 
high (76.1 % and 74.4% of the first observation values respectively), and very high 
for the brain stem and cerebellar lesion loads (122.2% and 137.5% of the first 
observation values respectively). 
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Table 7.3 Intra-rater reliability of lesion load analysis 
Time 1 Time 2 Mean Variability RC 
Mean (SD) * Mean (SD) * (95% CI) difference 
T2-weighted 
Total lesion load 26.79 (42.09) 26.00 (40.44) 0.79 (-1.17 to 2.75) 3.1% 3.16 
Cerebral 26.03 (42.04) 25.23 (40.41) 0.80 (-1.06 to 2.66) 3.4% 3.48 
Brain stem 0.49 (0.23) 0.51 (0.31) -0.02 (-0.18 to 0.14) 3.3% 0.29 
Cerebellar 0.27 (0.32) 0.26 (0.33) 0.01 (-0.01 to 0.06) 3.1% 0.11 
TI -weighted 
Total lesion load 10.81 (16.07) 12.38 (20.18) -1.58 (-5.98 to 2.83) 14.5% 8.23 
Cerebral 10.58 (15.83) 12.07 (19.77) -1.49 (-5.70 to 2.73) 14.1% 7.87 
Brain stem 0.09 (0.06) 0.14 (0.07) -0.05 (-0.01 to 0.04) 52.5% 0.11 
Cerebellar 0.32 (0.24) 0.44 (0.43) -0.11 (-0.67 to 0.45) 35.6% 0.44 
RC = repeatability coefficient; * cm3 
7.8.2 Correlation with clinical scales: 
Patients' characteristics in terms of their impairment, disability, handicap, 
and health related quality of life scores are detailed in Tables 7.4 and 7.9. 
A). Correlation with impairment outcome measures 
Modest correlations were found between T2-weighted total lesion load and 
the cerebellar and brain stem Functional Systems; T2-weighted cerebral lesion 
load and the cerebellar and the brain stem Functional Systems; T2-weighted brain 
stem lesion load and the cerebellar and the brain stem Functional Systems; T2- 
weighted cerebellar lesion load and the cerebellar Functional System; and 
between T2-weighted cerebellar lesion load and the bladder and bowel Functional 
System (Table 7.4). 
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Table 7.4 Correlation between T2-lesion loads and the EDSS 
Functional Systems Score * Correlation with MRI lesion loads 
Cerebral Brain Stem Cerebellar Total lesion load 
Pyramidal 3 [0 to 5] 0.11 0.08 0.38 0.10 
Cerebellar 2 [0 to 5] 0.29 (0.044) 0.41 (0.02) 0.59 (0.001) 0.30 (0.039) 
Brain stem 0 [0 to 4] 0.42 (0.003) 0.56 (0.001) 0.29 0.48 (0.002) 
Sensory 0 [0 to 5] 0.09 0.10 0.11 0.09 
Bladder and bowel 1 [0 to 4] 0.11 0.04 0.49 (0.009) 0.11 
Mental 0 [0 to 3] 0.27 0.24 0.14 0.27 
Visual 0 [0 to 6] 0.22 0.18 0.11 0.23 
* Median (range); figures in parenthesis represent the statistically significant p values 
Modest correlations were also found between T 1-weighted total lesion 
load and the cerebellar, brain stem, and mental Functional Systems; T 1-weighted 
cerebral lesion load and the cerebellar, brain stem, and mental Functional 
Systems; TI-weighted brain stem lesion load and the brain stem Functional 
System; and between TI-weighted cerebellar lesion load and the cerebellar 
Functional System (Table 7.5). 
Table 7.5 Correlation between T1-lesion loads and the EDSS 
Functional Systems Score * Correlation with MRI lesion loads 
Cerebral Brain Stem Cerebellar Total lesion load 
Pyramidal 3 [0 to 5] 0.18 0.16 0.39 0.18 
Cerebellar 2 [0 to 5] 0.34 (0.019) 0.39 (0.032) 0.66 (0.022) 0.36 (0.013) 
Brain stem 0 [0 to 4] 0.39 (0.006) 0.50 (0.012) 0.27 0.43 (0.003) 
Sensory 0 [0 to 5] 0.15 0.22 0.11 0.16 
Bladder and bowel 1 [0 to 4] 0.19 0.23 0.38 0.19 
Mental 0 [0 to 3] 0.34 (0.017) -0.13 0.09 0.35 (0.016) 
Visual 0 [0 to 6] 0.29 (0.045) -0.35 0.35 0.30 (0.042) 
* Median (range); figures in parenthesis represent the statistically significant p values 
Modest correlations were also found between Ti- and T2-weighted total 
lesion loads and lesion loads in the different anatomical sites and the SNRS sum 
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B). Correlation with disability outcome measures 
Modest correlations were found between TI-weighted total and cerebral 
lesion loads and the cognitive disability domain of the GNDS-R (Table 6.9); Ti- 
and T2-weighted brain stem lesion load and the swallowing and the upper limb 
disability domains and the sum score of the GNDS-R (Tables 6.8 and 6.9) and the 
disability domain of the CAMBS (Tables 7.6 and 7.7); TI- and T2-weighted 
cerebellar lesion load and the upper limb disability domain of the GNDS-R 
(Tables 7.8 and 7.9), the FIM sum score and the Al (Tables 7.6 and 7.7); and 
between T2-weignted cerebellar lesion load and the bladder disability domain of 
the GNDS-R (Table 6.8). 
Q. Correlation with handicap and health related quality of life outcome 
measures 
Modest correlations were found between TI-weighted total and cerebral 
lesion loads and the handicap domain of the CAMBS, the EuroQol VAS, the 
emotional role limitation, and mental health domain of the SF-36 (Table 7.9). 
Sub-group analysis of patients with relapsing-remitting and secondary 
progressive MS showed similar results. 
Table 7.8 Correlation between T2-lesion loads and the GNDS-R 
Scale item Score * Correlation with MRI lesion loads 
Cerebral Brain Stem Cerebellar Total lesion load 
Cognitive disability 0 [0 to 3] 0.24 0.34 -0.09 0.25 
Mood disability 0 [0 to 4] -0.04 0.17 0.48 -0.03 
Visual disability 0 [0 to 3] 0.15 0.22 0.26 0.17 
Speech disability 0 [0 to 3] 0.12 0.28 0.18 0.13 
Swallowing disability 0 [0 to 2] 0.18 0.51 (0.003) 0.04 0.20 
Upper limb disability 1 [0 to 4] 0.17 0.39 (0.003) 0.49 (0.009) 0.19 
Lower limb disability 2 [0 to 4] -0.01 0.32 0.32 0.01 
Bladder disability 2 [0 to 4] 0.04 -0.01 0.23 0.04 
Bowel disability 0 [0 to 5] -0.01 0.01 0.06 -0.01 
Fatigue 2 [0 to 4] 0.11 0.28 0.27 0.11 
Sexual disability 0 [0 to 5] 0.16 0.21 0.17 0.16 
Other disabilities 1 [0 to 4] -0.05 0.21 0.17 -0.04 
* Median (range); figures in parenthesis represent the statistically significant p values 
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Table 7.9 Correlation between T 1-lesion loads and the GNDS 
Scale item Score * Correlation with MRI lesion loads 
Cerebral Brain Stem Cerebellar Total lesion load 
Cognitive disability 0 [0 to 3] 0.32 (0.028) 0.23 -0.03 0.32 (0.029) 
Mood disability 0 [0 to 4] -0.02 0.01 -0.07 -0.01 
Visual disability 0 [0 to 3] 0.22 -0.28 0.23 0.24 
Speech disability 0 [0 to 3] 0.21 0.01 0.25 0.21 
Swallowing disability 0 [0 to 2] 0.29 (0.043) 0.39 (0.042) 0.25 0.32 (0.031) 
Upper limb disability 1 [0 to 4] 0.23 0.32 (0.035) 0.34 (0.031) 0.24 
Lower limb disability 2 [0 to 4] 0.08 -0.31 0.34 0.09 
Bladder disability 2 [0 to 4] 0.09 0.39 0.33 0.09 
Bowel disability 0 [0 to 5] 0.26 0.14 0.02 0.03 
Fatigue 2 [0 to 4] 0.16 0.15 0.11 0.15 
Sexual disability 0 [0 to 5] 0.22 -0.11 0.32 0.22 
Other disabilities 1 [0 to 4] -0.04 -0.17 0.23 -0.03 
* Median (range); figures in parenthesis represent the statistically significant p values 
7.9 Discussion 
Mean T2- and TI-weighted lesion volumes in this study were similar to 
the previously reported figures from other large cohorts with similar patients' 
characteristics indicating that the study cohort constituted an unbiased sample 
from the general multiple sclerosis population (Truyen et al., 1996; Simon et al., 
1998). As reported in the literature, I found the T2-weighted lesion loads to be 
higher than the TI-weighted lesion loads in the three anatomical sites (van 
Walderveen et al., 1995; Truyen et al., 1996). Similar to the report by 
Baumhefner and co-workers (Baumhefner et al., 1990), I also found the cerebral 
T2- and T2-weighted lesions to comprise the majority of the total lesion load, and 
the brain stem lesion load to be higher than the cerebellar lesion load on T2- 
weighted imaging. By contrast, the cerebellar lesion load was higher than brain 
stem lesion load on T1-weighted imaging. There are no published reports 
addressing infratentoral T 1-weighted lesion loads. 
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7.9.1 Reliability of analysis 
Although inter- and intra-rater reliability of quantitative MRI analysis has 
been assessed by many workers (Miller et al., 1998), there is only one published 
study assessing intra-rater reliability of both T2- and T1-weighted lesion load 
which used a methodology similar to one used in my study (van Walderveen et 
al., 1995). As in my study, the investigator in the van Walderveen study 
identified all multiple sclerosis lesions themselves on electronic data before 
segmenting them, and their reliability figures therefore included the reliability of 
both lesion recognition and delineation. In contrast, multiple sclerosis lesions in 
other studies of higher reliability figures were identified for the investigators on 
hard copies by expert neuroradiologists, and the reliability figures in such studies 
therefore only address the delineation process and exclude any variability related 
to lesion identification. 
As in my study, van Walderveen and co-workers found the intra-rater 
variability of lesion load quantification to depend on the MRI acquisition and the 
extent of the abnormalities, being smaller for larger lesion loads on T2-weighted 
images (1.8% to 6.1%) than for smaller lesion loads on TI-weighted images 
(2.0% to 10.3%) (van Walderveen et al., 1995). Mean T l- and T2- weighted 
lesion loads and intra-rater variability in the van Walderveen study and my study 
were similar. However brain stem and cerebellar lesion loads in the van 
Walderveen study were much higher than my study, and this may explain, at least 
partly, the low reliability of lesion load estimation in these two regions of interest 
obtained in my study. Infratentorial lesions in multiple sclerosis are usually very 
small and difficult to recognise and delineate which is partly related to the 
presence of disturbing flow artefacts from the third and fourth ventricles and to 
the relatively poor contrast of these lesions due to the cerebellum not being in the 
centre of the coil (Miller et al., 1998). 
Intra-rater variability of lesion quantification in the van Walderveen study 
fell well below their median annual increase of lesion load, which was 9% on the 
T2-weighted and 40% on the TI-weighted images (van Walderveen et al., 1995). 
With the exception of the brain stem and cerebellar TI-weighted lesion volumes, 
these figures are well above my intra-rater variability values suggesting that my 
analysis is sufficiently reliable not only for cross-sectional but also for 
longitudinal studies. 
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7.9.2 Clinical correlates 
The most consistent correlations were found between T 1- and T2-weighted 
lesion loads and the different measure of impairment particularly the cerebellar 
and the brain stem Functional System scores and the SNRS sum scores. These 
correlations were particularly high when TI- and T2-weighted brain stem lesion 
loads were correlated with the brain stem Functional System scores, and the T l- 
and T2-weighted cerebellar lesion loads correlated with the cerebellar Functional 
System scores. A modest correlation was also found between T 1-weighted (but 
not T2-weighted) total and cerebral lesion loads and the mental Functional System 
scores. Modest correlations were also found between TI-weighted cerebellar 
lesion load and the EDSS which reflect the effect of cerebellar dysfunction on this 
ambulation biased scale. 
Modest correlations were also found between the Ti- and T2-weighted 
brain stem lesion loads and various disability measures including the swallowing, 
upper limb, and GNDS-R sum scores and the disability domain of the CAMBS; 
and between the T l- and T2-weighted cerebellar lesion loads and the upper limb 
disability domain of the GNDS-R, the FIM sum score, and the Al reflecting the 
effect of cerebellar dysfunction on these disabilities. A weak correlation was also 
found between TI-weighted total and cerebral lesion loads and cognitive 
disability domain of the GNDS-R. 
Modest correlations were also found between TI-weighted total and 
cerebral lesion loads and overall health related quality of life as assessed by the 
EuroQol, and the emotional role limitation and the mental heath components of 
the SF-36. Interestingly the handicap domain of the CAMBS, but not the London 
Handicap Scale, showed similar degrees of correlation with T 1-weighted total and 
cerebral lesion loads as the EuroQol suggesting that this scale is tapping health 
related quality of life rather than handicap. The significance of the observed 
correlations between bladder and bowel impairment and disability measures and 
T 1- and T2- cerebellar lesion load remains unclear. 
These results are compatible with the ICIDH model which predicts a high 
correlation between pathology and impairment but a weak correlation between 
pathology and disability or between pathology and handicap, and with the 
previously published reports of modest correlations between conventional MRI 
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parameters and the various impairment and disability clinical outcome measures. 
These results also support the previously reported high correlations between 
lesions at specific sites and relevant impairment and disability measures as 
discussed earlier. The interaction between the site of the pathological process and 
its severity has recently been addressed in an MRI spectroscopy study in which N- 
acetyl-aspartate resonance intensity in the cerebellum was found to be normal in 
non-ataxic multiple sclerosis patients but reduced in ataxic patients to the levels 
present in patients with autosomal dominant spino-cerebellar degeneration (Davie 
et al., 1995). Although some of the correlations between the various clinical 
measures and the TI-weighted lesion loads were slightly higher or more 
significant than with the T2-weighted lesion loads, all the observed correlations 
were only mild or moderate. 
In discussing the complex relationship between MRI and clinical 
disablement and health related quality of life measures, several factors need to be 
considered (Miller et al., 1998): 
A). Clinical outcome measures 
Existing disablement and health related quality of life measures have 
important limitations. Correlations with more detailed and specific outcomes, 
such as the neuropsychological measures, have achieved higher scores. 
B). Lesion size 
The size of individual MS lesions may determine the nature and evolution 
of functional deficits. For instance, a large lesion in a fibre tract may cause an 
acute relapse while many small lesions developing over time may cause a 
progressive deficit. 
Q. Lesion site 
Some sites in the central nervous system will when damaged by lesions 
have more obvious disabling consequences than others. For instance cortical 
lesions may have little effect on physical disability whereas lesions in eloquent 
sites (brain stem and the spinal cord) can have a devastating impact on the 
person's mobility. 
D). Lesion severity 
The pathological severity (demyelination or axonal loss) of lesions is 
crucial in determining the ultimate outcome in terms of recovery. 
E). Normal appearing white matter 
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Although normal in appearance, white matter may have quantitative MR 
deficits due to microscopic pathology which contribute to disability without being 
abnormal on conventional MR. 
Until these issues are resolved clinical and MRI measures of disease 
activity and burden will remain divergent. The ultimate goal of further research 
should not only concentrate on refining clinical and MRI correlations but also on 
investigating the correlations between MRI and the pathological processes within 
lesions. Clinical and MRI parameters should both be thought of as surrogates of 
the underlying disease pathology. 
7.10 Conclusions 
This study has confirmed the presence of a modest relation between the 
extent of pathology in multiple sclerosis as measured by brain lesion load on T l- 
and T2-weighted MRI and some clinical measures of impairment, disability and 
health related quality of life but not handicap. The strongest correlations were 
observed between brain stem and cerebellar lesion loads and the corresponding 
impairment measures. Although the correlation between the various clinical 
measures and the TI-weighted lesion loads were slightly higher than with T2- 




Outcome measures allow the classification of patients according to the 
presence and severity of the disease process (pathology), the resulting disablement 
in terms of the clinical condition (impairment), functional capacity (disability / 
activities limitation), and social disadvantage (handicap / participation restriction), 
or according to the subjectively perceived health related quality of life. The 
choice of a specific outcome measure for a clinical trial depends on the nature of 
the study and the research hypothesis being tested. In phase II studies, which are 
designed to assess the biological effects of therapeutic interventions on patients, a 
measure of pathology or impairment would be appropriate. In phase III studies, 
which are designed to assess the clinical effect of therapeutic interventions on the 
functional capacity of patients, a measure of disability, handicap, or health related 
quality of life would be more desirable. Regardless of their conceptual nature, the 
practical value of any outcome measure depends on its clinical usefulness in terms 
of acceptability, ease of administration, and cost effectiveness, and on its 
scientific integrity in terms of reliability, validity, and responsiveness. 
Multiple sclerosis is the most common cause of chronic neurological 
disability in young adults. It often begins with a relapsing and remitting course 
which progresses subsequently into a progressive phase with a gradual 
accumulation of wide ranging disabilities resulting in a major burden of suffering 
for patients and their families and substantial demands on health and social 
services. Many rating scales have been devised to assess the effect of experimental 
interventions on this illness. The scales most commonly used are the Kurtzke's 
Expanded Disability Status Scale, the Scripps Neurological Rating Scale, the 
Functional Independence Measure, the Ambulation Index, and the Cambridge 
Multiple Sclerosis Basic Score. The psychometric properties of these scales were 
investigated in this thesis and none was found to have satisfied all the 
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requirements of an ideal outcome measure although all had some desirable 
properties. Furthermore a postal survey showed that the majority of 49 leading 
international neurologists involved with multiple sclerosis research felt that 
currently existing outcome measures for multiple sclerosis are inadequate, and 
that there is a need for a new measure which should be patient orientated, 
multidimensional, and not biased towards any particular disability. 
To fulfil this need, the Guy's Neurological Disability Scale was 
subsequently devised as a simple and user-friendly clinical disability scale capable 
of embracing the whole range of disabilities which could be encountered in the 
course of this illness in 12 separate categories which include cognition, mood, 
vision, speech, swallowing, upper limb function, lower limb function, bladder 
function, bowel function, sexual function, fatigue, and `other disabilities'. In our 
hands, the Guy's Neurological Disability Scale was found to be reliable, 
responsive, and valid as a measure of disability. The scale was also found to be 
acceptable to neurologists and patients, and valid when applied by non- 
neurologists, over the telephone, or via a postal questionnaire. The results in this 
thesis lacks supportive psychometric data on a naive patient sample with more 
widespread disability by independent investigators. Such data will be provided by 
a study which now underway in four centres throughout the UK. 
The correlation between pathology on one hand and impairment, disability 
and handicap on the other was also investigated in this thesis by assessing the 
correlation between T l- and T2-weighted MRI lesion load as a measure of 
pathology and various impairment, disability, handicap, and health related quality 
of life outcome measures. As predicted by the ICIDH, this study showed modest 
relation between the extent of pathology and clinical measures of impairment, 
disability and health related quality of life but not handicap. However, the 
strongest correlations were observed between brain stem and cerebellar lesion 
loads and the corresponding impairment measures. 
The data discussed in this thesis have a number of limitations in relation to 
the reliability of the methodology and the generalisability of the results. 
The reproducibility methods used in this thesis were sub-optimal in some 
respects. The various scales assessed were applied repeatedly on the same sample 
of patients by the same raters and the possibility of patients' and raters' bias 
cannot be excluded. However, as discussed in chapter 5 and chapter 6, all the 
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raters were blinded to their own and other raters' previous scores, and open 
discussions about patients' clinical conditions were avoided amongst themselves. 
In the inter-rater reliability studies, patients were assessed independently by the 
two raters and no fixed order for the examination was observed so as to reduce the 
effect of patients' bias which might have resulted from practice effect or fatigue. 
Data for the intra-rater reliability and responsiveness studies were collected at 
three monthly intervals so as to reduce raters' and patients' bias which might have 
resulted from recall of the previous assessments. The effect of this potential 
source of bias is unlikely to have been significant since the inter-rater reliability 
figures were often higher than the intra-rater reliability figures. It is also unlikely 
that the familiarity of the patients to the assessors or the frequent administrations 
of the Guy's Neurological Disability Scale have biased the results significantly 
since the reliability figures of the various methods of scale administration were 
often lower then the initial inter-rater reliability figures which were obtained when 
the scale was administered by the two raters for the first time. It is also worth 
noting that the repeated administration of this scale did not result in any 
significant 'regression to the mean' of the various sub-and sum scores as the 
median (range) scores remained relatively stable throughout the repeated scale 
administration during the second phase of the study. 
The number patients recruited for this study was small. Sample size 
estimation was not done a priori since I was constrained by the number of patients 
in the ongoing interferon beta la trials. Although this stricture might have 
resulted in a degree of type II statistical error (false negative results), the 
confidence intervals of the various reliability results were relatively narrow 
indicating that the true reliability coefficients were reasonably close to those 
estimates in this study. Streiner and Norman (1995) proposed that sample sizes 
should vary according to the magnitude of the expected reliability coefficients and 
the width of the confidence intervals. They suggested that for confidence 
intervals of ± 0.10 and an a of 0.05 a sample of 50 and 35 patients will result in a 
"statistical overkill" for any reliability coefficients over 0.85 and 0.90 
respectively. 
The measurement properties of the various scales have also been examined 
in a selected sample of highly motivated patients with mild to moderate degree of 
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disability (EDSS 0-7.5). Ideally such a study should have been conducted in a 
population based sample from a geographically defined area to ensure the accurate 
representation of the patients in the general MS population. Natural history 
studies suggest that only 78-85% of patients have EDSS scores <8.0 (Goodkin et 
al., 1989; Swingler and Compston, 1992; Rodriguez et al., 1994; Midgard et al., 
1996). As the sample in this study was restricted, the results discussed in this 
thesis should only be generalised to patients with EDSS <8.0. 
The majority of the Guy's Neurological Disability sub-scales in the 
studied cohort were skewed to the less disabled end of the scale suggesting a 
`floor' effect. This skewness is likely to have been related to the nature of 
disability in this sample rather than the scale itself since the frequency distribution 
of these sub-scales was near Normal in the postal survey data set. Although such 
a strong `floor' effect limits the legitimate use of parametric statistics, particularly 
factor and regression analysis, it does not affect the results of non-parametric 
statistics or kappa coefficients. The use of parametric statistics for the calculation 
of mean score differences and repeatability coefficients remains appropriate since 
score differences are likely to have Normal distribution (Bland and Altman, 
1986). Furthermore, the Guy's Neurological Disability Scale was developed as a 
multi-item rather than a single item measure and the frequency distribution of its 
sum scores was Normal. 
Multi-item rating scales are known have superior measurement properties 
to single item measures. This is not surprising since single item measures are 
conceptually unlikely to fully represent complex theoretical concepts such as 
disability (Nunnally, 1978). Furthermore single items are unable to make the fine 
differentiations between patients which are desirable for most measurement 
problems. Perhaps the most important limitation of single item measure is the fact 
that their measurement properties, particularly validity, are difficult to examine 
(Mclever and Carmines, 1981). 
The assessment of responsiveness was also sub-optimal in this study. As 
discussed in chapter 3, the notion of responsiveness was originally based on the 
simple construct that the goal of therapy is to induce change in health status 
(Norman et al., 1997). A number of measures of responsiveness based on the 
measurement of change following therapeutic interventions, including Student-t 
test, Wilcoxon Signed Rank test and effect size, have been proposed. Although 
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the computation of these methods is straightforward, this approach has some 
theoretical limitations since the magnitude of the resulting coefficients is 
dependent on the actual change induced by treatment and cannot therefore be 
viewed as the sole property of the instrument itself. As a consequence some 
investigators have abandoned this strategy and opted to estimate responsiveness 
independent of any particular intervention by identifying those patients who have 
and have not changed over time to a clinically important extent using other criteria 
of change, such as patient or physician perception of change (Guyatt et al., 1987). 
This strategy was adopted in this thesis. Unfortunately the reliability and validity 
of this method have never been established (Norman et al., 1997). The judgement 
of change is psychologically difficult. Patients must be able to quantify their 
present and initial status and then perform a mental subtraction. There is evidence 
that patients are in fact unable to recall their initial health status and their 
judgements are usually biased towards their present status (Ross, 1989). The use 
of clinician judgement of change is unlikely to have avoided this bias since I had 
to use the patients as informants and the same confounding might have occurred. 
The patients in this study were also taking part in a therapeutic trial of 
interferon beta l a, and such treatment might have affected their clinical condition 
and shaped their appraisal of their clinical status. However this effect is unlikely 
to have been important since all patients were blinded as to the treatment and the 
study was done under common overall treatment effect. 
Finally, although the Guy's Neurological Disability Scale was devised as a 
disability scale, its sum scores and many of its sub-scales correlated highly not 
only with other disability measures but also with many impairment measures 
suggesting that the scale is tapping a combination of impairment and disability. 
This is likely to have been due to the nature of the scale itself and to the 
conceptual difficulties in separating impairment from disability within the ICIDH 
model. The three basic constructs in this model describe closely related 
theoretical entities which overlap considerably. The distinction between 
impairment and disability is particularly difficult as evident in the mood, visual, 
speech, swallowing, bladder, and bowel disability Guy's Neurological Disability 
sub-scales. These `disabilities' are graded according to the presence and severity 
of the relevant symptoms, i. e. according to the subjective degree of `impairment'. 
Visual `impairment' on the other hand is traditionally assessed by measuring 
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patients' `disability' in reading various visual charts (Hughes and Sharrack, 1996). 
This imperfection of the ICIDH model explains the surprisingly high correlation 
between the Scripps Neurological Rating Scale as a measure of impairment and 
the Functional Independence Measure, the disability domain of the Cambridge 
Multiple Sclerosis Basic Score, and the physical functioning domain of the Short 
Form 36 which has been discussed in chapter 5. Despite these difficulties, the 
ICIDH model remains the best framework currently available for health science 
research. 
Provided that the currently ongoing additional study on the Guy's 
Neurological Disability Scale shows that the results discussed in this thesis can be 
generalised, this scale will be a helpful new clinical outcome measure for multiple 
sclerosis which is capable of providing relevant information on the wide range of 
disability as experienced by patients. Additional assessment of impairment, 
handicap, and health related quality of life would be necessary to provide a more 
comprehensive appraisal which incorporates the objective and the subjective 
aspects of patients' health status. 
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Appendix 1 
THE REVISED GUY'S NEUROLOGICAL DISABILITY SCALE 
1). Cognitive Disability 
A. Interview: 
Do you have any problems with your memory or your ability to concentrate and 
work things out? 
Q yes Q no 
Do your family or friends think that you have such a problem? 
Q yes Q no 
If the answer to either question is `yes': 
Do you need help from other people for planing your normal daily affairs, 
handling money or making decisions? 
Q yes Q no 
If 'yes': s: (To the examiner) 
Is the patient orientated in time, place and person? 
Q yes, fully 
Q yes, partially 
Q no, totally disorientated 
* If the patient is not fully orientated, all their answers should be verified by the 
main carer(s) whose answers should take precedence. 
B)-Scoring: 
0- No cognitive problems. 
1- Cognitive problems not noticeable to family or friends. 
2- Cognitive problems noticeable to family or friends but not requiring help from 
others. 
3- Cognitive problems requiring help from others for normal daily affairs; patient 
is fully orientated in time, place and person. 
4- Cognitive problems requiring help from others for normal daily affairs; patient 
is not fully orientated. 
5- Patient is completely disorientated in time, place and person. 
198 
2). Mood Disability 
A) Interview: 
Have you been feeling anxious, irritable, depressed, or had any mood swings 
during the last month? 
Q yes Q no 
Are you taking any medications for such problems? 
Q yes Q no 
If the answer to the first question is `yes': 
Has this problem affected your ability to do ay of your usual daily activities 
such as work, housework, or normal social activities with family and friends? 
Q yes Q no 
If 'yes': 
Has this problem been severe enough to prevent you from doing all your 
usual activities? 
Q yes Q no 
Have you been admitted to hospital for treatment of your mood problem 
during the last month? 
Q yes Q no 
B. Scoring: 
0- No mood problems. 
1- Asymptomatic on current drug treatment. 
2- Mood problems present but not affecting the patient's ability to perform any of 
their usual daily activities. 
3- Mood problems affecting the patient's ability to perform some of their usual 
daily activities. 
4- Mood problems preventing the patients from doing all their usual daily 
activities. 
5- Mood problems requiring inpatient management. 
X- Unknown, please score as the mean of the cognitive and fatigue disability 
scores rounded to the nearest integer (see results of factor analysis). 
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3). Visual disability 
A. Interview: 
Do you have any problems with your vision which can't be corrected with 
ordinary glasses? 
Q yes Q no 
If 'yes': 
Can you read ordinary newspaper print (with ordinary glasses if worn, but not 
magnifying lenses)? 
Q ves Q no 
If `no': 
Can you read large newspaper print? 
Q ves Q no 
If `no': 
Can you count your fingers if you hold your hand out in front of you? 
Q ves Q no 
If `no': 
Can you see your hand if you move it in front of you? 
Q yes Q no 
B. Scoring: 
0- No visual problems. 
1- Visual problems (blurred vision, diplopia, scotomas) but patient is still able to 
read ordinary newspaper print. 
2- Unable to read ordinary newspaper print. 
3- Unable to read large newspaper print. 
4- Unable to count fingers if they hold their hand out in front of them. 
5- Unable to see hand movement if they move their hand in front of them. 
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4). Speech disability 
A. Interview 
Do you have any problems with your speech? 
Q yes Q no 
If 'yes': 
Do you have to repeat yourself when speaking to strangers? 
Q yes Q no 
If 'yes': 
Do you have to repeat yourself when speaking to your family or close 
friends? 
Q yes Q no 
If 'yes': 
Do you need to use sign language, or the help of your carer to make 
people understand you? 
Q yes Q no 
If `yes': (to the examiner) 
Is the patient able to communicate effectively using these methods? 
Q yes Q no 
B. Scoring: 
0- No speech problems. 
1- Speech problems which does not require the patient to repeat themselves when 
speaking to strangers. 
2- Speech problems which require the patient to repeat themselves when 
speaking to strangers. 
3- Speech problems which require the patient to repeat themselves when 
speaking to their family and close friends. 
4- Speech problems making speech difficult to understand; patient is able to 
communicate effectively by using sign language or the help of their carers. 
5-Speech problems making speech difficult to understand, patient is unable to 
communicate effectively by using sign language or the help of their carers. 
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5). Swallowing disability 
A. Interview: 
Do you have to take care when swallowing solids or fluids? 
Q yes Q no 
If` es': 
Do you have to take care when swallowing with most meals? 
Q yes Q no 
If 'yes': 
Do you need a special diet such as soft or liquidated food to help with your 
swallowing? 
Q yes Q no 
If ' 
Do you choke with most meals? 
Q yes Q no 
If y 
Do you have a feeding tube (nasogastric or gastrostomy tube)? 
Q yes Q no 
B)-Scoring: 
0- No swallowing problems. 
1- Needs to be careful when swallowing solids or liquids but not with most 
meals. 
2- Needs to be careful when swallowing solids or liquids with most meals; patient 
is able to eat food of normal consistency. 
3- Needs specially prepared food of modified consistency. 
4- Tendency to choke with most meal. 
5- Dysphagia requiring nasogastric or gastrostomy tube. 
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6). Upper limb disability 
A . -Interview: 
Do you have any problems with your hands or arms? 
Q yes Q no 
If` es': 
Do you have any difficulty in doing any of your zips or buttons? 
Q yes Q no 
If 'yes': 
Are you able to do all of your zips and buttons without help? 
Q yes Q no 
Do you have any difficulty in tying a bow in laces or strings? 
Q yes Q no 
If 'yes': 
Are you able to tie a bow in laces or strings without help? 
Q yes Q no 
Do you have any difficulty washing and brushing your hair? 
Q yes Q no 
If `Yes'_ 
Are you able to wash and brush your hair without help? 
Q yes Q no 
Do you have any difficulty feeding yourself? 
Q ves Q no 
If `yes'_ 
Are you able to feed yourself without help? 
Q yes Q no 
If unable to do any of the functions listed: 
Can you use your hands or arms for any other function? 
Q yes Q no 
B. Scoring: 
0- No upper limb problems. 
1- Problems in one or both arms, not affecting the ability to do any of the functions 
listed. 
2- Problems in one or both arms, affecting some but not preventing any of the 
functions listed. 
3- Problems in one or both arms, affecting all or preventing one or two of the 
functions listed. 
4- Problems in one or both arms preventing three or all of the functions listed. 
5- Unable to use either arm for any purposeful movements. 
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7). Lower limb disability 
A. Interview: 
Do you have any problems with your walking? 
Q yes Q no 
If 'yes': 
Do you use a walking aid? 
Q yes Q no 
If `yes': 
A. How do you usually get around outdoors? 
Q without aid 
OR Q with one stick or crutch or holding to someone's arm 
OR Q with two sticks or crutches or one stick or crutch and holding to 
someone's arm 
OR Q with a wheelchair 
B. How do you usuall get around indoors? 
Q without aid 
OR Q with one stick or crutch or holding to someone's arm 
OR Q with two sticks or crutches or one stick or crutch and holding to 
someone's arm 
OR Q with a wheelchair 
If you use a wheelchair: 
Can you stand and walk few steps with help? 
Q yes Q no 
B. Scoring: 
0- Walking is not affected. 
1- Walking is affected but patient is able to walk independently. 
2- Usually uses unilateral support (single stick or crutch, one arm) to walk 
outdoors, but walks independently indoors. 
3- Usually uses bilateral support (two sticks or crutches, frame, or two arms) to 
walk outdoors, or unilateral support (single stick or crutch, or one arm) to walk 
indoors. 
4- Usually uses wheelchair to travel outdoors, or bilateral support (two sticks 
or crutches, frame, or two arms) to walk indoors. 
5- Usually uses a wheelchair indoors. 
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8). Bladder disability 
A. Interview 
Do you have any problems with your bladder? 
Q yes Q no 
Are you taking any medications for such problems? 
Q yes Q no 
If the answer to the first question is `, yes': 
Do you have to rush to the toilet, go frequently, or have difficulty in starting to 
pass urine? 
Q yes Q no 
Have you been incontinent last month? 
Q yes Q no 
If `yes': 
Have you been incontinent last week? 
Q yes Q no 
If 'yes': 
Have you been incontinent every day? 
Q yes Q no 
Do you need to use a catheter to empty your bladder? 
Q yes Q no 
Do you need a permanent catheter in the bladder, or (for men only) do you use a 
sheath to collect your urine? 
Q yes Q no 
B. Scoring: 
0- Normal bladder problems. 
1- Aasymptomatic on current drug treatment. 
2- Urinary frequency, urgency, or hesitancy with no incontinence. 
3- Occasional urinary incontinence (once or more during the last month but not 
every week) or intermittent catheterisation without incontinence. 
4- Frequent urinary incontinence (once a week or more during the last month but 
not daily), or occasional urinary incontinence despite regular intermittent 
catheterisation. 
5- Daily urinary incontinence or permanent catheter (urethral / suprapubic) or 
penile sheath. 
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9). Bowel disability 
A. Interview: 
Do you have any problems with your bowel movements? 
Q yes Q no 
Are you on any medicines for such problems? 
Q yes Q no 
If the answer to the first question is `, yes': 
Do you suffer with constipation? 
Q ves Q no 
If 'Yes': 
Do you need to take any laxatives or use suppositories for this? 
Q ves Q no 
Do you usually use enemas? 
Q yes Q no 
Do you usually evacuate your stools manually? 
Q yes Q no 
Do you have to rush to the toilet to open your bowels? 
Q yes Q no 
Have you had any bowel accidents (been incontinent of faeces) last week? 
Q ves Q no 
Iff' 
Have you had bowel accidents every week? 
Q yes Q no 
B)-Scoring: 
0- No bowel problems. 
1- Asymptomatic on current drug treatment or constipation not requiring any 
treatment. 
2- Constipation requiring laxatives or suppositories or faecal urgency. 
3- Constipation requiring the use of enemas. 
4- Constipation requiring manual evacuation of stools or occasional faecal 
incontinence (once or more during the last month but not every week). 
5- Weekly faecal incontinence. 
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10). Fatigue disability 
A. Interview: 
Have you been feeling tired or getting tired easily during the last month? 
Q yes Q no 
If `yes': 
Have you been feeling tired most days? 
Q yes Q no 
Has this tiredness affected your ability to do ay of your usual activities such as 
work, housework, or normal social activities with family and friends? 
Q yes Q no 
If 'yes': 
Has this tiredness been severe enough o prevent you from doing all of your 
usual activities? 
Q yes Q no 
If 'yes': 
Has the tiredness been severe enough to prevent you from doing all physical 
activities? 
Q yes Q no 
B. Scoring: 
0- Absent. 
1- Occasional fatigue present some days. 
2- Frequent fatigue present most days. 
3- Fatigue affecting the patient's ability to perform some of their usual daily 
activities. 
4- Fatigue preventing the patient from doing all their usual daily activities. 
5- Fatigue preventing the patient from doing all physical activities. 
X- Unknown, please score as the mean of the cognitive and mood disability 
scores rounded to the nearest integer (see results of factor analysis). 
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11). Sexual disability 
A. Interview: 




Q not applicable (celibate) 
If the patient agrees: 
Do you have any problems in relation to your sexual function? 
Q yes Q no 
If 'yes': 
Do you suffer with lack of sexual interest? 
Q yes Q no 
Do you have any problems satisfying yourself or your sexual partner? 
Q yes Q no 
Is your sexual function affected by any physical problem such as altered 
genital sensation, pain, or spasms? 
Q yes Q no 
Do you have any problems with: 
for men : erection / ejaculation? 
(for women): vaginal lubrication / orgasm? 
Q yes Q no 
If physical or sexual problems are present: 
Do any of these difficulties totally prevent your sexual activities? 
Q yes Q no 
B. Scoring: 
0- Normal sexual function or persons who are voluntarily celibate. 
1- Reduced sexual interest. 
2- Problems satisfying oneself or sexual partner. 
3- Physical problems interfering but not preventing sexual function. 
4- Autonomic problems interfering but not preventing sexual function. 
5- Physical or autonomic problems totally preventing sexual function. 
X- Unknown, please score as the mean of the lower limb, bladder, and bowel 
disability scores rounded to the nearest integer (see results of factor analysis). 
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12). Other disabilities 
A. Interview: 
Do you have other problems due to MS such as pain, spasms, or dizziness which 
have not been mentioned so far? 
Q yes Q no 
Are you taking any medicines for such problems? 
Q yes Q no 
If the answer to either question is `yes': 
Please name your worst problem: ............................... 
Has this problem affected your ability to do any of your usual daily 
activities? 
Q yes Q no 
Has this problem been severe enough to prevent you from doing all your usual 
daily activities? 
Q yes Q no 
Have you been admitted to hospital for treatment of this problem? 
Q yes Q no 
B. Scoring: 
0- Absent. 
1- Asymptomatic on current drug treatment. 
2- Problems present, but are not affecting the patient's ability to perform any of 
their usual daily activities. 
3- Problems affecting the patient's ability to perform some of their usual daily 
activities. 
4- Problems preventing the patient from doing all their usual daily activities. 
5- Problems requiring hospital admission for assessment or treatment. 
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Appendix 2 
THE POSTAL GUY'S NEUROLOGICAL DISABILITY SCALE 
A. About your MS 
1) Memory and Concentration 
1.1 a. Do you have any problems with your memory or 
your ability to concentrate and work things out? 
b. Do your family or friends think that you have 
such a problem? 
If you answered "No" to both previous 
questions, go straight to question 2.1. 
If you answered "Yes" to either of the 
previous questions: 
1.2 a. Do you need help from other people for planing 
your daily affairs, handling money or making 
decisions? 
b. If you answered "Yes" to 1.2a, have you been 
feeling confused and not sure where you are or 
what time of the day, week, or month it is? 
2) Mood and Anxiety 
2.1 a. Have you been feeling anxious, irritable, 
depressed, or had any mood swings during the 
last month? 










If you answered "No" to both previous 
questions, go straight to question 3.1. 
If you answered "Yes" to 2.1a: 
2.2 a. Has this problem affected your ability to do any 
of your usual daily activities such as work, 
housework, or normal social activities with 
family and friends? 
b. If you answered "Yes" to 2.2a, has this 
problem been severe enough to prevent you from 
QQ 
doing all your usual activities? 
c. Have you been admitted to hospital for treatment 
of your mood problem during the last month? 
3) Eyes and Vision 
YES NO 
3.1 Do you have any problems with your vision that QQ 
can't be corrected with ordinary glasses? 
If you answered "No", go straight to question 
4.1. 
If you answered "Yes": 
3.2 a. Can you read ordinary newspaper print (with 
ordinary glasses if worn, but not magnifying 
lenses)? 
b. If you answered "No" to 3.2a, can you read F1 F1 
large newspaper print? 
C. If you answered "No" to 3.2b, can you count 
your fingers if you hold your hand out in front of 
QQ 
you? 
d. If you answered "No" to 3.2c, can you see 
your hand if you move it in front of you? 
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4) S eakin and Communicating 
YES NO 
4.1 Do you have any problems with your speech? F] F1 
If you answered "No", go straight to question 
5.1. 
If you answered "Yes": 
4.2 a. Do you have to repeat yourself when speaking to QQ 
your family or close friends? 
b" If you answered "Yes" to 4.2a, do you need to 
use sign language or the help of your carer to 
QQ 
make people understand you? 
C. If you answered "Yes" to 4.2b, are you able to 




5.1. Do you have to take care when swallowing Q 
solids or fluids? 
If you answered "No", go straight to question 
6.1. 
If you answered "Yes": 
5.2. a. Do you have to take care when swallowing with QQ 
most meals? 
b. If you answered "Yes" to 5.2a, do you need a F1 
special diet such as soft or liquidated food to 
help with your swallowing? 
C. If you answered "Yes" to 5.2b, do you choke 
with most meals? 
QQ 
d. If you answered "Yes" to 5.2c, do you have a 
feeding tube (nasogastric or gastrostomy tube)? 
QQ 
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6) Arms and Hands 
YES NO 
6.1 Do you have any problems with your hands or 
arms? 
QQ 
If you answered "No", go straight to question 
7.1. 
If you answered "Yes", 
6.2 a. Do you have any difficulty in doing any of your 
zips or buttons? 
QQ 
b" If you answered "Yes" to 6.2a, are you able to 
do all your zips and buttons without help? 
6.3 a. Do you have any difficulty in washing and QQ 
brushing your hair? 
b. If you answered "Yes" to 6.3a, are you able to 
wash and brush your hair without help? 
6.4 a. Do you have any difficulties in tying a bow in QQ 
laces or strings? 
b. If you answered "Yes" to 6.4a, are you able to 
tie a bow in laces or strings without help? 
6.5 a. Do you have any difficulty in feeding yourself QQ 
b" If you answered "Yes" to 6.5a, are you able to F1 F1 
feed yourself without help? 
6.6 If unable to do any of the functions listed in 
Question 6 above, are you able to use your 
hands or arms for any other function? 
7) Legs 
YES NO 
7.1 Do you have any problems with your walking? F1 Q 
If you answered "No", go straight to question 
8.1. 
If you answered "Yes": 
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7.2 a. Do you use a walking aid? F1 F 
b" If you answered "Yes" to 7.2a, how do you 
usually get around outdoors? (please tick only 
one of the 4 boxes below) 
" Without aid 1-1 
" With one stick or crutch or holding Q 
someone's arm 
" With two sticks or crutches, a frame, or one 
stick or crutch and holding someone's arm 
Q 
" With a wheelchair F1 
c. How do you usually get around indoors? (please 
tick only one of the 4 boxes below) 
" Without aid F1 
" With one stick or crutch or holding Q 
someone's arm 
" With two sticks or crutches, a frame, or one 
stick or crutch and holding someone's arm 
Q 
" With a wheelchair 
d. If you answered "With a wheelchair", can you QQ 
stand and walk a few steps with help? 
8) Going to the toilet (bladder) 
YES NO 
8.1. a. Do you have any problems with your bladder? QQ 
b. Are you taking any medications for such QQ 
problems? 
If you answered "No" to both previous 
questions, go straight to question 9.1. 
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If you answered "Yes" to 8.1a : 
8.2. a. Do you have to rush to the toilet? QQ 
b. Do you have to go to the toilet frequently? QQ 
c. Do you have difficulty in starting to pass urine? 
8.3 a. Have you been incontinent last month? Q 
b" If you answered "Yes" to 8.3a, have you been 
incontinent in the last week? 
c. If you answered "Yes" to 8.3b, have you been 
incontinent every day? 
8.4. Do you need to use a catheter to empty your QQ 
bladder? 
8.5. Do you need a permanent catheter in the bladder, 
or (for men only) do you use a sheath to catch 
the urine? 
9) Going to the toilet (bowel) 
YES NO 
9.1. a. Do you have any problems with your bowel QQ 
movements? 
b Are you on any treatment for such problems? Q F1 
If you answered "No", to both questions, go 
straight to question 10.1. 
If you answered "Yes" to 9.1a: 
9.2. a. Do you suffer with constipation? F F1 
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b. If you answered "Yes" to 9.2a, do you need to 
take laxatives or use suppositories for this? 
F1 F1 
c. Do you need to use enemas for this? 1-1 F1 
d. Do you have to evacuate your stools manually? F1 1ý 
9.3 Do you have to rush to the toilet to open your 
bowels? 
QQ 
9.4 a. Have you had any bowel accidents (been 
incontinent of faeces) in the last week? 
QQ 
b. If you answered "Yes" to 9.4a, have you had 




10.1 Have you been feeling tired or getting tired QQ 
easily during the last month? 
If you answered "No", go straight to 
question 11.1. 
If you answered "Yes" 
10.2 Have you been feeling tired or getting tired 
easily most days? 
F1 F1 
10.3 a. Has this tiredness affected your abilities to do 
any of your usual activities such as work or 
normal social activities with family and friends? 
b. If you answered "Yes" to 10.3a, has this 
tiredness been severe enough to prevent you 
QQ 
from doing all your usual activities? 
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C. If you answered "Yes" to 10.3b, has this 
tiredness been severe enough to confine you to 
QQ 
bed or chair and prevent you from doing all 
physical activities? 
11) Sexual activity 
YES NO 
11.1 Do you have any problems in relation to your 
sexual function? 
QQ 
If you answered "No", go straight to 
question 12.1 
If you answered "Yes" 
11.2 a. Do you suffer with lack of sexual interest? QQ 
b. Do you have any problems satisfying yourself QQ 
or your sexual partner? 
11.3 Is your sexual function affected by any physical 
problem such as altered genital sensation, pain, 
or spasms? 
Please state which: 
11.4 Do you have any problems: 
a. (For men): erection? QQ 
b. (For men): ejaculation? QQ 
c. (For women): vaginal lubrication? QQ 
d. (For women): orgasm? Q 
11.5 If you answered "Yes" to 11.3 - 11.4, do any 




12) Other problems 
YES NO 
12.1 Do you have any other problems due to MS 
such as pain, spasms, or dizziness which have 
not been mentioned so far? 
12.2 If you answered "No", go straight to part B 
of the questionnaire. 
If you answered "Yes", please name your 
worst problem: 
12.3 a. Has this problem affected your ability to do QQ 
any of your usual daily activities? 
b. If you answered "Yes" to 12.3a, has this 
problem been severe enough to prevent you 
QQ 
from doing all your usual daily activities? 
C. If you answered "Yes" to 12.3b, have you 
been admitted to hospital for treatment of this 
QQ 
problem during the last month? 
B. About you: 





2. How old are you? .................... years 
3. Are you currently working? 
Q 
Yes, full time 
Q 




D. Completing this questionnaire 





2. If yes, what type of help did you need? 
QI 
needed help reading the questions 
QI 
needed help in writing the answers 
QI 
needed help to work out how to answer the questions. 
Thank you for completing this questionnaire. 
Please return it in the envelope provided 
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